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CHAPTER 1GENERAL INTRODUCTION
Uveitis
Uveitis is an inflammation of the vascular layer of the eye (uveal tract), which includes the iris, 
ciliary body and choroid. However, in practice the term uveitis is usually used as a collective 
term for any form of intraocular inflammation. Uveitis is a major cause of visual impairment or 
even blindness. The annual prevalence of uveitis in the western world is increasing and varies 
between 85-115 cases per 100.000 persons. The incidence is around 25-52 cases per 100.000 
person-years with a peak at the age of 25-44 year, affecting predominantly the adult working 
population.1,2
Uveitis is usually classified according the anatomical location of the inflammation into anterior, 
intermediate, posterior or panuveitis group.3 The most common location encountered by primary 
care ophthalmologists is anterior uveitis, whereas the involvement of posterior eye segment is 
typically referred to tertiary care institutions.1 In approximately one third of uveitis cases the cause 
remains elusive (idiopathic uveitis), but the remainder may be either associated with systemic 
infectious (e.g. syphilis, toxoplasmosis), or an underlying systemic autoimmune or auto-inflam-
matory diseases.4-6 In these systemic non-infectious diseases, the eye is usually one of the several 
organs involved and uveitis might be the first clinical sign of a more widespread systemic disease.
Scleritis represents also an inflammatory disease of the eye, involving predominantly the sclera, 
but corneal, episcleral and retinal tissue may also be involved. Scleritis can be very severe, pain-
ful and result in blindness. As in uveitis, scleritis is sometimes associated with an underlying 
non-infectious systemic disease such as rheumatoid arthritis or granulomatosis with polyangiitis. 
Scleritis is formally not a subtype of uveitis, but these ocular inflammations may have similar 
causes and associations, as well as comparable diagnostic and therapeutic approaches. 
Autoimmunity in uveitis
The pathogenesis of uveitis is not fully clarified, but a crucial role of autoimmune reactions has 
been suggested. Autoimmunity is characterized by an aberrant activity of the immune system 
directed against the body’s own cells and tissues. It occurs when the immune system stops 
tolerating ‘self’ antigens and autoreactive cells attack the body’s own antigens. An exogenous or 
endogenous trigger (for example tissue damage) causes activation of the immune system, result-
ing in production of pathogenic antibodies and/or T-cells directed against ocular antigens. Several 
theories have been proposed about why this expansion occurs, including molecular mimicry in 
which autoantigens are mistaken for peptides from micro-organisms.7 
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without systemic manifestations (e.g. birdshot chorioretinopathy). Indirect evidence for involve-
ment of autoimmunity in uveitis has been provided by induction of autoimmune uveitis after 
immunization of animals with retinal autoantigens in combination with Freund adjuvant.8-10 These 
animal models, representing experimental autoimmune uveitis (EAU), have provided insight into 
the pathogenesis of human uveitis. In EAU predominantly mice are injected with different anti-
gens (such as S-arrestin and interphotoreceptor retinal binding protein) causing inflammation 
of  intraocular tissue similar to human uveitis. More recently, models with genetic manipulated 
mouse and spontaneously emerging uveitis, have been developed.2,5 Similar to the heterogeneity 
of human uveitis, clinical manifestations of uveitis in animal models may differ and is probably 
related dose and type of immunization as well as genetic sensibility. 
Antiretinal antibodies
The activity of our humoral immune system can be studied in the laboratory by measuring auto-
antibodies directed against retinal tissue. These so-called antiretinal antibodies (ARAs) can be 
detected by various laboratory techniques including immunohistochemistry, Western blot and 
enzyme-linked immunosorbent assay (ELISA). However, a standardized assay to measure ARAs 
is lacking and results may vary depending on the laboratory tool.11
The exact role of ARAs in uveitis and other chorioretinal diseases such as retinitis pigmentosa 
(RP), age-related macular degeneration (AMD) and glaucoma, was scarcely investigated. It has 
been suggested that ARAs might be involved in the inciting process of the ocular disease. Another 
hypothesis addresses a secondary phenomenon of ARAs induced by retinal damage. It has been 
proposed that ARAs in ocular disease might cause a mild inflammation in the retina and subse-
quently aggravate and/or prolong the ocular disease.12,13
Autoimmune retinopathy
ARAs have been described also in the context of autoimmune retinopathy (AIR). AIR encompasses 
a spectrum of rare autoimmune diseases that primarily affect retinal cells, and includes cancer-as-
sociated retinopathy (CAR), melanoma-associated retinopathy (MAR) and non-paraneoplastic 
autoimmune retinopathy. The affected patients produce ARAs directed against their own retina, 
which are thought to play a pathogenic role and being able to attack and destroy retinal cells, 
leading rapidly to visual loss or even blindness. It is hypothesized that the underlying mechanism 
of AIR is an immune response to tumor antigens sharing homology with retinal antigens (molec-
ular mimicry).14,15 AIR has been associated with the presence of various serum ARAs including 
antibodies directed against recoverin, α-enolase, transducin-α, carbonic anhydrase, arrestin and 
various other retinal antigens. While the patients with anti-recoverin antibodies frequently suffer 
from associated cancer and severe loss of rod and cone function, the anti-enolase retinopathy 
is characteristically associated with cone dysfunction and is also prevalent in patients without 
General introduction
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different antigens might be associated with distinct clinical signs. However, since most AIR patients 
exhibit multiple antiretinal antibodies, it is not yet known which antibodies are pathologic and 
clinically relevant, and which represent innocent bystanders. 
Current dilemmas
Although humoral autoimmune reactions directed against retinal tissue are thought to play an 
important role in either initiation or modification of diverse chorioretinal disorders including 
uveitis, they were not as yet systematically measured and their possible clinical impact in retinal 
diseases was not examined. It is not known which specific retinal antigens provoke the forma-
tion of antibodies  (and the repertoire of retinal autoimmune reactions). Furthermore, possible 
associations between ARAs and clinical characteristics, such as phase of the disease and being 
on immunosuppressive treatment, were not systematically examined. In addition, determination 
of ARAs was so far performed predominantly in serum of patients with chorioretinal diseases, 
which does not give precise information on what is exactly happening within the eye itself. The 
eye represents an immune-privileged organ, in which the immune reactions might be downplayed 
and/or different than observed in the peripheral blood. Information on the autoimmune reactions 
measured in intraocular fluid is scarce and the prevalence of ARAs in chorioretinal diseases has 
not been determined.
Understanding of autoimmune processes in ocular diseases might help to further elucidate 
their pathogeneses and may have consequences for the design of new diagnostic and treatment 
modalities. More detailed insight in the immuno-pathogenesis may be extremely valuable for 
patients, because the inhibition (or prevention) of inflammation (if present) in specific phases 
of the ocular disease might beneficially influence the course of disease and hopefully its visual 
outcome.
AIM AND SCOPE OF THIS THESIS
This thesis aims to assess the presence of humoral autoimmunity in uveitis and other chorio-
retinal diseases, including AIR, and to gain insight its role. To achieve this, we start by providing 
an overview of a large series of patients with uveitis and/or scleritis and examine the prevalence 
of systemic autoimmune and autoinflammatory diseases in this population. We review specific 
ocular diagnoses and clinical manifestations of patients affected by systemic autoimmune dis-
eases. Further, we critically evaluate the  term “autoimmune uveitis” (chapter 2). In chapter 3 we 
measure the prevalence of common systemic autoantibodies (antinuclear antibodies; ANA) in 
serum of uveitis patients. Subsequently, we determined the presence of retina specific antibod-
ies (ARAs) in serum of patients with uveitis, AIR and central serous chorioretinopathy (CSC), and 
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CHAPTER 1 discuss their possible pathogenic role (chapter 4-9). In the last chapters of this thesis we explore 
the determination of humoral autoimmune reactions in intraocular fluid samples of patients with 
uveitis (chapter 10). In addition, in chapter 11 we investigate intraocular fluid samples further 
and determine the presence of ARAs and inflammatory cytokines in intraocular fluid samples of 
patients with diverse ocular diseases, including RP, AMD, glaucoma and cataract.   
General introduction
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ABSTRACT
Purpose: Recent insights into the pathogenesis of immune-mediated diseases proposed a new 
classification, which includes autoimmune and auto-inflammatory diseases. The prevalence of 
specific autoimmune and auto-inflammatory diseases in uveitis and/or scleritis is not yet known. 
In this study we examine the presence of systemic immune-mediated diseases in patients with 
uveitis and/or scleritis and put a special emphasis on autoimmune disorders by reporting on 
their clinical manifestations and visual prognosis.
Methods: In this retrospective study we reviewed data of 1327 patients presenting with uveitis 
and/or scleritis between January 2010 and July 2016 at the Erasmus Medical Center Rotterdam, 
the Netherlands. All patients with non-infectious uveitis and/or scleritis were classified according 
to novel criteria for immune-mediated diseases. Various clinical data, including visual acuity, of 
patients with uveitis of autoimmune origin were registered during five-year follow-up. 
Results: The origin of uveitis was in 5% (62/1327) autoimmune, in 15% (197/1327) auto-inflam-
matory and in 14% (180/1327) mixed autoimmune/auto-inflammatory. Patients with classical 
autoimmune connective tissue disease (N=17) suffered mostly from rheumatoid arthritis and 
granulomatosis with polyangiitis and exhibited predominantly scleritis (53%). After five years of 
follow-up none of the eyes of these patients developed legal blindness (visual acuity of <0.1). 
The visual acuity in patients with uveitis associated with autoimmune neuro-ophthalmological 
diseases (multiple sclerosis and neuromyelitis optica; N=27) remained stable over time. 
Conclusion: Uveitis and scleritis of autoimmune origin were observed in 5% of the total series. 
The term autoimmune uveitis should not be used as a synonym for intraocular inflammation of 
non-infectious origin.
Autoimmunity in uveitis
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INTRODUCTION
Uveitis is a potentially blinding ocular disease of multiple causes. It may be associated with various 
systemic infectious and non-infectious diseases. Various non-infectious uveitis cases are caused 
by an underlying systemic autoimmune or auto-inflammatory disease.1-3 
The label “autoimmune uveitis” is commonly (and in our view unjustly) used for all types of uveitis 
associated with a systemic disease. Autoimmune diseases are characterized by an aberrant activ-
ity of the immune system directed against the body’s own cells and tissues. Recent advances in the 
understanding of the pathogenesis of immune-mediated diseases proposed a new classification, 
which includes autoimmune and auto-inflammatory diseases.4-6 The prevalence of these specific 
diseases in patients with uveitis and scleritis has not yet been assessed. 
In this study, we examine the presence of autoimmune diseases, according to current classifi-
cation of autoimmune- and auto-inflammatory diseases in a large series of patients with uveitis 
and/or scleritis. Further, we report on the prevalence, clinical features and visual prognosis of 
patients with autoimmune uveitis. 
METHODS
At the department of Ophthalmology at the Erasmus Medical Center Rotterdam (a tertiary referral 
center), we conducted a retrospective study in patients with uveitis and/or scleritis to examine the 
prevalence of associated diseases. All patients presenting with uveitis and/or scleritis between 
January 2010 and July 2016 were identified. A total of 1327 patient files were reviewed. This 
study was performed in accordance with the Declaration of Helsinki and in agreement with our 
institutional regulations and after approval of our institutional review board.
Clinical data of patients were collected, and included patient demographics (age, gender and 
race), specific diagnoses and anatomical location of uveitis. Furthermore, all patients were divided 
according to specific cause or association with systemic diseases into following groups: infectious 
origin, associated with a non-infectious systemic disease, clinically established ocular syndrome, 
masquerade syndrome and idiopathic types.7 To be classified as infectious uveitis, either micro-
biological proof for presence of specific pathogens in ocular fluids or evidence of active systemic 
infection was required. Patients with a positive IGRA test in the presence of otherwise unex-
plained uveitis were classified as of unknown origin and further specified as IGRA positive uveitis 
of unknown cause. 
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Patients with uveitis associated with a non-infectious systemic disease were further classified into 
four groups based on recent classification of their degree of autoimmunity: autoimmune, mixed 
autoimmune / auto-inflammatory, auto-inflammatory or not classified.4-6,8-10 Additional clinical data 
of patients with uveitis and autoimmune disease were collected, and included the manifestation 
at the time of first presentation (ocular versus non-ocular). Data regarding visual acuity (of both 
eyes) and use of systemic immunosuppressive medication were collected at onset of uveitis, and 
during follow-up at 1, 3 and 5 years. In patients with sympathetic ophthalmia also both eyes were 
included for visual acuity outcomes. Furthermore, we registered ocular complications including 
the presence of cystoid macular edema (CME) and optic neuropathy. 
All patients underwent a standardized diagnostic investigation protocol according to the local-
ization of the inflammation.7 This protocol included erythrocyte sedimentation rate (ESR), blood 
counts, serum angiotensin-converting enzyme levels, serology for syphilis and Lyme disease, 
interferon gamma release assay (IGRA) test (QuantiFERON–TB Gold In-Tube test) and radiologic 
chest imaging. In patients with scleritis, anterior uveitis or panuveitis presence of Human Leu-
kocyte Antigen (HLA) B27 was determined. Depending on the clinical manifestations, additional 
examinations were performed (tailored approach). Patients with juvenile idiopathic arthritis were 
screened for the presence of antinuclear antibodies (ANA). In patients with scleritis anti-neutrophil 
cytoplasmic antibodies (ANCA), anti-citrullinated protein antibodies (ACPA) and rheumatoid factor 
were determined. All diagnoses were made according to current diagnostic and internationally 
accepted criteria.
RESULTS
The causes and associations in the entire uveitis series are depicted in Table 1. Specific causes 
of uveitis and/or associations with systemic diseases were found in the majority of patients (62%, 
820/1327), of which 186/1327 (14%) were of infectious origin and 438/1327 (33%) were associ-
ated with non-infectious systemic diseases. 
The classification of systemic non-infectious diseases according to current classification of auto-
immune- and auto-inflammatory diseases is indicated in Table 2. An association with a systemic 
disease of established autoimmune origin was identified in 4% (59/1327), which was lower than 
the percentage of patients with auto-inflammatory (15%, 197/1327) and mixed autoimmune-/
auto-inflammatory diseases (14%, 180/1327). The association with classic autoimmune connec-
tive tissue diseases was even lower, (1%, 17/1327). The most commonly associated autoimmune 
disease was MS (24 patients) followed by VKH (14 patients). In our series, sarcoidosis (38% pre-
sumed and 62% biopsy proven) represented the most common non-infectious systemic disease 
associated with uveitis (13%, 172/1327). 
Autoimmunity in uveitis
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Three patients did not show association with systemic autoimmune disease, but had ocular 
inflammation of autoimmune origin, specifically sympathetic ophthalmia, resulting in a total of 
62 patients (5%) affected by autoimmune uveitis and/or scleritis.
Table 1. Causes and association of uveitis and scleritis patients
Number (%)
Total 1327 (100%)
Infections
Toxoplasma gondii
Rubella virus
Cytomegalovirus
Varicella zoster virus 
Herpes simplex virus
Remainder
186  (14%)
52 (4%)
23  (2%)
23 (2%)
22 (2%)
19 (1%)
47 (4%)
Non-infectious systemic diseases
Sarcoidosis
HLA-B27 associated (without (defined) systemic disease)
Juvenile idiopathic arthritis
Remainder
438  (33%)
172 (13%)
52 (4%)
48 (4%)
166 (13%)
Clinical ocular entity
Birdshot chorioretinopathy
Fuchs’ uveitis syndrome*
Presumed ocular histoplasmosis syndrome
Remainder **
98 (7%)
53 (4%)
12 (1%)
7 (1%)
26 (2%)
Masquerade syndrome
Benign
Malignant
70 (5%)
49 (4%)
21 (2%)
Miscellaneous
Toxic
Post traumatic
28 (2%)
20  (2%)
8 (1%)
Unknown ǂ
IGRA positive
507  (38%)
46 (3%)
* Rubella virus negative or not investigated 
** Includes two patients with immune recovery uveitis and three patients with sympathetic ophthalmia
ǂ In three patients the cause of uveitis might have been attributed to their diabetes mellitus 
Most patients with uveitis and/or scleritis of autoimmune origin were initially referred to an oph-
thalmologist (57%; 33/58, 5/63 missing data). Other patients were referred the departments of 
neurology (19%, 11/58), internal medicine (22%, 13/58) or otolaryngology (2%, 1/58). The median 
time between the moment of first presentation of complaints and making the definite diagnosis 
was 365 (0-8234) days. 
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Table 2. Overview of non-infectious systemic diseases associated with uveitis and scleritis
Number (%)*
Total 438  (33%)
Autoimmune diseases, total
Multiple sclerosis
Vogt-Koyanagi-Harada disease
Granulomatosis with polyangiitis
Rheumatoid arthritis
Systemic lupus erythematosus
Neuromyelitis optica
Sjögren syndrome
Autoimmune hepatitis 
Systemic sclerosis
59  (4%)
24  (2%)
14  (1%)
7  (<1%)
4  (<1%)
4  (<1%)
3  (<1%)
1  (<1%)
1  (<1%)
1  (<1%)
Mixed autoimmune / auto-inflammatory, total
HLA-B27 associated (without (defined) systemic disease)
Juvenile idiopathic arthritis
Ankylosing spondylitis**
Behçet syndrome
Psoriatic arthritis**
Reactive arthritis
Tubulointerstitial nephritis and uveitis 
Relapsing polychondritis
180  (14%)
52  (4%)
48  (4%)
28  (2%)
26  (2%)
9  (1%)
8  (1%)
5 (<1%)
4  (<1%)
Auto-inflammatory diseases, total
Sarcoidosis
Inflammatory bowel diseases**
Systemic vasculitis, ANCA negativeǂ
Muckle-Wells syndrome
197  (15%)
172  (13%)
18  (1%)
6  (<1%)
1  (<1%)
Not classified, total
Graft versus host disease
Immune deficiency 
2  (<1%)
1  (<1%)
1  (<1%)
* Percentage of total patients with uveitis (N=1327)
** In these groups, 26/28 patients with ankylosing spondylitis, 6/9 patients with psoriatic arthritis and 
4/18 patients with inflammatory bowel diseases were HLA B27 positive.
ǂ Includes three patients with arteritis temporalis and one patient with Kawasaki disease
Uveitis of autoimmune origin affected all segments of the eye (Table 3). The most common loca-
tion for autoimmune uveitis was the vitreous and peripheral retina (intermediate uveitis; 31%, 
19/62), followed by panuveitis (27%, 17/62). Intermediate uveitis was present only in (the majority 
of) patients with MS (70%, 19/24). Patients with connective tissue disease, specifically patients with 
rheumatoid arthritis (RA) and granulomatosis with polyangiitis (GPA), exhibited predominantly 
scleritis (53%, 9/17). Uveitis associated to other autoimmune diseases, including VKH disease 
and sympathetic ophthalmia (SO), was most frequently associated with panuveitis (86%, 12/14 
and 100%, 3/3, respectively). Posterior uveitis was present in all patients with systemic lupus 
erythematosus (100%, 4/4) and neuromyelitis optica (100%, 3/3), and was seldom seen in other 
autoimmune uveitis entities.
Autoimmunity in uveitis
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The prevalence of complications in patients with uveitis of autoimmune origin is presented in 
Table 3. CME was present in 24% (15/62) and was most frequently observed in patients with 
MS (38%, 9/24), VKH disease (29%, 4/14) and SO (33%, 1/3). None of the patients with uveitis/
scleritis associated with connective tissue disease exhibited CME. The optic disk was involved 
in 44% (27/62) of patients with uveitis of autoimmune origin. Almost all patients with VKH had 
involvement of the optic disk (93%, 13/14). In patients with neuro-ophthalmological diseases, the 
optic disk was involved in 41% (11/27), predominantly in patients with neuromyelitis optica (100%, 
3/3). Involvement of the optic disk in other entities of autoimmune uveitis was only occasionally 
observed.
Overall, visual prognosis was favorable as none of the patients developed bilateral visual acuity 
of less than 0.1 after five years of follow-up. At onset, visual acuity less than 0.1 in at least one 
eye was present in 8/46 (17%) patients. The overall prevalence of a visual acuity of <0.1 in at 
least one eye remained stable over the first five years of follow-up (Table 4). Visual acuity <0.1 
in at least one eye in patients with uveitis associated with neurological diseases varied between 
6% and 13% and did not change over time. Patients with VKH disease improved; 25% of these 
patients started with a visual acuity of <0.1 in at least one eye, but after five years this percentage 
was reduced to none.  
The use of systemic immunosuppressive medications and/or systemic corticosteroids for sys-
temic and/or ocular inflammation during the first five years of follow-up in patients with uveitis of 
autoimmune origin reached 76% (Table 4). The majority of patients with uveitis associated with 
connective tissue disease were successfully treated with systemic immunosuppressive medica-
tion and/or systemic corticosteroids during the follow-up period of five years (75% - 83%). In the 
group of patients with neuro-ophthalmological diseases immunosuppressive systemic medication 
was least frequently used (37% during year one and 56% during year 3-5).
Autoimmunity in uveitis
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DISCUSSION
Our results show that uveitis and/or scleritis of autoimmune origin was identified in 5% (62/1327) 
of all patients. The most common autoimmune disease in patients with uveitis was MS (39%, 
24/62), followed by VKH disease (23%, 14/62) and GPA (11%, 7/62). Scleritis was only observed in 
patients with uveitis associated with connective tissue diseases (RA and GPA), and intermediate 
uveitis was present only in patients with MS. Optic neuropathy was the most frequent complica-
tion (44%, 27/62). Use of systemic immunosuppressive treatment was frequent (up to 76%), and 
visual outcomes were favorable as none of the patients developed permanent bilateral visual 
acuity of less than 0.1 and only 13% of patients with uveitis of autoimmune origin developed 
unilateral visual acuity < 0.1 after five years of follow-up. 
Autoimmune diseases are classically defined by the Witebsky’s postulates:  1. presence of an 
autoantibody or cell-mediated autoimmune reaction, 2. identification of a corresponding auto-
antigen, and 3. an analogous autoimmune response inducible in an experimental animal model 
with development of a similar disease.11 These postulates have been revisited in 1993 by Rose 
and Bona, which resulted in three types of evidence to establish an autoimmune origin: direct 
proof, indirect proof and circumstantial evidence.12 Reproducing the disease by transfer of auto-
antibody or auto-reactive T-cells, or documenting the involvement of immunological reactions 
after immunization with the autoantigen provides (in)direct proof of autoimmunity. Associations 
with other autoimmune diseases, favorable response to immunosuppression or other distinctive 
clinical clues such as presence of autoantibodies represent circumstantial evidence. 
Autoimmune diseases predominantly involve the adaptive immune system, and are characterized 
by the production of autoantibodies and / or auto-reactive T-cells that recognize specific cells or 
tissues.4 Various autoantibodies are specific for individual autoimmune diseases, although their 
exact role in the pathogenesis of the disease is often unknown. Since diverse autoantibodies (e.g. 
antinuclear antibodies) appear also in healthy subjects, the mere presence of autoantibodies 
does not always indicate the presence of an autoimmune disease.13 Self-directed inflamma-
tion by auto-inflammatory diseases is caused by an over-activity of the adaptive and/or innate 
immune system, without specific identification of auto-reactive B- and T-cell responses (e.g. Crohn 
disease).4 Recent classification of inflammatory diseases into autoimmune, mixed and auto-in-
flammatory diseases takes these differences into account.4-6,8-10
The eye is an immune privileged organ, which indicates that immune responses to foreign- and 
self-antigens are suppressed or inhibited.14-16 This phenomenon prevents ocular damage and 
preserves vision. Features that contribute to the mechanism of ocular immune privilege include 
the blood-retina barrier, decreased lymphatic drainage, and soluble factors with immunosuppres-
sive properties in aqueous humor known as the anterior chamber associated immune deviation. 
Autoimmunity in uveitis
25
CHAPTER 2
Autoimmune reactions against retinal antigens have repeatedly been suggested to play a crucial 
role in diverse clinical uveitis entities. Direct evidence for an autoimmune pathogenesis has been 
described in cancer-associated retinopathies by reproducing the disease after transfer of auto-
antibodies.17,18 In uveitis however definite proof of autoimmune reactions and inciting antigens 
is very limited. Secondary contribution of autoimmune reactions has been proposed to play a 
role diverse uveitis entities, including intraocular infections.19 Indirect evidence for autoimmunity 
in uveitis has been provided by induction of autoimmune uveitis after immunization of animals 
with retinal antigens and Freund adjuvant.20,21 These animal models, so called experimental auto-
immune uveitis (EAU), have provided insight into the immuno-pathogenesis of human uveitis. In 
EAU predominantly mice are injected with different antigens (such as S-arrestin and interphoto-
receptor retinoid-binding protein) causing inflammation of intraocular tissue similar to human 
uveitis. Other animal models induced autoimmune uveitis by transfer of retina specific T-cells. 
For autoimmunity in human uveitis only circumstantial evidence was reported, for example by an 
increasing number of T-helper 17 cells during active uveitis and scleritis, and a decreasing number 
during treatment.22 So far, human autoimmune uveitis was only proven in uveitis when it is part 
of a systemic autoimmune disease and is highly suspected in sympathetic ophthalmia. It is not 
unlikely that other ocular entities (e.g. birdshot chorioretinopathy) might also be of autoimmune 
origin, but direct evidence for an autoimmune pathogenesis is lacking.
Despite the high number of patients included in our series from a tertiary center, our study has 
certain limitations. First, a bias to a more severe uveitis population is evident and is valid for 
most studies from tertiary centers. Furthermore, it should be noted that our hospital represents 
one of the national referral centers for sarcoidosis, which is probably in part responsible for a 
somewhat higher prevalence of ocular sarcoidosis in our series (13%, 172/1327).23 In addition, at 
5-year follow-up a significant number of patients with autoimmune uveitis was lost to follow-up 
(65%, 40/62). The most probable explanation is that in the majority of these cases uveitis stabi-
lized or diminished and the patients were referred back to the ophthalmologists in peripheral 
centers. Last, it cannot be ruled out that uveitis appearing with a systemic disease represent an 
epiphenomena and is not associated with the systemic disease, although this is highly unlikely.
In conclusion, autoimmune uveitis is a rare diagnosis, which comprises 5% of our large uveitis/
scleritis population. It is feasible that secondary autoimmune reactions might play a role in some 
uveitis entities (e.g. infections), as a consequence of damage and subsequent exposure of (so 
far hidden or altered) retinal/choroidal antigens. Clinicians caring for uveitis patients should be 
aware of the variety of diagnoses and the high prevalence of uveitis associated to sarcoidosis. 
In our view, the term autoimmune uveitis should be reserved for intraocular inflammations of 
confirmed autoimmune origin and should not be used as a synonym for non-infectious uveitis. 
26
CHAPTER 2
REFERENCES
1. Pras E, Neumann R, Zandman-Goddard G, et al. Intraocular inflammation in autoimmune diseases. Semin 
Arthritis Rheum. 2004;34(3):602-609.
2. Lee RW, Nicholson LB, Sen HN, et al. Autoimmune and autoinflammatory mechanisms in uveitis. Semin 
Immunopathol. 2014;36(5):581-594.
3. Willermain F, Rosenbaum JT, Bodaghi B, et al. Interplay between innate and adaptive immunity in the 
development of non-infectious uveitis. Prog Retin Eye Res. 2012;31(2):182-194.
4. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 
2006;3(8):e297.
5. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. 
Cell. 2010;140(6):784-790.
6. Pathak S, McDermott MF, Savic S. Autoinflammatory diseases: update on classification diagnosis and 
management. J Clin Pathol. 2017;70(1):1-8.
7. Trusko B, Thorne J, Jabs D, et al. The Standardization of Uveitis Nomenclature (SUN) Project. Development 
of a clinical evidence base utilizing informatics tools and techniques. Methods Inf Med. 2013;52(3):259-
265, S251-256.
8. Abramovits W, Oquendo M. Introduction to autoinflammatory syndromes and diseases. Dermatol Clin. 
2013;31(3):363-385.
9. van Kempen TS, Wenink MH, Leijten EF, Radstake TR, Boes M. Perception of self: distinguishing autoim-
munity from autoinflammation. Nat Rev Rheumatol. 2015;11(8):483-492.
10. Davila-Seijo P, Hernandez-Martin A, Torrelo A. Autoinflammatory syndromes for the dermatologist. Clin 
Dermatol. 2014;32(4):488-501.
11. Witebsky E. Experimental evidence for the role of auto-immunization in chronic thyroiditis. Proc R Soc 
Med. 1957;50(11):955-958.
12. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky’s postulates revisited). Immunol 
Today. 1993;14(9):426-430.
13. Marin GG, Cardiel MH, Cornejo H, Viveros ME. Prevalence of antinuclear antibodies in 3 groups of healthy 
individuals: blood donors, hospital personnel, and relatives of patients with autoimmune diseases. J Clin 
Rheumatol. 2009;15(7):325-329.
14. Kaplan HJ, Streilein JW. Immune response to immunization via the anterior chamber of the eye. II. An 
analysis of F1 lymphocyte-induced immune deviation. J Immunol. 1978;120(3):689-693.
15. Kaplan HJ, Streilein JW. Immune response to immunization via the anterior chamber of the eye. I. F. 
lymphocyte-induced immune deviation. J Immunol. 1977;118(3):809-814.
16. Streilein JW. Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation. 
J Leukoc Biol. 2003;74(2):179-185.
17. Ohguro H, Ogawa K, Maeda T, Maeda A, Maruyama I. Cancer-associated retinopathy induced by both 
anti-recoverin and anti-hsc70 antibodies in vivo. Invest Ophthalmol Vis Sci. 1999;40(13):3160-3167.
18. Adamus G, Machnicki M, Elerding H, Sugden B, Blocker YS, Fox DA. Antibodies to recoverin induce apop-
tosis of photoreceptor and bipolar cells in vivo. J Autoimmun. 1998;11(5):523-533.
19. Whittle RM, Wallace GR, Whiston RA, Dumonde DC, Stanford MR. Human antiretinal antibodies in toxo-
plasma retinochoroiditis. Br J Ophthalmol. 1998;82(9):1017-1021.
20. de Kozak Y, Sakai J, Thillaye B, Faure JP. S antigen-induced experimental autoimmune uveo-retinitis in rats. 
Curr Eye Res. 1981;1(6):327-337.
21. Broekhuyse RM, Winkens HJ, Kuhlmann ED. Induction of experimental autoimmune uveoretinitis 
Autoimmunity in uveitis
27
CHAPTER 2
and pinealitis by IRBP. Comparison to uveoretinitis induced by S-antigen and opsin. Curr Eye Res. 
1986;5(3):231-240.
22. Amadi-Obi A, Yu CR, Liu X, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 
and inhibited by IL-27/STAT1. Nat Med. 2007;13(6):711-718.
23. Tsirouki T, Dastiridou A, Symeonidis C, et al. A Focus on the Epidemiology of Uveitis. Ocul Immunol 
Inflamm. 2016:1-15.

ANTINUCLEAR ANTIBODY PROFILING 
IN UVEITIS
Josianne C.E.M. ten Berge, F. Groen-Hakan, Aniki Rothova, Marco W.J. Schreurs
Adapted version accepted for publication in Acta Ophthalmologica
3
30
CHAPTER 3
ABSTRACT
Purpose: Antinuclear antibody (ANA) profiling plays an important role in diagnosis of various 
autoimmune and autoinflammatory diseases. ANA is associated with the development of uveitis 
in children and its poor prognosis. In contrast, the diagnostic value of ANA in work-up of adults 
with uveitis is debatable. The aim of this study is to assess the diagnostic value of ANA profiling 
in adult patients with uveitis. 
Methods: In this prospective study, we assessed the presence of ANA in serum of 105 consecu-
tive adult patients with uveitis. In samples positive for ANA, ANA titer, ANA subtypes and staining 
patterns on IIF were also determined. Clinical data from uveitis patients were collected and 
statistical analyses were performed to relate laboratory results to clinical data of the patients. 
Results: A positive ANA result was observed in 29/105 (28%) patients with uveitis, and the median 
ANA titer was 160. Positive ANA titers were associated with longer duration of uveitis (p=0.037). No 
other associations were found between the presence of ANA, ANA titer or ANA staining pattern 
and specific diagnosis and various clinical characteristics of uveitis (all p-values > 0.05).
Conclusion: A positive ANA was found in 28% of patients with uveitis. The ANA profile was not 
distinctive for specific causes or clinical manifestations of uveitis. The diagnostic value of ANA 
assessment in the adult uveitis population is limited.
Antinuclear antibody profiling in uveitis
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INTRODUCTION
Uveitis is a clinical syndrome, which can be associated with different causes, including infections 
and systemic diseases. The pathogenesis of most uveitis entities in not clarified, although the 
immune system has been considered to play a major role. Various uveitis entities are associated 
with autoimmune and autoinflammatory diseases.1
Antinuclear antibodies (ANA) are antibodies directed against a variety of nuclear antigens, and 
can be detected in patients with autoimmune diseases. The presence of ANA is not specific for 
disease, since it has also been observed in the healthy population (predominantly women and 
elderly).2 In the past, ANA were determined in all patients with uveitis for diagnostic screening 
purposes, but this approach has been abandoned since its diagnostic value in adult patients 
with uveitis shown to be limited.3 In contrast, in patients with juvenile idiopathic arthritis (JIA) the 
presence of ANA has been demonstrated to be valuable, because its presence increases the risk 
of developing uveitis.4,5
In the last decades, the analysis of ANA has been improved and various subtypes and staining 
patterns are being determined. Profiling of ANA has been proven to play a significant role for diag-
nostic purposes in various diseases, including systemic lupus erythematosus, Sjögren syndrome 
and systemic sclerosis.6,7 The diagnostic relevance of the ANA profile and its possible association 
with clinical features in uveitis are not known. The aim of this study is to assess the presence, 
subtypes and titers of ANA in adult patients with uveitis of different etiologies and evaluate its 
possible value for diagnostic screening in uveitis. 
METHODS
We conducted a prospective study at the department of Ophthalmology, Erasmus MC, University 
Medical Center Rotterdam and determined ANA profile in 105 consecutive adult patients with 
uveitis who underwent a standardized screening protocol for the cause of their uveitis between 
January 2016 and July 2017. The study was performed in accordance with the Declaration of 
Helsinki and in agreement with the institutional regulations and approval of our institutional 
review board.
In addition to ANA screening, all patients underwent a diagnostic screening protocol, which was 
related to the location of uveitis (according to the Standardization of Uveitis Nomenclature (SUN) 
Working Group) and included chest radiography, erythrocyte sedimentation rate, blood counts, 
serum angiotensin converting enzyme levels, serology for syphilis and Lyme disease and inter-
feron gamma release assay test (QuantiFERON–TB Gold In-Tube test). Patients with anterior 
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uveitis or panuveitis were also tested for presence of human leucocyte antigen-B27. A tailored 
approach was applied for further examinations.
Data from included patients were collected from medical charts and registered were patients’ 
demographics (age, gender and race), definitive diagnosis of uveitis as well as ocular character-
istics (laterality, duration and activity of uveitis), use of systemic immunomodulating medications 
and ANA characteristics (presence, titer, staining pattern and ANA subtype). 
Screening for ANA in serum samples from included patients was performed by indirect immu-
nofluorescence (IIF) according to standard protocol. In short; HEp-2 cells (Inova, San Diego, CA) 
were incubated with 1:80 diluted serum samples for 30 minutes, and after being washed, the 
slides were incubated for 30 minutes with goat anti-human IgG conjugated with fluorescein iso-
thiocyanate with propidium iodide for counterstaining (Inova, San Diego, CA) to label antibodies. 
ANA titers of 1:80 or higher were considered positive and in these samples the ANA pattern 
and exact ANA titer were also analyzed. ANA patterns were classified according to international 
consensus and include only nuclear and mitotic patterns, whereas cytoplasmic HEp-2 staining 
was considered negative.8 In ANA positive samples, further identification for detection of anti-ex-
tractable nuclear antigens (anti-ENA antibodies) and anti-double stranded DNA (anti-dsDNA) was 
performed by EliA (Thermo Fisher Scientific/Phadia, Freiburg, Germany), ELISA (Inova, San Diego, 
CA) and/or LIA (Euroimmun, Lübeck, Germany). The ENA-panel consisted of anti-SS-A, anti-SS-B, 
anti-RNP, anti-Smith (anti-Sm), anti-CenpB, anti-Scl-70, and anti-Jo-1. 
Statistical analyses were performed to evaluate the presence and characteristics of ANA in uveitis 
patients. Continuous variables were described by median and range, and categorical variables 
were summarized by percentages (proportions). We used Fisher’s exact test for categorical data 
and Mann Whitney U test, Kruskall-Wallis 1-way ANOVA test and Spearman’s Rank Correlation 
for continues variables. All statistical analyses were performed using SPSS software (version 22.0, 
Chicago, IL). A p-value of <0.05 was considered statistically significant and all tests were two-sided. 
RESULTS
The clinical characteristics of included uveitis patients are shown in Table 1. The majority of 
patients were female (69/105, 66%) and the median age was 51 years. Most patients had an 
active uveitis (77/105 73%) and did not use systemic immunosuppressive medication (96/105, 
91%) during blood sampling. 
Positive ANA results were observed in 29/105 (28%) of patients with uveitis. The presence of ANA 
was equally distributed between genders and no association was observed between age and 
Antinuclear antibody profiling in uveitis
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presence of ANA. Most ANA positive samples were observed in idiopathic uveitis (18/55, 33%) 
and no positive ANA were seen in patients with uveitis classified as a clinical ocular syndromes 
(e.g. birdshot chorioretinopathy; Table 1). Prevalence of ANA was higher in patients with anterior 
uveitis (12/28, 43%) compared to other locations, but this difference did not reach significance. 
A visual acuity of <0.5 was observed in 7/26 (27%) ANA positive patients and in 22/82 (27%) of 
patients without ANA. Positive ANA titers were associated with longer duration of uveitis (p=0.037). 
All other clinical characteristics of uveitis were not significantly associated to the presence of ANA 
(all p-values > 0.05).  Activity of uveitis could not be related to ANA presence (p=0.90). 
Table 1. Presence of antinuclear antibodies (ANA) in uveitis patients 
All uveitis ANA positive ANA negative 
Total 105 (100%) 29/105 (28%) 76/105 (72%)
Median age in years (range) 51 (19-88) 49 (21-87) 52 (19-88)
Gender 
Male
Female
36/105 (34%)
69/105 (66%)
11/36 (31%)
18/69 (26%)
25/36 (69%)
51/69(74%)
Race 
Caucasian
Non-Caucasian
73/105 (70%)
32/105 (30%)
18/73 (25%)
11/32 (34%)
55/73 (75%)
21/32 (66%)
Cause of uveitis
Clinical ocular syndrome
Immune mediated systemic disease
Infection
Masquerade
Idiopathic
6/105 (6%)
15/105 (14%)
16/105 (15%)
13/105 (12%)
55/105 (52%)
0/6 (0%)
3/15 (20%)
5/16 (31%)
3/13 (23%)
18/55 (33%)
6/6 (100%)
12/15 (80%)
11/16 (69%)
10/13 (77%)
37/55 (67%)
Laterality of uveitis
Unilateral
Bilateral
49/105 (47%)
56/105 (53%)
13/49 (27%)
16/56 (29%)
36/49 (73%)
40/56 (71%)
Median duration of uveitis in years* (range) 1 (0-50) 1 (0-50) 0 (0-19)
Location of uveitis
Anterior
Intermediate
Posterior
Panuveitis
Sclero-/kerato-uveitis 
28/105 (27%)
9/105 (9%)
36/105 (34%)
20/105 (19%)
12/105 (11%)
12/28 (43%)
2/9 (22%)
9/36 (25%)
4/20 (20%)
2/12 (17%)
16/28 (57%)
7/9 (78%)
27/36 (75%)
16/20 (80%)
10/12 (83%)
Activity of uveitis
Active
Quiet
77/105 (73%)
28/105 (27%)
21/77 (27%)
8/28 (29%)
56/77 (73%)
20/28 (71%)
Immunocompromised **
Yes
No
14/105 (13%)
91/105 (87%)
5/14 (36%)
24/91 (26%)
9/14 (64%)
67/91 (74%)
*p = 0.037
** Use of immunosuppressive medications, malignant disorder or HIV with CD4 cell count of <300 
during blood collection 
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The median ANA titer (within ANA positive uveitis patients) was 160 and ranged from 80 to 640 
(Table 2). Clinical features of uveitis were not associated to ANA titer (all p-values > 0.05). The 
ANA pattern was classified as nuclear in 23/25 (92%) of patients and as mitotic in the remaining 
2/25 (8%) patients. A speckled ANA pattern was the most frequent observed pattern (13/29, 45%), 
followed by a homogeneous ANA (9/29, 31%). The speckled pattern was most frequently observed 
in uveitis with an unknown cause (9/13, 69%). The distribution of ANA patterns was however not 
characteristic for specific causes, locations or clinical manifestations of uveitis. Two patients were 
anti-dsDNA positive and one patient was positive for anti- ribonucleoprotein (anti-RNP); none 
exhibited any signs of autoimmune systemic disorder on examination by immunologist and all 
three were (so far) classified as uveitis of unknown origin. 
Table 2. Antinuclear antibody (ANA) characteristics of uveitis population (N=29)
Number (%)
Total ANA positive uveitis 29/105 (28%)
Median ANA titer 160 (80-640)
ANA patterns
Speckled
Homogeneous
Nucleolar
Speckled + nucleolar 
Centriole
Mitotic spindle apparatus
13/29 (45%)
9/29 (31%)
3/29 (10%)
2/29 (7%)
1/29 (3%)
1/29 (3%)
Anti-double stranded DNA 2/29 (7%)
Anti-extractable nuclear antigens (ENA)
(anti- ribonucleoprotein (RNP))
1/29 (3%)
DISCUSSION
Our prospective study shows that ANA is positive in 28% of patients with uveitis. No significant asso-
ciations were found between the presence of ANA, ANA titer, or specific ANA patterns and various 
clinical characteristics of uveitis, including specific diagnoses or activity of intraocular inflammation. 
The prevalence of 28% is higher than in the age-matched healthy population.9-11 The prevalence 
of ANA in healthy population varies between 8-17% and tends to be higher in female individuals 
and elderly.9-11 In our series, the relationship between age, gender and positive ANA could not be 
confirmed, probably due to the limited number of patients in various age groups. Although the 
ANA prevalence in our study was higher compared to the healthy age-matched population, no 
clinical relevance for the work-up of uveitis in adult patients could be identified. Therefore, routine 
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ANA determination as a part of the diagnostic testing of uveitis patients cannot be recommended. 
Determining ANA should however be performed in cases with signs suggesting specific systemic 
diseases such as systemic lupus erythematosus. 
Three decades ago, approximately 14% prevalence of ANA in uveitis population was observed 
in a setting similar to our series.3,12 This percentage is lower compared to the 28% ANA positivity 
found in our cohort and might reflect the changing spectrum of uveitis entities over time. Further 
it is possible that referral pattern might also play a role. In line with previous studies we did not 
find associations between specific uveitis entities, their characteristics and ANA, with exception 
of a borderline association between ANA positivity and longer duration of uveitis. Although our 
study is prospective, it includes a limited number of patients and therefore we cannot exclude 
that a specific uveitis entity could be associated with ANA. 
The prevalence of positive ANA in autoimmune- and autoinflammatory diseases varies widely. 
Almost all patients with systemic lupus erythematosus (SLE) are ANA positive and in systemic 
sclerosis and rheumatoid arthritis ANA prevalence varies between 30%-70%.13 Therefore, one 
could expect a higher ANA prevalence in uveitis associated with systemic non-infectious disor-
ders. However, in our series only 3/15 (20%) of the patients with systemic immune mediated 
disorders were ANA positive. Interestingly, ANA was more prevalent in patients with infectious 
uveitis (5/16, 31%) than in other uveitis entities. A transiently positive ANA test was previously 
noted in systemic infectious diseases.14 The relationship between ANA and ocular infections has 
not been specified in earlier studies.
Reactivity to specific ENA discriminates between various types of systemic autoimmune diseases 
and plays herein also a prognostic role. For example, in SLE, antibodies directed against the Sm 
antigen are specific for the disease and presence of anti-Topo-I antibodies is associated with more 
severe course of systemic sclerosis.15 We identified 3/29 (10%) with positive anti-ENA in our ANA 
positive patients but found no associations with uveitis characteristics, including its severity. This 
low proportion of anti-ENA positivity is not surprising, since still many anti-ENA specificities are 
not known. Usually anti-ENA antibodies occur more frequently in patients with high ANA titers.16 
The low to moderate ANA titers in our study appears in agreement with the small proportion of 
anti-ENA presence. The distribution of ANA patterns in our cohort seems similar compared to 
previous studies on ANA positive samples.17
Our findings in adult uveitis population differ from uveitis in children. Specifically, in JIA-associated 
uveitis the proportion of ANA positivity has been described in up to 86%.3,12 Presence of ANA in 
JIA has been documented to impose a significant risk for the development of uveitis.18 The most 
common pattern of ANA in JIA-uveitis is (partly) homogeneous (86%) and no specific anti-ENA 
have been identified.18
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In conclusion, positive serum ANA was observed in 28% of adult patients with uveitis. Specific 
associations between ANA positivity, ANA titer and ANA subtype, and ocular characteristics of 
uveitis were not identified. Based on our results, we do not recommend including ANA for the 
screening purposes of patients with uveitis.
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ABSTRACT
Purpose:  To determine the prevalence of serum antiretinal antibodies (ARAs) among patients 
with uveitis and establish their clinical relevance.
Methods: This prospective study assessed the presence of ARAs by indirect immunofluorescence 
(IIF) using primate retina in 126 patients with uveitis and 60 healthy controls. Clinical data of uveitis 
patients were collected from medical charts and included the classification of uveitis, cause of 
uveitis or its association with systemic disease, stage and activity of uveitis and specific retinal 
features. Correlations between the presence of specific ARAs and various clinical characteristics 
were analyzed. 
Results: The presence of ARAs was observed in 49/104 (47%) of patients with uveitis and in 10/59 
(17%) of healthy controls (p<0.001). Staining of the nuclear layers and the photoreceptors were 
both more often observed in patients with uveitis compared to healthy controls (p=0.002 and 
p=0.047, respectively). No specific associations were found between the presence of serum ARAs 
and various clinical characteristics. 
Conclusion: Serum ARAs were more frequent in patients with uveitis compared to healthy con-
trols, but their clinical role remains elusive. The assessment of intraocular production of specific 
ARAs may provide further insight into the role of ocular autoantibodies in diverse uveitis entities. 
Antiretinal antibodies in uveitis
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INTRODUCTION
Ocular autoimmunity characterized by the presence of multiple antiretinal antibodies (ARAs) 
has been documented in auto-immune retinopathy (AIR), including carcinoma associated reti-
nopathy, melanoma associated retinopathy or non-paraneoplastic autoimmune retinopathy.1-3 
In addition, retinal autoimmune reactions are considered to play an important role in the patho-
genesis of diverse retinal and uveo-retinal disorders. Multiple serum ARAs have been observed 
in various cohorts of patients with diverse uveitis entities but were also observed in up to 62% 
of the healthy population (Table 1).4-13 In addition, the decrease of serum ARAs in patients with 
exudative age-related macular degeneration following treatment with bevacuzimab injections has 
been described.14 Previous reports hypothesized that retinal damage caused by inflammation 
might induce a secondary formation of autoantibodies and cellular auto-immune responses 
which might subsequently contribute to continuation, recurrence rate and/or aggravation of the 
original inciting process. The precise sequence of events that might result in autoimmune attack 
of retinal cells is not yet elucidated. 
Uveitis is an inflammatory process of the uvea and is a major cause of blindness, resulting in 
10% of all cases of blindness. Uveitis can be caused by infection, systemic inflammatory disease, 
trauma or malignancy, however the etiology of uveitis remains unknown for up to 50% of the 
cases. Usually uveitis is classified according to its localization in the eye; anterior, intermediate, 
posterior or panuveitis.15 The eye is an immune privileged organ, because of its blood-retina 
barrier and the absence of lymphatic drainage. Furthermore, the introduction of foreign anti-
gens into the anterior chamber of the eye can induce a tolerance to the foreign antigen, called 
the anterior chamber associated immune deviation (ACAID). Absence of these features might 
enhance intraocular inflammation and subsequent loss of vision.  
The clinical relevance of serum ARAs in uveitis is still unknown. Previous studies on serum ARAs 
in uveitis lacked clinical data such as ocular features, activity of uveitis and use of medications 
(with the exception of a Polish publication).7 Furthermore, only small cohorts of specific uveitis 
entities were analyzed using S-antigen, interphotoreceptor retinoid-binding protein (IRBP) or 
crude human or bovine retinal extract. The identification of autoimmune processes in uveitis 
will help to elucidate the pathogenesis, and will also aid in the development of new diagnostic 
and treatment modalities.
In this study, we investigate the presence of serum ARAs in 126 patients with uveitis and 60 
healthy controls and correlate their clinical manifestations to laboratory findings.
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METHODS
Patients and sample collection
Blood samples from 126 patients with uveitis were prospectively collected from April 2013 until 
November 2014 at the department of Ophthalmology, Erasmus MC, University Medical Center 
Rotterdam and stored at minus 80°Celsius at the biobank of our department. All patient signed 
informed consent. Our laboratory assessments were performed in May and June 2015. The study 
was performed in accordance with the Declaration of Helsinki and in agreement with the institu-
tional regulations and approval of our institutional review board. Patients were classified according 
to SUN classification of their anatomical locations.16 All patients with uveitis underwent a standard-
ized diagnostic protocol according to the localization of the inflammation. This protocol included 
radiologic chest examination erythrocyte sedimentation rate, blood counts, serum angiotensin-con-
verting enzyme levels, serology for syphilis and Lyme disease as well as interferon gamma release 
assay (IGRA) test (QuantiFERON–TB Gold In-Tube test). In those with anterior and panuveitis Human 
Leukocyte Antigen (HLA)-B27 testing was also performed. According to the clinical manifestations, 
additional examinations were performed (tailored approach). Serum samples of 60 presumably 
healthy individuals (blood bank donors) were used as controls (gender and age unknown).
Data collection
Clinical data of uveitis patients were collected from medical data files and included patient demo-
graphic and ocular characteristics such as age, gender, onset and duration of uveitis, cause of 
uveitis or association with systemic disorder, anatomical location and activity of uveitis, visual 
acuity, use of immunosuppressive medications, laterality, presence of retinal lesions, vasculitis, 
cystoid macular edema (CME) and presence of glaucoma. 
Detection of ARAs using indirect immunofluorescence (IIF)
Initial screening of sera was performed using primate retinal tissue. Cryosections manufactured 
by Euroimmun (Lubeck, Germany) were left unfixed. The quality of the cryosections of primate 
retinal tissue was checked with immunohistochemistry and staining with DAPI. Serum was diluted 
1:100 with phosphate phosphate buffered saline (PBS), pH 7.8. Retinal tissue was then incu-
bated with the diluted serum from a patient for 30 minutes at room temperature. Sections were 
washed in stagnant PBS (pH 7.8) for 15 minutes. After the washing, sections were incubated with 
goat-anti-human IgG conjugated with fluorescein isothiocyanate that was provided in the previous 
mentioned Euroimmun kit for 30 minutes at room temperature to label the bound antibodies. 
The sections were washed again in stagnant PBS (pH 7.8) for 15 minutes. Embedding medium was 
placed onto the cryosections and were covered with a cover glass. The positive control consisted 
of retinal tissue incubated with 1:100 diluted serum of an antinuclear antibody (ANA) positive 
patient, which also allowed visual identification of the different retinal layers. Retinal tissue incu-
bated with PBS or with 1:100 diluted serum of a healthy control were used as negative controls.
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Detection of ANA using IIF
All sera showing any kind of antiretinal immunoreactivity by IIF were analyzed for the presence of 
antinuclear antibodies. ANA detection was performed by IIF using Hep-2 cells (Inova, San Diego, 
California). Serum samples were diluted 1:80 with PBS (pH 7.8). Hep-2 cells were incubated with 
the diluted serum for 30 minutes at room temperature. After washing in PBS with continuous 
stirring, slides were incubated for another 30 minutes with goat anti-human IgG conjugated with 
fluorescein isothiocyanate with propidium iodide for counterstaining (Inova, San Diego, California) 
to label specifically bound antibodies. Subsequently, slides were washed and embedded.
Evaluation of laboratory results
All slides were evaluated on a fluorescence microscope (20x magnification) by two independent 
observers. Specific retinal layers (ganglion cell layer, inner plexiform layer, inner nuclear layer, 
outer plexiform layer, outer nuclear layer, and rods and cones layer) were separately evaluated 
for presence of fluorescent staining and the location of staining was noted. In addition, specific 
repetitive patterns of staining were noted (Figure 1); band A (fluorescence between the inner 
nuclear layer and the outer plexiform layer) and band B (fluorescence between the outer nuclear 
layer and the photoreceptors). In case both ANA and ARA were positive, a sample was scored as 
‘unknown’ because this combination does not allow a proper discrimination between the pres-
ence or absence of ARAs (by possible masking of ANAs). These samples (n= 23) were excluded 
from the final analyses.
Statistical analysis
Chi-square tests and Mann Whitney U-tests were employed to evaluate differences in auto-
antibody presence between groups and to determine possible associations between clinical 
characteristics and presence of ARAs. P<0.05 was considered as statistically significant. 
Antiretinal antibodies in uveitis
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Figure 1. Examples of different staining patterns on IIF of patients with uveitis
Indirect immunofluorescence test on primate retinal tissue incubated with serum of patients with 
uveitis. Fluorescein isothiocyanate (FITC) labeled antiretinal antibodies (arrows) react upon incubation 
with serum of the patients with staining of: a. specific cells in the outer nuclear layer; b: photoreceptors, 
band B, bipolar cells and parts of the ganglion cell layer; c. outer segments of the photoreceptors; and 
d. nuclei in the inner nuclear layer, outer nuclear layer and ganglion cell layer (this serum was positive 
for antinuclear antibodies).
RESULTS
Patient characteristics
The general characteristics of the patients are indicated in Table 2. The median age of patients 
was 54 years and the majority was female (84/126, 67%). The median duration of uveitis at sample 
collection  was 4 years with a wide range of 0 - 57 years. Most patients were diagnosed with 
posterior uveitis (45/126, 36%) or panuveitis (38/126, 30%; Table 2), and most cases were bilat-
eral (101/126, 80%). Uveitis was associated with a systemic disease in 40/126 patients (32%), of 
which most patients had sarcoidosis. An established clinically defined ocular syndrome was seen 
in 20/126 (16%) of the cases with uveitis, with birdshot chorioretinopathy as the most common 
diagnosis (N=16). During sample collection more than half of the patients had an active uveitis 
(74/126, 59%) and immunosuppressive treatment was administered in 45/126 patients (36%).
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Table 2. General and ocular characteristics of uveitis patients (N=126)
Characteristic Study participants
Male-to-female ratio 42 - 84  (33% - 67%)
Median age in years (range) 54 (16 – 80)
Median duration of uveitis in years (range) 4 (0 – 57)
Location uveitis 
Anterior uveitis
Intermediate uveitis
Posterior uveitis
Panuveitis
Scleritis
19/126 (15%)
18/126 (14%)
45/126 (36%)
38/126 (30%)
6/126 (5%)
Specific cause or association
Association with systemic disease
Sarcoidosis
Multiple sclerosis
Inflammatory bowel disease
HLA B27 associated uveitis
Psoriasis
Miscellaneous group
Clinical ocular syndrome
Birdshot chorioretinopathy
Miscellaneous group 
Proven ocular infection
Toxoplasmosis
Miscellaneous group
Unknown cause
Unknown 
Unknown with latent tuberculosis infection
40/126 (32%)
10/40 (8%)
8/40 (6%)
4/40 (3%)
3/40 (2%)
3/40 (2%)
12/40 (2%)
20/126 (16%)
16/126 (13%)
4/126 (3%)
8/126 (6%)
4/126 (3%)
4/126 (3%)
58/126 (46%)
49/126 (39%)
9/126 (7%)
Active uveitis 74/ 126  (59%)
Systemic immunosuppressive treatment 45/126 (36%)
Retinal lesions 59/126 (47%)
Vasculitis 16/126 (13%)
Cystoid macular edema 33/126 (26%)
Bilateral uveitis 101/126 (80%)
Glaucoma 22/126 (18%)
Visual acuity in the worst eye
≥ 0.5
≥ 0.1 & < 0.5
< 0.1
66/126 (52%)
35/126 (28%)
25/126 (20%)
Serum ARAs in uveitis and healthy controls
A positive retinal IIF staining was observed in 71/126 (56%) patients with uveitis and in 11/60 
(18%) healthy controls (p<0.001; Table 3). ANAs were positive in 22/126 (17%) cases and in 1/60 
(2%) of the healthy controls; in these ANA-positive subjects the presence of ARAs was scored as 
‘unknown’. After adjustment of the results for the presence of ANAs, 49/104 (47%) patients with 
uveitis and in 10/59 (17%) of the healthy controls (p<0.001) had ARAs.
Antiretinal antibodies in uveitis
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Several retinal staining patterns were recognized in patients with uveitis. Specifically staining of 
nuclear layers (29/98, 30%), the photoreceptors (19/104, 18%) and band A and/or band B were 
more often observed in patients with uveitis compared to healthy controls (5/58 (9%), 3/59 (5%) 
and 2/59 (3%); p=0.002, p=0.018 and p=0.027, respectively).
Table 3. Antiretinal antibodies (ARAs) and antinuclear antibodies (ANAs) in uveitis patients 
and healthy controls
Uveitis (N=126) Healthy controls (N=60) p-value
Any retinal staining
ARA considered  unknown due to ANA+
71/126 (56%)
22/71 (31%)
11/60 (18%)
1/11 (10%)
< 0.001
Retina specific staining
Nuclear layers*
Photoreceptors
Band A and/or band B
49/104 (47%)
29/98 (30%)
19/104  (18%)
15/104 (14%)
10/59 (17%)
5/58 (9%)
3/59 (5%)
2/59 (3%)
< 0.001
0.002
0.018
0.027
* Presence of retina specific staining could be determined in some cases with ANA positivity, since 
photoreceptors and band A/B were not masked by ANA. Therefore the number of patients with ARA 
is higher in the analysis of staining of the retina, photoreceptors and band A and/or band B compared 
to staining of the nuclear layers.
Serum ARAs and clinical characteristics of uveitis
We observed no significant associations between the presence of any retinal IIF staining or spe-
cific patterns of ARAs and various demographic and clinical manifestations, specifically the age 
of patients; cause, duration, location or laterality of uveitis; presence of retinal lesions, vasculitis, 
cystoid macular edema or glaucoma; use of immunosuppressive treatment; or history of carci-
noma (Table 4). Furthermore, the presence of ARAs did not differ between patients with specific 
chorioretinal lesions when comparing peripheral multifocal chorioretinitis, birdshot- lesions and 
focal retinitis. Several borderline associations were noted such as the presence of total ARAs and 
uveitis in remission (Table 4).
Staining of photoreceptors was not associated with any clinical manifestation of uveitis. Staining 
of the nuclear retinal layers was less prevalent in patients with birdshot chorioretinopathy (0/11%) 
and more prevalent in patients with acute multifocal placoid pigment epitheliopathy (2/3,67%) 
compared to other causes of uveitis. Staining of band A/B was more often seen in the female 
population (20%), patients with uveitis caused by more rare systemic diseases (50%) and in visu-
ally compromised (visual acuity of < 0.1) patients (32%). No other relationships between clinical 
manifestations and staining of the nuclear layers or band A/B were observed. 
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DISCUSSION
Our results show that serum ocular antibodies, specifically ARAs, are more prevalent in patients 
with uveitis as compared to healthy controls (47% versus 17%, p<0.001). However, specific associ-
ations between the presence of serum ARAs (or typical staining patterns on IIF) and clinical ocular 
characteristics were not observed so far, except for the association between patients with a visual 
acuity of less than 0.1 and the presence of positive staining of band A/B (p=0.013). Furthermore, 
some marginal associations were noted, though this probably a coincidence occurring due to 
multiple comparisons in a small cohort (in perspective to number of tested variables). Our study 
includes a heterogeneous population of uveitis patients in which major groups of etiology are rep-
resented. Due to the limited number of patients in specific subgroups, it cannot be fully excluded 
that some associations were missed and that in a larger population of patients with specific 
uveitis entities the associations between clinical manifestations and serum ARA’s could be found. 
The involvement of autoimmunity in uveitis has repeatedly been implicated and the term autoim-
mune uveitis was sometimes even used as a synonym for all non-infectious types of uveitis. The 
proposed autoimmune pathogenesis is often being explained by mimicry between the ocular 
and other infectious or non-infectious antigens, but actual autoimmune processes in uveitis have 
seldom been proved. The autoimmune reactions against S-antigen, the best-known uveitogenic 
antigen, were examined and found to be involved in the pathogenesis of infectious uveitis.5,10,11 
In several animal models with monkeys and rats, vaccination with retinal S antigen induced an 
ocular disease similar to human uveoretinitis.17-19
The results of our study on the prevalence of serum ARAs in uveitis are in line with previous 
reports. Cohorts with different specific entities of uveitis have been analyzed for the presence 
of ARAs in serum, including cohorts of patients with juvenile associated uveitis, idiopathic retinal 
vasculitis, toxoplasmosis, onchocherciasis, or a variation of noninfectious or idiopathic posterior 
uveitis (Table 1). The presence of any ARA in serum was noted in approximately 70% in patients 
with retinal vasculitis and up to 100% in patients with toxoplasmosis.5,10,12 Since the aforemen-
tioned studies usually lacked clinical data and information on laboratory techniques the exact 
comparison with previous results is not possible. In our series, we have chosen to use (commer-
cially available) primate retinal tissue to investigate the presence of ARAs by IIF. Primate tissue 
from an evolutionary perspective closely resembles human tissue and is also used for diagnostic 
purposes. Furthermore, in human retinal tissue certain antigens may induce higher background 
staining, including blood group-associated antigens. In addition, the use of commercially available 
tissues may facilitate future comparisons of results.
The presence of diverse patterns on IIF indicates that different ARAs are produced by individual 
patients. However, IIF does not allow the precise identification of ARAs, i.e. their antigen speci-
Antiretinal antibodies in uveitis
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ficity. To clarify the type and complexity of the ARAs detected in our study, specific IIF patterns 
must be correlated to specific retinal antigen reactivity. In the past, patterns of specific ARAs 
have been determined, however, IIF showed different patterns in various studies even with the 
use of purified antibodies.20-23 The cause of this inconsistency could be explained by the use of 
variable tissues and reagents and the recognition of different epitopes. More useful techniques 
for confirmation of specific type of ARA and determination of multiple ARAs consist of Western 
Blot and/or ELISA. 3,24 
The higher prevalence of serum ARAs in uveitis remains unexplained as well as their possible clin-
ical role. Hypothetically, the presence of serum ARA’s (and absence of their clinical impact) might 
be due to local tissue damage, leakage of (altered) retinal antigens into the circulation and subse-
quent reaction of the immune system and production of diverse serum ARAs. This implicates that 
the production of serum ARAs might develop due to the general response of the immune system 
to ocular tissue damage. The systemic production of coincidental ARAs might be responsible for 
the lack of associations between the serum ARAs and ocular clinical manifestations in parallel to 
the presence of multiple autoantibodies, which are commonly observed in systemic autoimmune 
disorders and sometimes in healthy elderly population.  In addition, the absence of ARAs in a 
subset of uveitis patients indicates that probably not antibodies but cell-mediated autoimmune 
reactions might play a primary role in the development of presumed autoimmunity in uveitis. 
Further, the levels of antibodies in the serum reflect their total systemic production and are 
probably not influenced by the additional production of specific antibodies within the eye. This 
phenomenon has also been observed in the diagnosis of infectious uveitis in which local pro-
duction of specific antibodies within the eye rather than serum levels is regarded as a proof of 
the ocular infection (determined with a Goldmann-Witmer coefficient.25 The importance of locally 
produced antibodies has also been shown in cerebrospinal fluid for the central nervous system, 
another immune privileged organ.26 The local production of ARAs might show an entirely differ-
ent pattern and clinical importance than ARAs found in the peripheral circulation and has - to 
our knowledge - so far not been examined. Further research assessing the intraocular levels of 
specific ARAs might elucidate the clinical relevance of autoimmune processes directed against 
the retinal tissue in uveitis.
Serum ARAs were observed in the majority of patients with uveitis and were more frequent 
compared to healthy controls. The cause of enhanced serum ARA production in patients with 
uveitis is currently not known. Specific associations between the presence of serum ARAs (or 
typical staining patterns on IIF) and clinical ocular characteristics were not identified. The role 
of presumed autoimmune reactions in uveitis could be further investigated by assessment of 
intraocular fluids within the eye instead of peripheral blood samples.
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ABSTRACT
Purpose: Although multiple serum antiretinal autoantibodies (ARAs) have been reported in 
patients with paraneoplastic and non-paraneoplastic autoimmune retinopathy ((n)pAIR), not all 
retinal antigens involved in (n)pAIR are specified. This study aims to serologically identify patients 
with presumed (n)pAIR through determination of both known and unknown ARAs by autoanti-
body profiling.
Methods: An antigen suspension bead array using 188 different antigens representing 97 ocular 
proteins was performed to detect ARAs in serum samples of patients with presumed (n)pAIR 
(N=24), uveitis (N=151) and cataract (N=21). Logistic regressions were used to estimate the 
associations between ocular antigens and diagnosis. Validation of interphotoreceptor matrix 
proteoglycan 2 (IMPG2) and recoverin antigens was performed by immunohistochemistry and 
immunoblot, respectively.
Results: Samples of patients with presumed (n)pAIR exhibited a broad spectrum of ARAs. We 
identified retinal antigens that have already been described previously (e.g. recoverin), but also 
identified novel ARA targets. Most ARAs were not specific for (n)pAIR since their presence was 
also observed in patients with cataract or uveitis. High titers of autoantibodies directed against 
photoreceptor-specific nuclear receptor and retinol-binding protein 3 were more common in 
patients with presumed (n)pAIR compared to uveitis (p=0.015 and p=0.018, respectively). The 
presence of all other ARAs did not significantly differ between groups. In patients with presumed 
(n)pAIR, anti-recoverin autoantibodies were the most prevalent ARAs. Validation of bead array 
results by immunohistochemistry (anti-IMPG2) and immunoblot (anti-recoverin) showed concor-
dant results in (n)pAIR patients.
Conclusions: Patients with (n)pAIR are characterized by the presence of a broad spectrum of 
ARAs. The diagnosis of (n)pAIR cannot be based on the mere presence of serum ARAs, as these 
are also commonly present in uveitis as well as in age-related cataract patients.
Autoantibody profiling of patients with autoimmune retinopathy
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INTRODUCTION
Paraneoplastic and non-paraneoplastic autoimmune retinopathy ((n)pAIR) is a rare blinding reti-
nal disorder of unknown pathogenesis. It is presumed that antiretinal autoantibodies (ARAs) are 
involved in the pathogenesis of (n)pAIR and damage ocular tissue causing poor visual outcome. 
Symptoms associated with (n)pAIR are progressive visual loss (most often bilateral), visual field 
loss frequently associated with a ring scotoma or loss of the peripheral field, and decreased 
amplitudes on electroretinogram (ERG).1-4 
Paraneoplastic autoimmune retinopathy (pAIR) includes two subgroups: cancer associated ret-
inopathy (CAR) and melanoma associated retinopathy (MAR). In pAIR the presence of the same 
auto-antigens in both retinal tissue and malignant tissue has previously been described (e.g. 
recoverin).5-7  The presence of ARAs however is not conclusive for the diagnosis of (n)pAIR, since 
several ARAs were also reported in patients with other ocular disorders and individuals without 
ocular disease.8 Nevertheless, ARAs are considered to support the diagnosis of (n)pAIR, which is 
often difficult to confirm by clinical symptoms only.9 
Multiple serum ARAs have regularly been reported in affected patients (Table 1), although not 
all retinal autoantibodies involved in the pathogenesis of (n)pAIR are known and information 
regarding their exact pathological roles is lacking.10 Further, a gold standard for the determination 
of ARAs is missing.11-13 The optimal approach for the determination and specification of ARAs is 
currently unknown. Different techniques, including indirect immunofluorescence, western blot 
and enzyme-linked immunosorbent assay (ELISA), have been used for the detection of ARAs; 
however, results and conclusions differ and cannot be reliably compared.
Currently, antigen bead arrays are being used to profile autoantibody reactivity in body fluids.38 
With this technique, very small volumes of body fluids can be tested for IgG reactivity across hun-
dreds of samples towards hundreds of different antigens. This technique has already successfully 
been used for the analysis of autoantibodies in serum and cerebrospinal fluid.39-41
Our study aimed to serologically identify patients with presumed (n)pAIR through determination 
of ARAs. For this purpose, we used a bead array-based multiplex assay for autoantibody profiling 
using 188 ocular antigens representing 97 different retinal proteins.
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Table 1. Previously described antiretinal autoantibodies in serum of patients with parane-
oplastic and non-paraneoplastic autoimmune retinopathy 1,14,15
Antigen Associated with Location in retina Size 
(kDa)CAR MAR npAIR
Recoverin 16 x x x Inner segments and nuclei 
of photoreceptor cells, outer 
plexiform layer
23
α - Enolase 17 x x x Inner segments of the 
cone cells, Müller cells and 
ganglion cell layer
46
Carbonic anhydrase II 18 x x x Ganglion cell layer, inner 
nuclear layer, outer 
segments of photoreceptors 
30
Heat shock cognate protein 70 19 x x x N/A 65
Transducin α (guanine 
nucleotide-binding protein G(t) 
subunit alpha-1) 20
x x x Outer and inner segments 
of photoreceptor cells, 
cytoplasm of ganglion cells
40
Transducin β (guanine 
nucleotide-binding protein 
G(I)/G(S)/G(T) subunit β-1)* 21
x x Photoreceptor cells, 
ganglion cell layer
35
Arrestin (S-antigen) 22,23 x x Photoreceptor cells 48
Interphotoreceptor binding 
protein (retinol binding protein 
3) 24-26
x x Outer and inner segments 
of photoreceptor cells
141
Rhodopsin 27,28 x x Rod photoreceptor cells 40
Photoreceptor-cell-specific 
nuclear receptor 29
x Outer nuclear layer 44.7
Müller-cell-specific antigen 30 x x N/A 35
Transient receptor potential 
cation channel subfamily M, 
member 1 31-34
x x x Bipolar cells 182
Tubby-like protein 1 35 x x Photoreceptor cells 78
Bestrophin-1 36 x Basal lateral membrane of 
retinal pigment epithelium
68
Aldolase A and C 15 x x Ganglion cell layer, inner 
nuclear layer (aldolase C)
39
Glyceraldehyde 3-phosphate 
dehydrogenase 37
x x x Rod outer segments 30 and 36
Abbreviations: CAR = cancer associated retinopathy, MAR = melanoma associated retinopathy, 
npAIR = non-paraneoplastic autoimmune retinopathy
Autoantibody profiling of patients with autoimmune retinopathy
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METHODS
Sample collection and patient selection
Serum samples were either collected during routine diagnostic analysis for the presence of 
anti-recoverin autoantibodies in the Laboratory of Medical Immunology of the Erasmus Univer-
sity Medical Center between April 2013 and August 2015 or were obtained from biobank of our 
department. The study was approved by the local ethical committee from the Erasmus University 
Medical Center (Medical Ethics Committee Erasmus MC) and adhered to the tenets of the Declara-
tion of Helsinki. The ethical committee decided that no informed consent of patients was required 
for the use of the remainder of the diagnostic material, as the samples were anonymized and 
the patients were not subjected to additional risk or procedures. Samples which were obtained 
from the biobank (for which an approval of the ethical committee was obtained) included signed 
informed consent from all participants. All whole blood samples were centrifuged after at least 
30’ clotting time at 3,000 rpm for 10 minutes, and serum was stored at -80°C.
According to the recently published report on the nomenclature of (n)pAIR, the general term 
autoimmune retinopathy (AIR) is recommended to indicate the non-paraneoplastic autoimmune 
retinopathy (npAIR) subtype. In our present series we indicate the specific subtype(s) of AIR (pAIR, 
npAIR or (n)pAIR) to prevent any misunderstanding regarding nomenclature.9 The diagnosis of 
presumed (n)pAIR was made if the patients fulfilled all of the following inclusion criteria: 1. visual 
complaints, 2. markedly decreased amplitudes on ERG, 3. visual field loss, and 4. no alternative 
explanation for their ocular disorder. In addition, patients with genetically proven retinitis pig-
mentosa or a family history of retinitis pigmentosa were excluded. A total of 17 patients fulfilled 
the criteria indicated above and were included in this study. Patients fulfilling the criteria without 
a malignancy were indicated as presumed npAIR (N=9), and patients with a malignancy were 
indicated as patients with presumed pAIR (N=8).
An additional group of presumed pAIR (CAR or MAR) patients (N=7) in whom ERG or visual field 
tests were not performed (choice of the patient or poor general condition), but who fulfilled all 
other inclusion criteria was included separately. An additional required criterion for these patients 
comprised the development of a malignancy before or within 3 months after presentation with 
ocular problems.  
We collected various clinical data of the patients with presumed (n)pAIR, including patient demo-
graphics (age and gender) and ocular characteristics such as complaints of photopsia, complaints 
of nyctalopia, subjective or objective problems with colour-vision, unilateral or bilateral visual 
problems and the presence of a malignancy in the medical history or during follow-up. 
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Controls consisted of two groups: 21 serum samples from cataract patients without retinal 
damage and 151 samples from patients with uveitis of different causes. Patients with age related 
cataract were included as controls rather than healthy people, as this disorders does not involve 
retina nor exhibits retinal damage, and represents a clinical setting in which the tests might be 
employed. Samples of control patients were collected at the department of Ophthalmology of the 
Erasmus University Medical Center between February 2009 and April 2015. Patient demographics 
(age and gender) and known malignancies of these patients were registered.
Antigen suspension bead array
Autoantibody profiling was performed in all serum samples from patients with presumed (n)
pAIR (N=24), uveitis (N=151) and cataract (N=21).  Antigens used for the autoantibody profiling 
were selected based on potential relevance to ocular diseases according to literature and pre-
vious positive retinal immunohistochemistry staining, resulting in 188 antigens (human protein 
fragments) representing 97 unique proteins. The protein fragments were produced within the 
Human Protein Atlas and designed to represent unique parts of each target protein.42,43 Protein 
fragments were 20-150 amino acids long (median 78 aa) and produced in Escherichia coli, with 
an affinity tag consisting of six histidines and an albumin binding domain from streptococcal 
protein G (His6ABP) (Supplementary Table). Immobilization onto color-coded magnetic beads 
was conducted as described previously.39 In short, diluted antigens were covalently coupled 
to activated carboxy groups on color coded polystyrene beads (MagPlex, Luminex Corp.) by 
undirected amine coupling. In addition to the selected protein targets, one bead identity was 
used for immobilization of anti-human IgG (positive control), one for Epstein-Barr virus nuclear 
antigen 1 (second positive control), one for His6ABP (negative control, to monitor binding to the 
affinity tag) and one bead identity went through the coupling process without addition of antigen 
(second negative control, to monitor binding to bare beads). After incubation, the coupled beads 
were washed and stored in a blocking reagent before combining all bead identities to create a 
bead array in suspension. Samples were distributed across 96-well microtiter plates, together 
with triplicate aliquots of a sample pool and a buffer blank in each plate for determination of the 
intra- and inter-reproducibility. Serum samples were diluted 1:250 in assay buffer before being 
mixed with the bead array. Incubation was performed at room temperature for 2 hours followed 
by detection of the IgG reactivity by a fluorophore conjugated anti-human IgG Fab fragment and 
measured in a FlexMap3D instrument (Luminex Corp.).
Recoverin immunoblot
For validation purposes, samples that tested positive for anti-recoverin autoantibodies on the 
antigen bead array, and all samples from patients with presumed (n)pAIR, were analysed on a 
recoverin specific immunoblot (Euroimmun AG, Lubeck, Germany). Membrane strips coated with 
recombinant human recoverin were incubated with a sample buffer for 5 minutes. After aspiration 
of the sample buffer, the membrane strips were incubated with diluted serum samples for 30 
Autoantibody profiling of patients with autoimmune retinopathy
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minutes on a shaking platform. Subsequently membrane strips were washed three times, incu-
bated with secondary antibodies (enzyme conjugated anti-human IgG), washed again for three 
times and stained with a substrate solution which was capable of promoting an enzymatic colour 
reaction. To identify positive reactions, assessment of visible bands was performed relative to 
the included control. Results from the antigen suspension bead array and the recoverin specific 
immunoblot were compared. 
Immunohistochemistry of interphotoreceptor matrix proteoglycan 2 on human retina tissue
Another method for validation was performed with the antigens of interphotoreceptor matrix 
proteoglycan 2 (IMPG2). Polyclonal antibodies affinity purified against the IMPG2 antigens no. 214 
and 205 were used as antigens for immunization of rabbits to generate polyclonal antibodies for 
immunohistochemistry on normal human tissues, in order to determine retina specificity and cell 
type expression. The antibodies were applied on tissue microarrays (TMAs) containing samples 
from 45 different human tissues, including retina from two individuals. TMAs from human tissues 
were generated essentially as previously described.44 The TMAs contained 1 mm diameter forma-
lin-fixed and paraffin-embedded tissue cores from 45 different histologically normal tissue types, 
including two samples of human eye: one male 75 years and one female 54 years. All samples 
were received from the Department of Pathology, Uppsala University Hospital, Sweden, approved 
by the local Research Ethics Committee (Uppsala, Sweden, Ups 02–577). Four-micrometer sec-
tions were cut from the TMA blocks, mounted on adhesive slides and baked at 60 °C for 45 min. 
TMA slides were then deparaffinised in Neo-Clear® (Merck Millipore, Darmstadt, Germany), fol-
lowed by hydration in graded alcohols and blocking for endogenous peroxidase in 0.3 % hydrogen 
peroxide. For antigen retrieval, slides were immersed and boiled in Citrate buffer®, pH6 (Lab 
Vision, Freemont, CA) for 4 min at 125 °C and then allowed to cool to 90 °C. Automated immu-
nohistochemistry was performed essentially as previously described, using an Autostainer 480 
instrument® (Lab Vision).44 Affinity purified polyclonal antibodies towards IMPG2 (HPA008779, 
antigen number 205, diluted 1:250 and HPA015907, antigen number 214, diluted 1:2500, both 
Atlas Antibodies AB) and a dextran polymer visualization system (UltraVision LP HRP polymer®, 
Lab Vision) were incubated for 30 min each at room temperature. Slides were developed for 10 
min using Diaminobenzidine (Lab Vision) as chromogen. All incubations were followed by rinse 
in Wash buffer® (Lab Vision) for 5 min. The slides were counterstained in Mayers hematoxylin 
(Histolab) and cover slipped using Pertex® (Histolab) as mounting medium. Digital whole slide 
high-resolution images were captured with a 20× objective using an AperioScanScope XT Slide 
Scanner (Aperio Technologies, Vista, CA).
Data analysis
Continuous variables were summarized using medians and ranges, and categorical variables 
were summarized using percentages. Patient demographics were compared between diagnosis 
groups using Mann Whitney U tests for continuous data and Fisher’s exact tests for categorical 
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data. All data from the antigen suspension bead array were represented as ratios (antigen specific 
reactivity over patient background (represented by the His6ABP negative control bead)). A ratio of 
>2 was considered positive and a ratio of >25 was considered highly positive for the presence of 
ARAs. Logistic regressions with correction for age and gender were performed to analyse differ-
ences between the diagnosis groups ((n)pAIR versus uveitis and (n)pAIR versus cataract) for both 
ratio’s. In the logistic regression analyses, confidence intervals of the estimated odds ratios were 
calculated using a profile likelihood method, and the differences between groups were tested 
using a likelihood ratio test. To adjust for the multiple comparisons of the different antigens, a 
Bonferroni correction was used for the p-values of the logistic regression analyses, so that only 
p-values ≤ 0.0002 were considered statistically significant in these analyses. Intra- and inter-assay 
reproducibility was calculated with the coefficient of variation using the technical replicates within 
and between plates, based on the pooled serum samples. 
The distribution of age, gender and the most prevalent ARAs (using the cut-off values for the ratio 
of 2 and 25) were compared between the subtypes of AIR (pAIR, npAIR) using Mann Whitney U 
tests for continuous data and Fisher’s exact tests for categorical data. The number of different 
ARAs per patient in highly positive titres were counted and compared between groups using a 
linear-by-linear association chi-square test. The association between the number of ARAs and age 
was assessed using Spearman’s rank correlation coefficient. All statistical tests were two-sided 
and used a significance level of 0.05. The analyses were performed using SPSS and R.45
RESULTS
Patient characteristics
Characteristics of the patients with presumed (n)pAIR (N=24) are specified in Table 2. The median 
age of patients was 67 years, with a range of 27-86 years. The majority of the patients were 
female (17/24, 71%). Most patients had bilateral visual complaints (21/24, 88%), and photopsia, 
nyctalopia and colour vision problems were noted frequently (12/19, 63%; 11/13, 85%; 9/11, 82%). 
A malignancy was seen in 15/24 (63%) patients (indicative for pAIR: CAR or MAR), of whom 8/24 
(33%) patients had a malignancy in the past and 7/24 (29%) patients developed a malignancy 
during follow-up. The most frequently diagnosed malignancy was a lung carcinoma (6/15; 40%). 
A total of 9/24 (38%) patients did not have a malignancy and were diagnosed with presumed 
npAIR. Comparison of patient demographics (age and gender) between groups showed that 
patients with uveitis were significantly younger than patients with AIR (p<0.001). Gender did not 
differ between groups.
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Table 2. General characteristics of patients
Patient characteristics (n)pAIR (N=24) Uveitis (N=151) Cataract (N=21)
Gender (male-female) 7 (29%) - 17 (71%) 63 (42%) – 88 (58%)
p=0.271 **
10 (48%) – 11 (52%)
p=0.233 **
Age in years (median; min-max) 67; 27-86 49; 17-86
p<0.001 **
69; 48-83
p=0.339 **
Bilateral visual complaints 21/24 (88%)
Complaints of photopsia 12/19 (63%) *
Complaints of nyctalopia 11/13 (85%) *
Colour-vision problems 9/11 (82%) *
Presence of malignancy (pAIR)
Malignancy in history
Malignancy during follow-up
15/24 (63%)
8/24 (33%)
7/24 (29%)
* Data not available for all patients
** p-value of comparison with (n)pAIR patients
Abbreviations: (n)pAIR = non-paraneoplastic and paraneoplastic autoimmune retinopathy
Antigen suspension bead array: highly positive titres of ARAs (ratio > 25)
Patients with presumed (n)pAIR were characterized by the presence of a wide spectrum of ARAs 
(Figure 1 and Supplementary Figure). There was no specific ARA associated with a majority of 
patients with presumed (n)pAIR. In patients with presumed (n)pAIR, anti-recoverin autoantibodies 
were the most prevalent ARAs (12.5%). The presence of anti-recoverin autoantibodies was not 
fully specific for (n)pAIR, since high titres were also present in sporadic patients with cataract 
(4.8%; p = 0.351) or uveitis (1.3%; p = 0.061). Further, no association between the presence of 
anti-recoverin autoantibodies and a malignancy was found. High titre autoantibodies to photo-
receptor-specific nuclear receptor and retinol-binding protein 3 were more prevalent in patients 
with (n)pAIR than in patients with uveitis (p=0.015 and p=0.018, respectively; p-values were not 
significant after applying correction for multiple testing). Autoantibodies towards IMPG2 (antigen 
number 205) were prevalent with highly positive titres in two patient samples with (n)pAIR (8.3%) 
and with lower prevalence in uveitis patients (2%). The results of the most prevalent ARAs present 
in high titres (ratio > 25) in patients with presumed (n)pAIR are shown in Table 3. The ARAs (in 
highly positive titres) indicated in Table 3 were only found in patients with presumed pAIR with 
the exception of two patients with presumed npAIR (one patients with npAIR was positive for high 
titres of antibodies against progressive rod-cone degeneration protein and one patient for high 
titres of Cbp/p300-interacting transactivator 1). The prevalence of high-titre ARAs (from Table 3), 
age and gender did not significantly differ between patients with npAIR and pAIR (all p > 0.05).
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Table 3. Prevalence of antiretinal autoantibodies in paraneoplastic and non-paraneoplastic auto-
immune retinopathy, uveitis and cataract *
Ratio > 25 Ratio >2
Prevalence of ARAs (n)pAIR vs uveitis (n)pAIR vs cataract Prevalence of ARAs (n)pAIR vs uveitis (n)pAIR vs cataract
Antigen 
number
Antigen (n)
pAIR
Uveitis Cataract OR; 
2.5% - 97.5%
p-value OR; 
2.5% - 97.5%
p-value (n)pAIR Uveitis Cataract OR; 
2.5% - 97.5%
p-value OR; 
2.5% - 97.5%
p-value
225 Recoverin ** 12.5% 
(3/24)
1.3% 
(2/151)
4.8% 
(1/21)
6.3;
0.91 - 54.7
0.061 2.98; 
0.32 - 6.49
0.351 20.8%
 (5/24)
11.9% 
(18/151)
14.3% (3/21) 2.21;
0.64 - 6.87
0.199 1.30; 
0.25 - 7.63
0.753
303 Progressive 
rod-cone 
degeneration 
protein
12.5% 
(3/24)
8.6% 
(13/151)
14.3% 
(3/21)
2.01; 
0.39 - 8.21
0.370 1.21; 
0.19 - 8.23
0.837 50.0% 
(12/24)
34.4% 
(52/151)
57.1% (12/21) 1.83;
0.73 - 4.58
0.195 0.73; 
0.20 - 2.50
0.611
205 Interphoto-
receptor matrix 
proteoglycan 2
8.3% 
(2/24)
2.0% 
(3/151)
0% 
(0/21)
3.82; 
0.46 - 6.43
0.195 NA 0.062 16.7% 
(4/24)
25.2% 
(38/151)
19.0% (4/21) 0.59; 
0.16 - 1.75
0.354 1.28; 
0.244 - 6.95
0.766
207 Photoreceptor-
specific nuclear 
receptor **
8.3% 
(2/24)
0% 
(0/151)
0% 
(0/21)
NA 0.015 NA 0.062 8.3% 
(2/24)
1.3% (2/151) 0% (0/21) 5.15; 
0.55 - 49.67
0.141 NA 0.062
378 G protein-
coupled 
receptor 
kinase 7
8.3% 
(2/24)
8.6% 
(13/151)
0% 
(0/21)
1.10; 
0.16 - 4.77
0.905 NA 0.081 41.7% 
(10/24)
55.6% 
(84/151)
57.1% (12/21) 0.67; 
0.26 - 1.69
0.399 0.47; 
0.12 - 1.72
0.253
245 Serotonin 
N-acetyl-
transferase
4.2% 
(1/24)
0% 
(0/151)
0% 
(0/21)
NA 0.126 NA 0.251 12.5%
 (3/24)
0% (0/151) 4.8% (1/21) NA 0.003 3.72; 
0.39 - 84.11
0.262
296 Retinol-binding 
protein 3 **
4.2% 
(1/24)
0% 
(0/151)
0% 
(0/21)
NA 0.018 NA 0.272 4.2% 
(1/24)
2.6% (4/151) 4.8% (1/21) 2.65; 
0.12 - 22.72
0.456 0.71; 
0.03 - 19.31
0.815
335 Cbp/p300-
interacting 
transactivator 1
4.2% 
(1/24)
0.6% 
(1/151)
0% 
(0/21)
7.07; 
0.27 - 7.13
0.203 NA 0.377 16.7% 
(4/24)
6.0% (9/151) 9.5% (2/21) 6.52; 
1.43 - 28.34
0.017 1.22; 
0.17 - 10.56
0.842
239 Retinitis 
pigmentosa 
1-like 1 protein
0% 
(0/24)
0.6% 
(1/151)
0% 
(0/21)
NA 0.537 NA NA 33.3%
 (8/24)
15.2% 
(23/151)
23.8% (5/21) 3.54; 
1.23 - 10.02
0.020 1.90; 
0.47 - 8.75
0.375
325 Sodium / 
potassium 
/ calcium 
exchanger 1
0% 
(0/24)
1.3% 
(2/151)
0% 
(0/21)
NA 0.674 NA NA 25.0%
 (6/24)
17.9% 
(27/151)
4.8% (1/21) 1.41; 
0.46 - 3.93
0.530 8.67; 
1.13 - 188.88
0.037
270 Pigment 
epithelium-
derived factor
0% 
(0/24)
0% 
(0/151)
0% 
(0/21)
NA NA NA NA 16.7% 
(4/24)
10.6% 
(16/151)
0% (0/21) 1.64; 
0.41 - 5.48
0.456 NA 0.030
* Calculation of OR was not possible in case of an ARA prevalence of 0 in either group
** ARAs which have been described also in previous studies as autoantibodies associated with (n)pAIR
Abbreviations: (n)pAIR = non-paraneoplastic and paraneoplastic autoimmune retinopathy, ARAs = antiretinal 
antibodies, OR = odds ratio, NA = not available
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Table 3. Prevalence of antiretinal autoantibodies in paraneoplastic and non-paraneoplastic auto-
immune retinopathy, uveitis and cataract *
Ratio > 25 Ratio >2
Prevalence of ARAs (n)pAIR vs uveitis (n)pAIR vs cataract Prevalence of ARAs (n)pAIR vs uveitis (n)pAIR vs cataract
Antigen 
number
Antigen (n)
pAIR
Uveitis Cataract OR; 
2.5% - 97.5%
p-value OR; 
2.5% - 97.5%
p-value (n)pAIR Uveitis Cataract OR; 
2.5% - 97.5%
p-value OR; 
2.5% - 97.5%
p-value
225 Recoverin ** 12.5% 
(3/24)
1.3% 
(2/151)
4.8% 
(1/21)
6.3;
0.91 - 54.7
0.061 2.98; 
0.32 - 6.49
0.351 20.8%
 (5/24)
11.9% 
(18/151)
14.3% (3/21) 2.21;
0.64 - 6.87
0.199 1.30; 
0.25 - 7.63
0.753
303 Progressive 
rod-cone 
degeneration 
protein
12.5% 
(3/24)
8.6% 
(13/151)
14.3% 
(3/21)
2.01; 
0.39 - 8.21
0.370 1.21; 
0.19 - 8.23
0.837 50.0% 
(12/24)
34.4% 
(52/151)
57.1% (12/21) 1.83;
0.73 - 4.58
0.195 0.73; 
0.20 - 2.50
0.611
205 Interphoto-
receptor matrix 
proteoglycan 2
8.3% 
(2/24)
2.0% 
(3/151)
0% 
(0/21)
3.82; 
0.46 - 6.43
0.195 NA 0.062 16.7% 
(4/24)
25.2% 
(38/151)
19.0% (4/21) 0.59; 
0.16 - 1.75
0.354 1.28; 
0.244 - 6.95
0.766
207 Photoreceptor-
specific nuclear 
receptor **
8.3% 
(2/24)
0% 
(0/151)
0% 
(0/21)
NA 0.015 NA 0.062 8.3% 
(2/24)
1.3% (2/151) 0% (0/21) 5.15; 
0.55 - 49.67
0.141 NA 0.062
378 G protein-
coupled 
receptor 
kinase 7
8.3% 
(2/24)
8.6% 
(13/151)
0% 
(0/21)
1.10; 
0.16 - 4.77
0.905 NA 0.081 41.7% 
(10/24)
55.6% 
(84/151)
57.1% (12/21) 0.67; 
0.26 - 1.69
0.399 0.47; 
0.12 - 1.72
0.253
245 Serotonin 
N-acetyl-
transferase
4.2% 
(1/24)
0% 
(0/151)
0% 
(0/21)
NA 0.126 NA 0.251 12.5%
 (3/24)
0% (0/151) 4.8% (1/21) NA 0.003 3.72; 
0.39 - 84.11
0.262
296 Retinol-binding 
protein 3 **
4.2% 
(1/24)
0% 
(0/151)
0% 
(0/21)
NA 0.018 NA 0.272 4.2% 
(1/24)
2.6% (4/151) 4.8% (1/21) 2.65; 
0.12 - 22.72
0.456 0.71; 
0.03 - 19.31
0.815
335 Cbp/p300-
interacting 
transactivator 1
4.2% 
(1/24)
0.6% 
(1/151)
0% 
(0/21)
7.07; 
0.27 - 7.13
0.203 NA 0.377 16.7% 
(4/24)
6.0% (9/151) 9.5% (2/21) 6.52; 
1.43 - 28.34
0.017 1.22; 
0.17 - 10.56
0.842
239 Retinitis 
pigmentosa 
1-like 1 protein
0% 
(0/24)
0.6% 
(1/151)
0% 
(0/21)
NA 0.537 NA NA 33.3%
 (8/24)
15.2% 
(23/151)
23.8% (5/21) 3.54; 
1.23 - 10.02
0.020 1.90; 
0.47 - 8.75
0.375
325 Sodium / 
potassium 
/ calcium 
exchanger 1
0% 
(0/24)
1.3% 
(2/151)
0% 
(0/21)
NA 0.674 NA NA 25.0%
 (6/24)
17.9% 
(27/151)
4.8% (1/21) 1.41; 
0.46 - 3.93
0.530 8.67; 
1.13 - 188.88
0.037
270 Pigment 
epithelium-
derived factor
0% 
(0/24)
0% 
(0/151)
0% 
(0/21)
NA NA NA NA 16.7% 
(4/24)
10.6% 
(16/151)
0% (0/21) 1.64; 
0.41 - 5.48
0.456 NA 0.030
* Calculation of OR was not possible in case of an ARA prevalence of 0 in either group
** ARAs which have been described also in previous studies as autoantibodies associated with (n)pAIR
Abbreviations: (n)pAIR = non-paraneoplastic and paraneoplastic autoimmune retinopathy, ARAs = antiretinal 
antibodies, OR = odds ratio, NA = not available
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Figure 1. Spectrum of antiretinal autoantibodies in patients suspected of paraneoplastic 
and non-paraneoplastic autoimmune retinopathy
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The number of highly positive ARAs present in individual patients is shown in Table 4. A higher 
number of different ARAs per patient was most prevalent in patients with  presumed (n)pAIR and 
least present in patients with cataract. Three or more different ARAs were present in 29% of the 
patients with presumed (n)pAIR, compared to 24% of the patients with uveitis and 14% of the 
patients with cataract. The number of highly positive ARAs did not show any statistical differences 
between presumed (n)pAIR and uveitis (p=0.457) or cataract (p=0.385). Furthermore, there was 
no correlation between the number of ARAs and age (p=0.926).
Table 4. Number of highly positive antiretinal autoantibodies per patient
No. of highly positive ARAs 
(ratio > 25)
(n)pAIR (N=24) Uveitis (N=151) Cataract (N=21)
0 37.5% (9/24) 45.7% (69/151) 52.4% (11/21)
1 33.3% (8/24) 29.8% (45/151) 33.3% (7/21)
2 12.5% (3/24) 13.2% (20/151) 4.8% (1/21)
3 12.5% (3/24) 7.9% (12/151) 4.8% (1/21)
4 4.2% (1/24) 2.6% (4/151) 0% (0/21)
5 0% (0/24) 0.6% (1/151) 4.8% (1/21)
Abbreviations: (n)pAIR = non-paraneoplastic and paraneoplastic autoimmune retinopathy,  
ARAs = antiretinal antibodies
Antigen suspension bead array: positive titres of ARAs (ratio > 2)
The samples of patients with presumed (n)pAIR as well as both control cohorts exhibited a broad 
spectrum of positive ARAs (Figure 1 and Supplementary Figure). None of the ARAs were specific 
for presumed (n)pAIR only. Autoantibodies directed against serotonin N-acetyltransferase, cbp/
p300-interacting transactivator 1 and retinitis pigmentosa 1-like 1 protein were more prevalent 
in patients with presumed (n)pAIR than in patients with uveitis (p=0.003, p=0.017 and p=0.020; 
p-values were not significant after applying correction for multiple testing). When comparing the 
serum of patients with presumed (n)pAIR to the serum of patients with cataract, in presumed 
(n)pAIR autoantibodies directed against sodium/potassium/calcium exchanger 1 and pigment 
epithelium-derived factor were more often present (p=0.037 and p=0.030). The presence of most 
ARAs indicated in Table 3 was predominantly found in patients with presumed pAIR (CAR or MAR), 
but (often less frequently) also in patients with presumed npAIR. The prevalence of low-titre ARAs 
(from Table 3) was not significantly different between patients with npAIR and pAIR (p > 0.05). 
The coefficient of variation based on replicates of the serum pools within and across plates (indi-
cating the intra- and inter-reproducibility) ranged between 5 and 23% (median = 13%) for all 188 
antigens. ARAs were present in all patients with presumed (n)pAIR and consequently all fulfilled 
the recent criteria for the diagnosis of (n)pAIR.9
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Figure 2. Screening and validation for interphotoreceptor matrix proteoglycan 2
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(Left panel, A-D) The path from antigen design and generation to autoantibody screening in serum and 
secondly protein expression in retinal tissue. (A) Two antigens representing non-overlapping regions 
with either an extracellular or cytoplasmic location of IMPG2 were selected for recombinant protein 
expression (antigen 214 and 205 respectively, amino acids highlighted in black). (B) Detection of auto-
antibody reactivity with IMPG2 antigens using the antigen suspension bead array. Ratios > 25 are 
displayed per disease group for antigen 214 (left) and 205 (right). (C) The antigens were further used 
as antigens for immunization of rabbits to generate polyclonal antibodies. (D) Antibodies HPA015907 
and HPA008779, affinity purified against antigens 214 and 205, were applied for immunohistochemical 
staining of human retina tissue. Both antibodies specifically showed cytoplasmic staining of cells in the 
photoreceptor layer in the retina (D, right). The antibody targeting the CP region of IMPG2 (HPA008779) 
stained only the inner segment of the photoreceptor layer, while HPA0015907 stained both inner and 
outer segment. 
Abbrevations: EC; extracellular, CP; cytoplasmic, IMPG2; Interphotoreceptor matrix proteoglycan 2. 
Color annotation for central panel: black; Human Protein Atlas antigens and antibodies, red; human 
sample serum and tissue and grey; assay consumables suspension bead array and labelled detection 
antibodies.
Recoverin immunoblot
Anti-recoverin autoantibodies on immunoblot were positive in 3 out of 24 (12.5%) patients with (n)
pAIR. These positive results were in accordance with the positive high titre results on the antigen 
suspension bead array.  Occasional discrepancy between the recoverin immunoblot and the 
antigen suspension bead array (using a high cut-off value, ratio > 25) was found in the controls 
(3 patients positive in antigen suspension bead array while negative on recoverin immunoblot).
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IMPG2 expression in human retina tissue
The antigens towards IMPG2 (antigen number 214 and 205) represent two non-overlapping 
domains of IMPG2, located either extracellularly or in the cytoplasm (Figure 2A).46 Antibodies 
directed against antigens 214 and 205, showed staining exclusively in cells in the photoreceptor 
layer of the retina. The antibodies targeting the cytoplasmic region of IMPG2 (against antigen 
number 205) stained only the inner segment of the photoreceptor layer, while HPA0015907 
(antibodies against antigen number 214) stained both inner and outer segment (Figure 2D).
DISCUSSION
Our study shows that patients with (n)pAIR are characterized by the presence of a broad spectrum 
of various ARAs. We identified ARAs that have already been described in previous studies, such as 
anti-recoverin autoantibodies, but also identified new retinal targets. Our findings illustrate that 
serum ARAs are not only present in patients with (n)pAIR, but also in patients with cataract and 
uveitis. Though some ARAs appeared to be specific for (n)pAIR, their prevalence and consequently 
their sensitivity as markers for (n)pAIR were low. This autoantibody screening using 188 antigen 
provides insight into the autoimmune repertoire of patients with (n)pAIR and a base for further 
validation with independent methods for protein analysis and independent sample cohorts.
A gold standard for the determination of ARAs is currently lacking.11 Different techniques are being 
used, hampering the comparison of results from various laboratories.47 Moreover, the mere pres-
ence of ARAs does not provide any information on the role of this specific antibody. In addition, 
information on clinical relevance of the specific ARAs and their pathological titres are lacking. A 
combination of different ARAs was observed in some cases and therefore their individual effects 
on retinal tissue could not be distinguished.
In our study, we performed statistical analyses using different cut-off levels. By using a high cut-off 
value, a ratio > 25, false positive results were minimized and retinal targets with a high specificity 
for (n)pAIR were found. The low cut-off value, a ratio of >2 (indicating ARAs with at least twice the 
reactivity of the negative control), was used for a more sensitive approach, limiting the exclusion 
of possibly relevant ARA targets with a lower titre. However, with both cut-off values, no ARAs 
were found eligible for diagnostic purposes. Some ARAs were specific for (n)pAIR, but had low 
prevalence while others were more frequently identified but lacked specificity.
In concordance with previous findings, positive results of serum anti-recoverin autoantibodies 
were not only observed in patients with presumed (n)pAIR, but also in patients with uveitis and 
cataract. Furthermore, no association between the presence of autoantibodies directed against 
recoverin and the presence of a malignancy was found. A discrepancy between the antigen 
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suspension bead array results for anti-recoverin and the anti-recoverin immunoblot was found 
in three control patients (one with cataract and two with uveitis). The difference in results could 
be explained by the different techniques used for determination of ARAs imposing differences in 
analytical performance. Possibly, the number and/or availability of recoverin antigenic epitopes 
differed between the antigen suspension bead array and the immunoblot technique. The protein 
fragments we used in this study to screen for autoantibody reactivity in serum were designed to 
represent unique parts of each target protein. The binding of the autoantibodies towards their 
target may be influenced by the protein folding of antigens and may differ in comparison to full-
length protein arrays or peptide arrays. Both linear and conformational epitopes, recognized by 
some ARAs, might be missed for some proteins, preventing recognition by certain autoantibodies.
The identification of new ARAs in (n)pAIR is in line with findings from previous studies using 
Western blot analysis for the determination of ARAs.11,48 Although many ARAs have already been 
identified, several studies have described so far unknown retinal autoantibodies presumably 
damaging retinal tissue and causing loss of vision.14 In our study, we were able to identify novel 
ARAs possibly associated with (n)pAIR, e.g. serotonin N-acetyltransferase. Serotonin N-acetyl-
transferase plays a role in melatonin synthesis and is expressed only in the pineal gland and 
retina.49 Autoantibodies directed against serotonin N-acetyltransferase have to our knowledge 
not been described in (n)pAIR so far. Another novel, although unspecific ARA found in this study 
is anti-G protein-coupled receptor kinase 7. Interestingly, it has been suggested previously that G 
protein-coupled receptor kinases in cancer cell lines are functionally associated with recoverin.50 
Moreover, protein IMPG2 was identified as an ARA and reactivity towards the cytoplasmic pro-
tein region (antigen number 205) was associated with (n)pAIR. Autoantibody reactivity towards a 
second antigen representing an extracellular region of IMPG2 was in contrast present in serum 
from uveitis patients. In short, ARAs targeting IMPG2 were identified using antigen arrays in serum 
samples and a retina specific protein expression of IMPG2 identified using immunohistochemistry 
in healthy human tissue.
Our present study focused on the autoantibodies prevalent in serum, which reflects systemic 
production and is probably not influenced by potential (additional) production or accumulation of 
specific autoantibodies within the eye. Analysis of local, intraocular retinal autoantibodies might 
show an entirely different pattern and may differ in clinical importance compared to retinal auto-
antibodies found in the peripheral circulation. The importance of locally produced autoantibodies 
has already been shown in cerebrospinal fluid for the central nervous system. In addition, it is 
unknown which autoantibodies penetrate from the circulation, through the blood retina bar-
rier, into the retina and cause a local inflammation. Further research addressing the intraocular 
presence of specific retinal autoantibodies might elucidate the clinically relevant autoimmune 
processes directed against the retinal tissue in (n)pAIR. 
Autoantibody profiling of patients with autoimmune retinopathy
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A gold standard for the definitive diagnosis of (n)pAIR is currently lacking.  Also in this study, the 
diagnosis of presumed (n)pAIR was based on clinical symptoms. To compensate for this inaccu-
racy, we used strict inclusion criteria and selected a uniform cohort of patients with unexplained 
visual loss, visual field defects and decreased or absent ERG while other diagnostic possibilities 
leading to this configuration of clinical characteristics were (so far as possible) excluded. The 
presence of ARAs was found in all our patients with presumed (n)pAIR and therefore all fulfilled 
the criteria for the diagnosis of (n)pAIR.9 
Although the mere presence of ARAs supports the diagnosis of (n)pAIR, it has been stated that 
there are no specific ARAs which would be exclusive for (n)pAIR and none of the ARAs were iden-
tified to be of higher diagnostic value than other ARAs.4,9,14 Our results are in full agreement with 
this statement. Proof for the definitive diagnosis of (n)pAIR is still missing and even the presence 
of ARAs is not specific for (n)pAIR, which has been illustrated by the finding of ARAs in control 
groups and healthy individuals.8,51,52 
In conclusion, our study identified a heterogenous reactivity pattern of ARAs in serum of patients 
with (n)pAIR, although the presence of ARAs was not discriminatory between (n)pAIR, cataract 
and uveitis and exhibited a low sensitivity. Therefore, the diagnosis of (n)pAIR cannot be based on 
the mere presence of serum ARAs and such presence thus warrants careful interpretation. The 
determination of ARAs in intraocular fluid might provide more insight into the pathogenesis of (n)
pAIR and might indicate more sensitive and specific diagnostic tools. Therefore, future research 
on the prevalence of ARAs in ocular fluid represents an important next step. 
 
SUPPLEMENTARY DATA
Supplementary Table. Amino acid sequence and uniprot ID of ocular antigens used for the auto-
antibody profiling
https://doi.org/10.1371/journal.pone.0167909.s001
Supplementary Figure. Spectrum of antiretinal autoantibodies in patients suspected of parane-
oplastic and non-paraneoplastic autoimmune retinopathy, uveitis and cataract 
https://doi.org/10.1371/journal.pone.0167909.s002
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SAMENVATTING
Achtergrond: Auto-immuunretinopathie (AIR) is een zeldzaam ziektebeeld dat onder andere 
als een paraneoplastisch syndroom kan voorkomen. AIR is geassocieerd met de aanwezigheid 
van anti-retinale antistoffen. Er wordt verondersteld dat deze antistoffen schade aan de retina 
veroorzaken, met progressieve visusdaling als gevolg.
Casus: Een 74-jarige man kwam bij de oogarts met ernstige, progressieve visusdaling, zonder 
noemenswaardige afwijkingen bij het standaard oogheelkundig onderzoek. Het elektroretinogram 
was kenmerkend voor functieverlies van de fotoreceptoren. In het serum werden anti-retinale 
antistoffen tegen recoverine aangetoond. Na doorverwijzing naar de internist vanwege de ver-
denking op een paraneoplastische AIR, werd een longcarcinoom gediagnostiseerd. De diagnose 
‘carcinoom-geassocieerde paraneoplastische AIR’ werd hiermee bevestigd.
Conclusie: De verdenking op een paraneoplastische AIR is hoog bij een onbegrepen visusdaling, 
ook bij patiënten zonder bekende maligniteit. Recent zijn in Nederland laboratoriumtechnieken 
geïmplementeerd voor de bepaling van de anti-retinale antistof tegen recoverine, waardoor het 
stellen van de diagnose ‘AIR’ beter mogelijk is.
Ernstige visusdaling door auto-immuun retinopathie
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ABSTRACT
Background: Autoimmune retinopathy (AIR) is a rare disorder which may present as a paraneo-
plastic syndrome. AIR is associated with the presence of antiretinal antibodies. These antibodies 
are assumed to cause damage to the retina, resulting in progressive vision loss.
Case description: A 74-year-old man visited the ophthalmologist with a serious, progressive loss 
of vision, without any noteworthy abnormalities at routine ophthalmological examination. The 
electroretinogram was characteristic of loss of photoreceptor function. Anti-retinal antibodies 
against recoverin were detected in serum. After referral to an internist on account of a suspected 
diagnosis of paraneoplastic AIR, the patient was diagnosed with a lung carcinoma, confirming the 
diagnosis of cancer-associated paraneoplastic AIR.
Conclusion: An unexplained loss of vision is highly suggestive of paraneoplastic AIR, even in 
patients without a known malignancy. Laboratory techniques for the detection of the antiretinal 
antibody against recoverin have recently been implemented in the Netherlands, facilitating the 
diagnosis of AIR.
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INTRODUCTIE
Auto-immuunretinopathie (AIR) omvat een zeldzame groep immuungemedieerde ziektebeelden 
die blijvende visusdaling tot gevolg kunnen hebben. AIR is geassocieerd met de aanwezigheid 
van anti-retinale antistoffen. Er wordt verondersteld dat deze antistoffen betrokken zijn bij de 
pathogenese van AIR. AIR kan als een paraneoplastische aandoening voorkomen, waarbij onder-
scheid wordt gemaakt tussen carcinoom-geassocieerde AIR en melanoom-geassocieerde AIR. 
Ook bestaat er non-paraneoplastische AIR; deze diagnose wordt per exclusionem gesteld.1-4 In dit 
artikel bespreken wij een man met ernstige visusdaling als gevolg van carcinoom-geassocieerde 
AIR bij een longcarcinoom, met anti-retinale antistoffen in zijn serum. 
ZIEKTEGESCHIEDENIS
Patiënt A, een 74-jarige blanke man, kwam bij de oogarts in verband met ernstige, progressieve, 
bilaterale visusdaling sinds enkele weken. Tevens had hij last van nachtblindheid en gekleurde 
lichtsensaties. In de voorgeschiedenis had patiënt goed gereguleerde diabetes mellitus type 
2 en primair openkamerhoekglaucoom, waarvoor hij adequaat werd behandeld. De visus van 
het rechter oog was 1/300 (handbewegingen op 1 meter afstand) en van het linker oog 0,2. De 
oogdrukken waren normaal en aan het voorsegment werden geen afwijkingen geconstateerd. In 
fundo was de papil rechts nauwelijks afwijkend en links was de papil glaucomateus geëxcaveerd; 
de arteriën waren vernauwd, maar er was geen diabetische retinopathie. In de maculae waren 
enkele drusen zichtbaar. Dit is op oudere leeftijd niet ongebruikelijk (Figuur 1).
Figuur 1. Fundusfoto van patiënt A
De papil rechts is nauwelijks afwijkend en de papil links is ruimer geëxcaveerd. De arteriën zijn nauw 
en er zijn enkele drusen in de maculae zichtbaar.
Ernstige visusdaling door auto-immuun retinopathie
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Patiënt werd opgenomen op de afdeling Neurologie voor aanvullend onderzoek. Differentiaal 
diagnostisch dachten wij aan een intracranieel proces of een vasculaire oorzaak. Op de CT- en 
MRI-scan van de hersenen en met duplexechografie van de carotiden zagen wij echter geen 
noemenswaardige afwijkingen. Het laboratoriumonderzoek liet evenmin afwijkingen zien die 
pasten bij een infectie. Beeldvorming van het netvlies middels optische coherentietomografie 
toonde beschadiging van de fotoreceptoren. Het fluorescentie-angiogram gaf geen aanwijzingen 
voor een neuritis optica of een opticusinfarct. Op het elektroretinogram (ERG), waarbij de functie 
van de fotoreceptoren van de retina wordt gemeten, zagen wij echter sterk verlaagde fotopische 
en scotopische responsies; dit is een maat voor de functie van respectievelijk de kegeltjes en 
staafjes (Figuur 2).  Op grond van deze bevinding en de klinische symptomen dachten wij aan AIR.
Figuur 2. Elektroretinogram (ERG) van het linker en het rechteroog van patiënt A
Hierbij wordt de elektrische activiteit van de retina geregistreerd als reactie op een stimulus (licht). De 
hoogte van de amplitude geeft de mate van respons weer. Zowel de fotopische (functie van de kegels) 
als de scotopische (functie van de staven) responsies zijn fors verlaagd in beide ogen.
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Het serologisch onderzoek naar anti-retinale antistoffen bleek positief voor antistoffen tegen 
recoverine. Hiermee werd de diagnose ‘AIR’ bevestigd (Figuur 3). Patiënt kreeg prednison oraal, 
80 mg/dag gedurende 3 dagen en vervolgens 45 mg/dag, om de visus te verbeteren. Deze behan-
deling had geen resultaat. Daarnaast werd patiënt door de oogarts verwezen naar de internist 
voor onderzoek naar een eventuele onderliggende maligniteit. De internist stelde vast dat patiënt 
een grootcellig neuro-endocrien carcinoom in stadium IIIA had. Hij kreeg chemotherapie en 
radiotherapie, waarop de tumor sterk in grootte afnam, maar dit leidde niet tot een verbetering 
van zijn visus. Op de CT-scan die 7 maanden na het begin van de therapie ter controle werd 
gemaakt, was slechts een resttumor zichtbaar. Er waren geen aanwijzingen voor metastases. 
Vanwege de blijvende ernstige visusdaling werden patiënt visuele hulpmiddelen en begeleiding 
aangeboden.  Patiënt woonde 6 maanden na het stellen van de diagnose longcarcinoom thuis, 
in redelijk goede conditie.
Figuur 3. Recoverine auto-antistoffen: immunoblot en immunofluorescentie
A.
B.
positieve controle
negatieve controle
patiënt A
Sample Label Controle Recoverine
(A) De immunoblot toont een sterke reactie van het serum van de patiënt op de test strip welke 
met het antigeen recoverine is gecoat. (B) Bij (indirecte) immunofluorescentie op een coupe van de 
retina (primaat) is bij het serum van de patient in het groen (FITC) een sterke fluorescentie te zien van 
gedeeltes van de fotoreceptoren en een gedeelte van de buitenste plexiforme laag, waarin in beide 
gevallen recoverine aanwezig is. De blauwe aankleuringen (DAPI) zijn de celkernen in de verschillende 
lagen van de retina.
Ernstige visusdaling door auto-immuun retinopathie
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BESCHOUWING
AIR kenmerkt zich door bilaterale, progressieve visusdaling die vaak gepaard gaat met lichtflitsen 
en andere visuele sensaties, gezichtsvelddefecten, nachtblindheid, kleurzienstoornissen en para-
centrale of centrale scotomen.1-6 Bij fundoscopie worden meestal geen of geringe afwijkingen 
gevonden; sommige patiënten tonen een bleke papil en dunne retinale vaten. Het ziektebeeld is 
bilateraal aanwezig, maar kan zich asymmetrisch presenteren.
Volgens de huidige hypothese wordt carcinoom-geassocieerde AIR  veroorzaakt door immu-
nologische kruisreactiviteit tussen tumorantigenen en retinale antigenen.1-5 De aanwezigheid 
van circulerende anti-retinale antistoffen ondersteunt de diagnose ‘AIR’. Sommige anti-retinale 
antistoffen kunnen ook voorkomen bij gezonde individuen, zij het in lage titer.1-5,7 Verder zijn er 
patiënten met AIR zonder aantoonbare retinale auto-antistoffen. Van het gehele spectrum van 
verschillende anti-retinale antistoffen zijn de bepalingen van anti-recoverine en anti-enolase het 
meest gebruikelijk voor het stellen van de diagnose AIR.4
Visusklachten als paraneoplastisch verschijnsel
Visusklachten zijn meestal het eerste symptoom bij patiënten met carcinoom-geassocieerde 
AIR.3-5 Pas nadat de verdenking op carcinoom-geassocieerde AIR is ontstaan, wordt de patiënt 
naar de internist doorverwezen en een carcinoom ontdekt. De latentietijd tussen carcinoom-ge-
associeerde AIR en de diagnose van een carcinoom varieert van weken tot jaren.1,3-5 Bij patiënten 
met melanoom-geassocieerde AIR zijn de visusklachten met fotopsieën vaak het eerste teken 
van metastasering van een reeds bekend melanoom.1,3-5 Onze patiënt werd in enkele weken zo 
goed als blind. Gezien zijn ernstige klachten, zonder duidelijke afwijkingen bij fundoscopie of 
aanwijzingen voor andere oorzaken, was de verdenking op AIR hoog. Een afwijkend ERG en de 
aanwezigheid van anti-retinale antistoffen ondersteunden deze diagnose.
AIR wordt meestal gezien als paraneoplastisch syndroom bij diverse soorten carcinomen. Het is 
daarom belangrijk verder onderzoek te verrichten naar een mogelijke maligniteit. Onze patiënt 
had een longcarcinoom, een van de typen carcinomen die gepaard gaan met paraneoplastische 
AIR. Andere carcinomen die met carcinoom-geassocieerde AIR kunnen voorkomen, zijn gynaeco-
logische en hematologische maligniteiten, long-, mamma-, prostaat-, en coloncarcinoom.1,3-5 De 
behandeling bestaat uit reductie van de tumorgrootte door middel van radiotherapie, chemo-
therapie of chirurgie.1-3 Ook immunomodulatoren zouden een positief effect kunnen hebben op 
de visus.8 Door de beperkte behandelingsmogelijkheden en de blijvende schade aan de retina is 
de prognose voor de visus vaak slecht.
Het ERG is cruciaal voor de diagnostiek naar AIR, maar de diagnostiek blijft lastig. Tot voor kort 
was het niet mogelijk om anti-retinale antistoffen in Nederland te laten bepalen. Op de afdeling 
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Immunologie van het Erasmus MC in Rotterdam is recent de diagnostiek naar de anti-retinale 
antistof tegen recoverine geïmplementeerd; deze methode bestaat uit indirecte immunofluores-
centie en immunoblot. Tot op heden is het alleen in Duitsland mogelijk anti-retinale antistoffen 
tegen enolase te bepalen; bepalingen van andere antistoffen worden alleen in het kader van 
onderzoek verricht. In de nabije toekomst verwacht men meerdere anti-retinale antistoffen te 
kunnen bepalen, waaronder antistoffen tegen enolase, transducine en bipolaire cellen. Deze 
diagnostiek, die ook met ELISA kan worden uitgevoerd, zal naar verwachting voor routinebepa-
lingen ter beschikking komen.
CONCLUSIE
Auto-immuunretinopathie is een zeldzame, snel progressieve oogaandoening waarbij anti-reti-
nale antistoffen voorkomen die vermoedelijk destructie van de retina veroorzaken, met blijvende 
visusdaling als gevolg. De verdenking op paraneoplastische AIR is hoog bij een onbegrepen visus-
daling bij patiënten met of zonder een maligniteit. Omgekeerd dient bij patiënten met AIR of de 
verdenking daarop onderzoek naar een mogelijke maligniteit verricht te worden. De anti-retinale 
antistof tegen recoverine kan sinds kort bepaald worden in het Erasmus MC, ter ondersteuning 
van de diagnose ‘AIR’. Een visusdaling door AIR is vaak ernstig en blijvend en behandeling met 
immunosuppressiva is niet altijd toereikend. Mogelijk bieden nieuwe behandelingen die de vor-
ming van antistoffen kunnen beïnvloeden, zoals rituximab, meer mogelijkheden in de toekomst.
Ernstige visusdaling door auto-immuun retinopathie
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CHAPTER 7
ABSTRACT
Purpose: To investigate the possible role of autoimmune reactions directed against retinal tissue 
in central serous chorioretinopathy (CSC), by analyzing the presence of serum antiretinal anti-
bodies (ARAs) and establishing their clinical relevance.
Methods: Sixty-three CSC patients were included and clinical characteristics were collected. 
Serum samples of all CSC patients, 101 uveitis patients, and 60 healthy donors were analysed 
for the presence of ARAs by indirect immunofluorescence. Furthermore, all CSC serum samples 
were analysed on Western blot. Correlations between laboratory findings and clinical features 
of CSC were determined by logistic regression.
Results: ARAs were present in 54% of the CSC patients, in 46% of uveitis patients (p=0.153), and in 
17% of healthy controls (p<0.001). The majority of ARAs in CSC were directed against photorecep-
tors (27%), which occurred significantly more often compared to uveitis patients (15%, p=0.039) 
and to healthy controls (5%, p=0.003). No associations between clinical CSC characteristics and 
the presence of ARAs were found. 
Conclusion: Serum ARAs are present in more than half of the CSC patients, and especially ARAs 
directed against photoreceptors were detected more frequently compared to both healthy 
controls and uveitis patients. Further research is warranted to unravel the role of ARAs in the 
pathogenesis of CSC.
Antiretinal antibodies in central serous chorioretinopathy
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INTRODUCTION
Central serous chorioretinopathy (CSC) is a specific and relatively common early-onset chorio-
retinal disease that primarily affects the macula. In CSC, a subretinal fluid (SRF) leakage through 
a dysfunctional retinal pigment epithelium (RPE) leads to detachment of the neuroretina.1-3 A 
prolonged neuroretinal detachment in the macula causes permanent central visual loss due to 
photoreceptor atrophy.1,2 Such a loss of visual acuity, sometimes associated with image distor-
tion and loss of colour and contrast vision, may have a high impact on a patient’s personal and 
professional life. Early diagnosis and treatment is desirable to try to improve the visual outcome 
and quality of life.1,3-12
The exact pathogenesis of CSC is currently obscure; presumably CSC occurs due to dysfunction of 
the RPE with hyperpermeability, swelling, and leakage of the underlying choroid.3,13 Moreover, the 
optimal treatment for CSC is unknown.14 CSC is up to six times more common in men (estimated 
mean annual age-adjusted incidence: 9.9 per 100,000) compared to women (estimated incidence: 
1.7 per 100,000).15 CSC is associated with the use of steroid containing medication, with odds ratios 
up to 37.1, as well as with endogenous hypercortisolism.16-19 Familial occurrence of CSC has been 
described and recent studies have found evidence of genetic associations in CSC patients, including 
genetic polymorphrisms in the CFH gene, the ARMS2 gene, the C4b gene, and the CD5 gene.20-27
Although little is known about the exact cause of CSC, a role of the immune system via the 
complement system has been suggested based on associations found in complement-related 
genes. Recent evidence suggests a role for antiretinal antibodies (ARAs) in uveitis and age-related 
macular degeneration.28-31 A systematic study on presence and the possible role of ARAs in CSC 
is currently lacking. 
We hypothesize that damage to the RPE outer blood-retinal barrier in CSC may result in a sec-
ondary formation of ARAs, which may affect the clinical course of CSC. In this study, we set out 
to investigate the presence of serum ARAs in CSC patients and to analyse a possible correlation 
of ARAs with the clinical characteristics of CSC.
METHODS
Patient and data selection
In this study, we included 63 Caucasian patients with chronic CSC who visited the outpatient 
clinic of the Department of Ophthalmology of the Leiden University Medical Center, Leiden, 
the Netherlands. The diagnosis of chronic CSC was based on ophthalmic examination and mul-
timodal imaging, including fundoscopy, optical coherence tomography (OCT) using either the 
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spectral-domain OCT or the Cirrus OCT device, fundus autofluorescence, fluorescein angiography 
(FA), and indocyanine green angiography. The diagnosis of chronic CSC was based on the pres-
ence of all of the following criteria: serous SRF on OCT, ≥1 area of multifocal diffuse leakage or 
irregular RPE window defects on FA, and corresponding hyperfluorescent areas on indocyanine 
green angiography. Patients diagnosed with acute CSC were excluded from this study, since it is 
currently unclear if acute CSC and chronic CSC represent a continuum or are separate disease 
entities. Patients with evidence of other retinal diagnoses, choroidal neovascularisation, and/or 
polypoidal choroidal vasculopathy were also excluded. Clinical data of CSC patients were collected 
from medical data files and included patient demographics (age, gender, and (family) history) and 
ocular characteristics comprising stage, duration, activity and laterality of CSC, use of steroids 
or immunosuppressive medications, presence of intraretinal edema, treatment for CSC, and 
central retinal thickness (distance from the outer part of the ellipsoid zone to the inner part of 
the internal limiting membrane; CRT). The CRT of the affected eye was selected; if both eyes were 
affected the right eye was included. Diffuse CSC was characterized by the presence of >5 disc 
areas of hyperfluorescent RPE changes or leakage on FA. Serum samples of 101 patients with 
uveitis (intermediate uveitis, posterior uveitis or panuveitis) were used as disease controls, since 
a higher prevalence of ARAs in serum in this cohort has been described previously.30  Serum of 
60 blood bank donors (gender and age unknown) was used as (presumed) healthy controls. The 
study adhered to the tenets of the Declaration of Helsinki. Approval of the ethics committee and 
institutional review board was obtained.
Detection of ARAs using indirect immunofluorescence (IIF)
Initial screening of sera for ARAs was performed as described previously.30 In short, cryosections 
of primate retinal tissue generated by Euroimmun (Lubeck, Germany) were left unfixed and incu-
bated with 1:100 diluted serum for 30 minutes at room temperature. Sections were washed in 
stagnant phosphate-buffered saline (PBS) and incubated with goat-anti-human IgG conjugated 
with fluorescein isothiocyanate (FITC) for 30 minutes at room temperature. Thereafter, sections 
were washed in stagnant PBS and embedded. The positive control consisted of retinal tissue 
incubated with 1:100 diluted serum of an antinuclear antibody (ANA) positive patient; for the 
negative controls we used incubation with PBS and 1:100 diluted serum of a healthy control.
Detection of ANA using IIF
All sera showing staining of the retinal nuclear layers (outer/inner nuclear layer, ganglion cell layer) 
on IIF were subsequently analysed for the presence of ANAs. ANA detection was performed by 
IIF using HEp-2 cells (Inova, San Diego, California, United States), as described before.30 In sum-
mary, HEp-2 cells were incubated with 1:80 diluted serum for 30 minutes at room temperature. 
After washing in PBS with continuous stirring, slides were incubated for another 30 minutes with 
FITC-conjugated goat anti-human IgG with propidium iodide (Inova, San Diego, California, United 
States). Subsequently, slides were washed and embedded.
Antiretinal antibodies in central serous chorioretinopathy
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Evaluation of IIF results
All slides were evaluated with a fluorescence microscope (20x magnification) by two independent 
observers. Specific retinal layers (ganglion cell layer, inner plexiform layer, inner nuclear layer, 
outer plexiform layer, outer nuclear layer, and rods and cones layer) were evaluated for the pres-
ence of fluorescent staining including intensity of the staining. When both ANA (on HEp-2-cells) 
and ARA (on primate retinal tissue) had an equivalent intensity of staining, a sample was scored 
as ‘unknown’ because this combination does not allow a proper discrimination between the 
presence and absence of ARAs, by possible masking due to ANAs. These samples were excluded 
from the final analyses.
Western blot analysis
All CSC patients were evaluated for the presence of ARAs using Western blot analysis. Healthy 
human retinal protein extract was obtained after retina tissue homogenization in PBS. Tissue 
fragments were removed by centrifugation and the supernatant was frozen at -80°C until use. 
Retinal tissue extract was fractionated by SDS-polyacrylamide gel electrophoresis and separated 
proteins were subsequently transferred to nitrocellulose membranes. The membranes were 
blocked by incubation with 5% non-fat dry milk and incubated with serum of CSC patients or 
with appropriate control serum at a dilution of 1:100 in 5% non-fat dry milk in tris-buffered 
saline (TBS) overnight. After multiple washes with 0.1% TBS, membrane bound human IgG was 
identified by horseradish peroxidase-conjugated F(ab’) 2 goat anti-human IgG (Thermo Fisher 
Scientific, Waltham, Massachusetts, United States) at a dilution of 1:5000 in 5% non-fat dry milk 
in TBS-Tween. Reactivity was visualized using enhanced chemiluminescence.
Statistics
First, descriptive analyses were performed to obtain information on the characteristics of the CSC 
patients. Second, logistic regression with correction for age and gender was employed to evaluate 
if the presence of ARAs is associated to CSC. Finally, logistic regression with correction for age 
and gender was used to identify any clinical characteristics that were possibly associated with 
the presence of ARAs. P<0.05 was considered statistically significant. All analyses were performed 
with IBM SPSS Statistics version 21.
RESULTS
Patient characteristics 
All patient characteristics are shown in Table 1. A total of 63 chronic CSC patients (56 male, 7 
female), with a mean age of 51 ± 9 years (range, 31-72 years) was included in this study. The 
median duration of CSC at the time of blood collection was 585 days (range, 3-7832 days). Diffuse 
CSC was present in 11/62 patients (18%; data not available for one patient). In 38/48 CSC patients 
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(79%; data not available for 15 patients) SRF was present at the moment of blood collection, 
indicating active CSC. The mean CRT was 134 ± 37 µm (range, 57-226 µm). Previous to blood 
collection, no treatment for CSC was given in 35/63 patients (56%), whereas 13/63 patients (21%) 
had received either micropulse or focal laser treatment and 10/63 patients (16%) had received 
photodynamic therapy. 
Table 1. Clinical characteristics of 63 patients with central serous chorioretinopathy at 
the moment of blood collection
Patient characteristics
Male-to-female ratio 8:1
Mean age (SD), in years 51 (9)
Median duration of CSC (min-max), in days* 585 (3-7832)
CSC characteristics Number (%)
Stage **
Focal CSC
Diffuse CSC
51/62 (82%)
11/62 (18%)
Active CSC **,‡ 38/48 (79%)
Bilateral CSC during follow-up ‡ 32/63 (51%)
Recurrent CSC **, ‡ 26/62 (42%)
Familial CSC 2/63 (3%)
Presence of intraretinal edema during follow-up 10/63 (16%)
Mean central retinal thickness (SD), in micrometers ** 134 (37) (46 patients)
Previous treatment for CSC
Photodynamic therapy
Micropulse or focal laser treatment
Other treatments or combinations of treatment
No treatment
10/63 (16%)
13/63 (21%)
5/63 (8%)
35/63 (56%)
Systemic corticosteroids medication
Never
During diagnosis of CSC
< 3 months before the diagnosis of CSC
After or > 3 months before the diagnosis of CSC
33/63 (52%)
30/63 (16%)
7/63 (11%)
13/63 (21%)
Use of systemic corticosteroids at the moment of blood collection 9/63 (14%)
Use of systemic immunosuppressive medication (excluding steroids) ** 1/49 (2%)
Comorbidities **
Autoimmune diseases
Malignancies
3/59 (5%)
4/59 (7%)
* Duration of CSC: interval between the initial diagnosis of CSC and the moment of blood collection
**  Data not available for all patients
‡	 Presence	of	subretinal	fluid	is	considered	to	be	the	indication	of	‘active’	CSC
Abbreviations: CSC = central serous chorioretinopathy, SD = standard deviation
Antiretinal antibodies in central serous chorioretinopathy
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ARAs on IIF in CSC patients
The IIF results are summarized in Table 2. Positive staining of the retina on IIF was present in 35/63 
CSC patients (56%). After adjustment for retinal staining due to ANA, the presence of ARAs was 
confirmed in 32/59 CSC patients (54%). Among different staining patterns observed, staining of 
the photoreceptors was the most prevalent pattern in CSC patients (17/63; 27%; Figure 1). Other 
observed staining patterns in serum of CSC patients included staining of nuclear layers (N=8), 
fluorescence between the inner nuclear layer and the outer plexiform layer (N=7), fluorescence 
between the outer nuclear layer and the photoreceptors (N=3), and/or staining of the inner 
plexiform layer (N=2). Nine CSC patients had a combination of different staining patterns on IIF.
Figure 1. Staining patterns on indirect immunofluorescence from serum of patients with 
central serous chorioretinopathy
Serum of central serous chorioretinopathy patients was tested for the presence of antiretinal antibod-
ies using indirect immunofluorescence with primate retinal tissue. Presence of antiretinal antibodies 
was visualized by labelling with fluorescein isothiocyanate (FITC). Panel A shows staining of the photo-
receptors (arrow); panel B shows no retinal staining (absence of antiretinal antibodies).
The prevalence of ARAs in CSC patients was higher than in healthy controls (10/59; 17%; p<0.001). 
In addition, staining of the photoreceptors occurred in a lower percentage of healthy controls (5%) 
compared to CSC patients (p=0.003). In patients with uveitis, any positive staining of the retina 
(after correction for ANA presence) was observed in 39/84 patients (46%), which was not signifi-
cantly different from CSC patients (p=0.153). In contrast, specific staining of the photoreceptors 
in uveitis patients (15%) was less prevalent compared to CSC patients (p=0.039). No significant 
differences in the prevalence of staining of other specific retinal layers between CSC patients and 
the two control groups were observed. 
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Clinical characteristics of CSC in relation to presence of ARAs on IIF
The presence of ARAs on IIF was higher in the six female CSC patients (100%) compared to the 
57 male CSC patients (46%; p=0.024; Table 3). Staining of the photoreceptors in the samples of 
female and male CSC patients (57% versus 23%) did not differ (p=0.078). All other clinical char-
acteristics of CSC (including age at onset, duration of CSC, stage of CSC, activity of CSC, unilateral 
versus bilateral CSC, recurrence of CSC, familial occurrence of CSC, CRT, presence of intraretinal 
edema, previous CSC treatment, and systemic steroid use during confirmation of the diagnosis of 
CSC) were not significantly associated with the presence of ARAs or specific staining of the pho-
toreceptors. Masked assessment of the OCT images of the 17 CSC patients with photoreceptor 
staining on IIF and of 17 CSC patients without photoreceptor staining on IIF (randomly selected) 
showed no remarkable differences in signs of retinal damage.
ARAs on Western blot in patients with CSC
Multiple ARAs were observed in the majority of CSC patients (Figure 2). The most abundant ARA 
reactivity on Western blot was observed with those CSC patients showing staining of the photore-
ceptors on IIF, when compared to patients without retinal staining patterns as well as to patients 
with other staining patterns on IIF. The most prevalent ARAs on Western blot in CSC patients 
showing staining of the photoreceptors on IIF had molecular weights of approximately 24 kDa 
and 45 kDa. However, these antibodies were not entirely specific for samples with photoreceptor 
staining, since they were also present in CSC patients showing no staining of the photoreceptors 
on IIF, and even in patients with no staining at all.
DISCUSSION
We show that serum ARAs were present in 54% of patients with chronic CSC and in 17% of healthy 
controls. No significant difference in the prevalence of overall ARAs in serum was found between 
CSC patients and uveitis patients (46%), although staining of the photoreceptors occurred more 
often in CSC patients (27%) than in uveitis patients (15%). No differences in the presence of ARAs 
were observed when CSC patients were subdivided into specific subgroups based on clinical 
characteristics. 
The multiple staining patterns on IIF in individual CSC patients indicate the presence of diverse 
ARAs, which was confirmed by Western blot analysis. Also, within patients who were solely 
showing staining of the photoreceptors on IIF, Western blot indicated the presence of diverse 
antibodies directed against the retina. This suggests that diverse retinal antibodies are associated 
with photoreceptor staining. 
Antiretinal antibodies in central serous chorioretinopathy
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Figure 2. Reactivity on Western blot from serum of patients with central serous chorio-
retinopathy
Serum of patients with central serous chorioretinopathy was evaluated for the presence and approxi-
mate size of antiretinal antibodies using Western blot analysis with retinal protein extract. The results 
are sorted based on staining patterns on indirect immunofluorescence : a. nuclear staining (antinuclear 
antibodies (ANA) negative); b. photoreceptor staining; c. diverse staining patterns; d. nuclear staining 
(ANA positive); e. no staining.
The reason for the higher prevalence of ARAs in CSC, especially those directed against photo-
receptors, and their clinical significance is currently not clear. Possibly, chronic retinal damage 
caused by the presence of SRF accumulation, associated with a breakdown of the RPE (which 
normally constitutes the outer blood-retinal barrier), may trigger formation of ARAs through an 
inflammatory reaction of the immune system.32 In the past, ARAs have been shown in autoimmune 
retinopathy, in which ARAs are suggested to have pathogenic properties. Elevated serum ARAs 
were also observed in other chorioretinal diseases (e.g. uveitis, macular degeneration, retinitis 
pigmentosa) as well as in the healthy population.28-30,33-44 Here, an immune response to ocular 
tissue damage has been previously suggested to play a role in aggravation of the various retinal 
diseases.42,45 Similarly, autoreactive immunologic responses have been found in patients with 
proven infectious uveitis, in which the primary cause (infection) presumably incited the secondary 
formation of antibodies, possibly due to tissue damage.46 Interestingly, recent genetic studies 
in CSC have found an association with genetic variants in the complement system, an essential 
part of the innate immune system.25,47 However, it is unclear if there is a primary role of the 
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immune system in the pathogenesis of CSC. The mere presence of serum autoantibodies does 
not necessarily indicate an autoimmune basis of the disease. Moreover, ARAs were not found in 
all patients and exhibited a wide variety. 
The presence of ARAs in serum of CSC patients might be hypothetically explained by their immune 
predisposition. CSC can occur in patients with various immune-mediated diseases including 
membranoproliferative glomerulonephritis and systemic lupus erythematosus.48,49 It is unclear 
whether CSC in these patients is only caused by glucocorticoid treatment prescribed for these 
conditions or if it is also influenced by the presence of inflammatory disease.22 Another potential 
systemic mechanism in the development of ARAs could be the mimicry between ocular antigens 
and microbial proteins, brought up by a previous systemic infection.50 However, the presence of 
antecedent infectious disorders in CSC has not previously been assigned as its cause. A higher 
prevalence of Helicobacter pylori infections in CSC patients has been described, although a firm 
association has never been proven.14,51,52 Moreover, autoimmune responses would be rather 
expected in a female-dominated disease. In CSC, particularly men between the age of 25 and 55 
are affected, analogous to the phase of life in which highest androgen levels can be detected, 
suggesting a possible role of this hormone within the development of CSC. In our study, the role 
of the immune system in CSC seemed to be most important in female CSC patients, as ARAs 
occurred in all six initially included female CSC patients. However, after our study was completed, 
we had the possibility to analyse three extra samples from female patients with CSC. All three 
samples showed absence of ARAs on IIF, resulting in similar occurrences of ARAs in male and 
female CSC patients (Table 3).
So far it is unclear whether ARAs are involved in the pathogenesis of CSC or whether their pres-
ence represents a secondary epiphenomenon. As CSC is mainly a disease of the choroid and RPE, 
experiments assessing antibodies directed against the choroid and RPE could give more insight 
to the pathogenesis.1-3,13 The assessment of intraocular ARAs might help to clarify the possible 
pathogenic role of ARAs.30 
The prevalence of ARAs in serum of blood bank donors of 17% is similar to the prevalences of 
ARAs in healthy controls in previous studies.29,30,43,45,46,53 One could argue that some of the blood 
donors might have ocular conditions which could also lead to the formation of ARAs. However, 
this would not affect our results as we found a difference in the prevalences of ARAs even with 
our blood bank controls.
In conclusion, serum ARAs are more common in CSC patients than in healthy controls. No clear 
association between the presence of ARAs and clinical CSC characteristics could be identified in 
the current cohort. To unravel the possible involvement of autoimmune reactivity in the patho-
genesis of CSC, further research is warranted.
Antiretinal antibodies in central serous chorioretinopathy
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The pathogenesis of uveitis in the setting of active and latent tuberculosis (TB) is not entirely clari-
fied. Next to genuine infection, an important part of pathogenesis was attributed to (auto)immune 
reactions initiated by Mycobacterium tuberculosis (Mtb).1 Infection with Mtb can be associated 
with the production of diverse serum autoantibodies.2 Herein, we investigate the influence of 
(latent) TB on the presence of serum antinuclear and antiretinal autoantibodies (ANA and ARA) 
in Indonesian patients with uveitis. 
Blood samples from patients with uveitis associated with active (not yet treated) pulmonary TB 
(N=10) and uveitis of unknown cause (N=85) were collected from June 2014 until May 2015. 
Classification of patients was performed according to SUN classification, and specific diagnoses 
were determined after the basic work-up for uveitis as indicated in our previous publication.3  The 
diagnosis of active pulmonary TB was based on clinical and/or microbiological and radiological 
findings.3  This study was performed with the approval of the local medical ethical committee.
All patients underwent QuantiFERON-Tb Gold (QFT) (Cellestis Inc., Carnegie, Australia). Screening 
for the presence of ANA using HEp-2 cells (Inova, San Diego, California) and the presence of ARA 
using primate retinal tissue (Euroimmun, Lubeck, Germany) was performed by indirect immu-
nofluorescence as described before.4 Logistic regressions with correction for age and gender 
were performed using SPSS to analyse differences in the presence of ANA and ARA between the 
diagnosis groups. 
Patients with uveitis of unknown cause were divided according to their QFT results in 58 patients 
with latent TB (QFT positive) and 27 patients without evidence of prior TB exposure (QFT negative). 
All QFT positive patients were assessed by the pulmonologist and examined for the possible 
presence of pulmonary and extrapulmonary TB, but no cases of extrapulmonary involvement 
were found. The group with an unknown cause of uveitis and latent TB consisted of more female 
patients compared to the other groups (72% vs 30% in uveitis in the setting of active pulmonary 
TB group and 41% in the uveitis of unknown cause and QFT negative group, p-value 0.044) and 
older age patients (mean age 46 years vs 40 years in uveitis in the setting of active pulmonary 
TB group and 39 years in uveitis of unknown cause and QFT negative group, p-value 0.003).  The 
median QFT value in patients with uveitis of unknown cause and latent TB was 5.0 IU/ml, and in 
patients with known tuberculosis induced uveitis 1.7 IU/ml.
Patients’ serum  ANA  and ARA results are shown in Table 1. Patients with uveitis and either active 
or latent TB were characterized by high prevalence of systemic autoreactivity (ANA positive). In 
contrast, a higher proportion of organ-specific autoreactivity (ARA positive) was found in uveitis 
patients without evidence of any previous contact with Mtb. Induction of ANA, reported previ-
ously for active TB, apparently also occurs in latent TB.5 Interestingly, organ-specific autoreactivity 
(ARA) appears to be suppressed in both active and latent TB, however, the local production of 
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ARA in ocular fluid samples was not investigated in this series. The presence of serum autoanti-
bodies, directed against endothelial cells, and their decrease following treatment was reported 
in age-related macular degeneration.6  Unfortunately, we have no samples of our patients after 
they completed the treatment. Further studies are warranted to dissect the pathogenesis of this 
selective systemic induction of autoreactivity in uveitis patients as a result of Mtb infection and 
its implication on disease course. 
Table 1. Prevalence of antinuclear and antiretinal antibodies in tuberculosis induced 
uveitis and uveitis of unknown cause with positive or negative QuantiFERON–TB Gold 
outcomes
  ANA positive ARA positive
Total 18/95 (19%) 39/87 (45%)
1. Uveitis in the setting of active pulmonary TB 5/10 (50%) 4/9 (44%)
2. Uveitis of unknown cause, QFT positive 12/58 (21%) 19/52 (37%)
3. Uveitis of unknown cause, QFT negative 1/27 (4%) 16/26 (62%)
p-value: 1 vs. 2 vs. 3 0.023 0.049
p-value: 1 vs. 2 >0.05 >0.05
p-value: 2 vs. 3 >0.05 0.014
p-value: 1+2 vs. 3 0.03 0.021
Serum ANA were more prevalent in patients with TB-induced uveitis (50%) than in patients with 
uveitis of unknown cause with latent TB (21%) or without latent TB (4%; p=0.023). The prevalence 
of ARA was higher in QFT negative patients with unknown uveitis cause (62%) than in QFT positive 
uveitis cases (p=0.049). Prevalence of ARA or ANA did not differ between TB-induced uveitis and QFT 
positive uveitis of unknown cause. 
Abbreviations: ANA = antinuclear antibodies, ARA = antiretinal antibodies, OR = odds ratio, QFT = 
QuantiFERON–TB Gold test
Antibodies in uveitis with latent and active tuberculosis
109
CHAPTER 8
REFERENCES
1. Wroblewski KJ, Hidayat AA, Neafie RC, Rao NA, Zapor M. Ocular tuberculosis: A clinicopathologic and 
molecular study. Ophthalmology. 2011;118(4):772-777.
2. Shen CY, Hsieh SC, Yu CL, Wang JY, Lee LN, Yu CJ. Autoantibody prevalence in active tuberculosis: reactive 
or pathognomonic? BMJ Open. 2013;3(7).
3. La Distia Nora R, Sitompul R, Bakker M, et al. Tuberculosis and other causes of uveitis in Indonesia. Eye 
(Lond). 2017.
4. Ten Berge JC, Schreurs MW, Vermeer J, Meester-Smoor MA, Rothova A. Prevalence and clinical impact of 
antiretinal antibodies in uveitis. Acta Ophthalmol. 2016;94(3):282-288.
5. Elkon K, Casali P. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol. 2008;4(9):491-498.
6. Kubicka-Trzaska A, Wilanska J, Romanowska-Dixon B, Sanak M. Serum anti-endothelial cell antibodies in 
patients with age-related macular degeneration treated with intravitreal bevacizumab. Acta Ophthalmol. 
2016;94(7):e617-e623.

ANTIRETINAL ANTIBODIES IN MEXICAN 
CHILDREN WITH SEVERE PARS PLANITIS
Luz Elena Concha-del Río, Maria de Lourdes Arellanes-García, Marco W.J. Schreurs, Aniki 
Rothova, Josianne C.E.M. ten Berge 
Submitted for publication
9
112
CHAPTER 9
ABSTRACT
Pars planitis (PP) is a subtype of intermediate uveitis and a particularly severe form of PP has 
been described in pediatric Mexican patients. Although the pathogenesis of PP is not clarified, 
autoimmune reactions have been suggested to play a role.  This study investigates the presence 
and possible clinical role of serum antiretinal antibodies (ARAs) of Mexican children with PP (N=16) 
and age-matched controls with strabismus (N= 19). All samples were tested for the presence of 
ARAs by indirect immunofluorescence using primate retinal tissue. Serum ARAs were noted in 
57% (8/14) of PP patients and in 40% (6/15) of controls (p=0.356), and no correlation was found 
between the presence of ARAs and clinical characteristics of PP. Insight in the cellular component 
of the immune system and / or analyses of intraocular fluids of PP eyes might provide further 
insight in the pathogenesis of PP.  
Antiretinal antibodies in pediatric pars planitis
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INTRODUCTION
Pars planitis (PP) is characterized predominantly by vitreous inflammation, with or without vit-
reous condensations (“snowballs”), pars plana exudates (“snowbanks”) in at least one eye, and 
peripheral retinal vasculitis. An exceptionally severe form of PP has been reported in children with 
uveitis from Mexico.1-3 The clinical course of PP is usually chronic with exacerbations and has great 
on patients’ well-being and quality of life. Despite the numerous reports on intermediate uveitis, 
the specific cause and pathogenesis of PP are unknown.4 PP is considered to be of autoimmune 
origin, but possible inciting antigens are so far entirely unknown. In this short report, we assess 
the presence of antiretinal antibodies (ARAs) in serum of in young patients with PP from Mexico 
and evaluate their possible clinical role. 
METHODS
We prospectively collected serum samples from 16 patients with PP and 19 age-matched children 
with strabismus who served as controls, from the Eye Inflammatory Disease Clinic at Hospital ”Dr. 
Luis Sánchez Bulnes”, Asociación Para Evitar la Ceguera in Mexico. Clinical data were collected 
from medical data files (Table 1). The study was performed in accordance with the Declaration 
of Helsinki and in agreement with the institutional regulations and approval of local institutional 
review boards.
Table 1. Clinical characteristics of patients with pars planitis
Characteristic Number (%)
Age onset (median; interquartile range) 8; 6-10
Gender (male:female) 9:7
Bilateral pars planitis 13/15 (87%)1
Anterior chamber inflammation 13/16 (81%)
Anterior synechiae 2/16 (13%)
Posterior synechiae 6/16 (38%)
Cyclitic membrane 6/16 (38%)
Snowballs 16/16 (100%)
Snowbanking 7/15 (47%)*
Phlebitis 15/15 (100%)*
Systemic treatment** 14/16 (88%)
* Data not available for all patients 
** Prednisone and/or systemic immunosuppressive therapy
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Screening of serum samples for the presence of ARAs was performed by indirect immunoflu-
orescence using primate retinal tissue (Euroimmun, Lubeck, Germany), as described before.5 
The determination of ARAs was not possible in 2 patients and 4 controls, due to positivity of 
antinuclear antibodies which mask the possible presence of ARAs. Mann Whitney U tests for 
continuous data and Chi-square tests for categorical data were performed to analyse differences 
on the presence of ARAs between the diagnosis groups and specific clinical characteristics of PP.
RESULTS AND DISCUSSION
Serum ARAs were found in 57% (8/14) of PP patients and in 40% (6/15) of controls (p=0.356). 
Staining of photoreceptors was the most frequently observed pattern with similar prevalence in 
both groups. The presence of ARAs was not associated to any clinical characteristic of PP. The 
high prevalence of ARAs in our young control patients without retinal disease (40%) is remark-
able and much higher than the 17% observed in the general population in Europe.6 The possible 
explanation might be a higher exposure to exogenous antigens such as infections in Mexican 
children. Despite the high prevalence of 57% of serum in young patients with PP, our results 
suggest that ARAs are not the primary cause of the ocular disease, but possibly represent a 
secondary phenomenon. 
In conclusion, the prevalence of serum ARAs is similar in pediatric PP and controls from Mexico. 
Further assessment of potential infectious agents and insight in the cellular component of the 
immune system and/or assessment of intraocular ARAs of PP eyes might provide further insight 
in the pathogenesis of PP. 
Antiretinal antibodies in pediatric pars planitis
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ABSTRACT
A high prevalence of serum antiretinal antibodies (ARAs) in patients with uveitis has been previ-
ously described, though their clinical role remains elusive. Assessment of intraocular ARAs may 
provide further insight into the pathogenesis of diverse uveitis entities. In this study we investigate 
the prevalence of multiple specific anti-ocular antibodies (AOcAs), including ARAs, in intraocular 
fluid of patients with uveitis. Autoantibody profiling with 188 different ocular antigens was per-
formed by a multiplex immunoassay with intraocular fluid samples of 76 patients with uveitis. 
Clinical data from uveitis patients were collected and statistical analyses were executed to evalu-
ate associations between intraocular AOcAs and clinical characteristics. Controls consisted of 19 
intraocular fluid samples from cataract patients. A spectrum of 22 different AOcAs was present 
in higher levels in patients with uveitis than in controls (p≤0.05), but in moderately elevated titers 
(<2x). High elevations of intraocular AOcAs in uveitis (>5x compared to cataract) were observed 
in varicella zoster virus-induced uveitis, multiple sclerosis-associated uveitis and patients with 
unexplained uveitis but positive quantiferon test. Presence of macular edema was associated 
with increased intraocular levels of tyrosinase antibodies. Our results show that patients with 
uveitis are characterized by the presence of a broad spectrum of moderately elevated levels of 
intraocular AOcAs, and high intraocular AOcA levels were found in several specific uveitis entities. 
This study favors secondary production of AOcAs and not their inciting role.
Autoantibody profiling in intraocular fluid of patients with uveitis
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INTRODUCTION
Uveitis is a severe ocular disease, which can result in permanent blindness. Uveitis has multiple 
causes including infections and shows strong associations with various systemic immune-medi-
ated diseases. The pathogenesis of most uveitis entities is not fully understood, but the immune 
system plays a crucial role; especially the development of autoimmune intraocular reactions in 
non-infectious uveitis has been repeatedly proposed, but scarcely proven. Serum antibodies 
directed against retinal tissue were more prevalent in patients with uveitis compared to healthy 
controls.1 It has been hypothesized that the antiretinal antibodies (ARAs) in uveitis might either 
incite the ocular disease or represent a secondary epiphenomenon induced by retinal damage. 
The possible pathogenic role of these ARAs is unknown, although it has been suggested that ARAs 
might aggravate and/or prolong the ocular disease.2-4 
The eye is an immune privileged organ and intraocular ARAs might show an entirely different 
profile than ARAs found in the peripheral blood. This phenomenon has been shown previously 
in infectious uveitis, in which local production of specific antibodies is regarded as indirect proof 
of the intraocular infection.5 Similarly, in neurological diseases including autoimmune encepha-
litis and multiple sclerosis the importance of analysis of cerebrospinal fluid has been previously 
proven.6, 7 Currently, antigen bead arrays are successfully being used for the analysis of autoanti-
bodies. This technique enables analysis of very small volumes (such as intraocular fluids) towards 
hundreds of different antigens and its potential for ARA detection has been suggested.8
Herein, we perform an autoantibody profiling of intraocular fluid samples of patients with diverse 
uveitis entities and assess the prevalence of antibodies directed against 188 different ocular 
antigens as potential targets, and relate the results to clinical manifestations of uveitis. 
METHODS
Remainders of diagnostic intraocular fluid samples from 76 patients with uveitis were collected 
from  the Laboratory of Virology of the Erasmus MC, University Medical Center Rotterdam 
between February 2009 and April 2015. Intraocular fluid samples of 19 patients with cataract 
stored in the biobank in the same time period were used as controls. All intraocular fluid samples 
were stored at -80°C. This study was approved by the local ethical committee from the Erasmus 
University Medical Center (Medical Ethics Committee Erasmus MC) and adhered to the tenets of 
the Declaration of Helsinki. 
All uveitis patients were classified according to the localization of uveitis using the Standardization 
of Uveitis Nomenclature SUN criteria.9,10 Patients underwent a standardized diagnostic protocol 
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based on this anatomical site of inflammation. The protocol included chest radiography, erythro-
cyte sedimentation rate, blood counts, serum angiotensin-converting enzyme levels, serology for 
syphilis and Lyme disease and interferon gamma release assay (IGRA) test (QuantiFERON–TB Gold 
In-Tube test). In patients with anterior uveitis or panuveitis Human Leukocyte Antigen (HLA)-B27 
testing was also performed. According to the clinical uveitis manifestations, further examinations 
were added (tailored approach). Specific diagnoses were determined after the various diagnostic 
procedures were completed. The diagnosis of intraocular infections was always confirmed by 
polymerase chain reaction (PCR) and/or Goldmann-Wittmer coefficient in intraocular fluid. The 
diagnosis of Fuchs uveitis syndrome (FUS) was based on clinical characteristics. The diagnosis of 
sarcoidosis was either histologically proven or based on chest imaging in patients with otherwise 
unexplained uveitis . All other specific diagnoses were made according to current diagnostic 
criteria. 
Clinical data of patients with uveitis were collected from medical data files. We registered age, 
gender, location of uveitis and specific cause of uveitis. Further, we registered the following char-
acteristics at the moment of sample collection: duration of uveitis, presence of cystoid macular 
edema (CME), presence of vasculitis, use of systemic immunosuppressive medication and activity 
of uveitis.  
Autoantibody profiling with 188 different ocular antigens, representing 97 unique ocular proteins, 
was performed on intraocular fluid samples from patients with uveitis (N=76) and cataract (N=19; 
Supplementary Table). Antigens were selected based on potential relevance to ocular diseases 
according to literature or previous retinal immunohistochemistry staining. The used antigens 
were protein fragments produced within the Human Protein Atlas, designed to have low homol-
ogy to other human proteins and expressed in Escherichia coli with an affinity tag consisting 
of six histidines and an albumin-binding domain from streptococcal protein G (His6ABP).11,12 A 
multiplex assay, previously validated by immunoblot and immunohistochemistry, was performed 
as described before with minor alterations.13 In short, the antigens were covalently coupled to 
color-coded magnetic beads to create a bead array. The samples were diluted 1:10 in assay 
buffer (0.1% PBS-Tween20, 3% BSA, 160 µg/ml His6ABP), let to pre-block potential antibodies 
towards the ABP-domain for 1 hour in room temperature, and subsequently incubated O/N in 
room temperature with the bead array. Interactions were fixated with 0.2% PFA for 10 min before 
incubation for 30 min with a fluorophore conjugated anti-human IgG Fab fragment. A FlexMap3D 
instrument (Luminex Corp.) was used to acquire a read-out. The autoantibody profiling was per-
formed at the SciLifeLab Autoimmunity Profiling Facility in Stockholm, Sweden.
For the statistical analyses, continuous variables were summarized using medians and ranges, 
and categorical variables were summarized using percentages. Patient demographics were com-
pared between diagnosis groups using Mann Whitney U tests for continuous data and Fisher’s 
Autoantibody profiling in intraocular fluid of patients with uveitis
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exact tests for categorical data. Linear regressions with correction for age and gender were per-
formed to analyse differences between the diagnosis groups (uveitis or specific uveitis entities 
versus cataract). In addition subgroup analyses of these linear regressions were performed to 
compare specific uveitis entities with cataract. To analyse differences within the uveitis group we 
performed linear regressions with age, gender, location of uveitis (reference category: anterior 
uveitis), uveitis entity (reference category: uveitis associated to sarcoidosis), uveitis activity, sys-
temic immunosuppressive therapy, presence of CME and presence of vasculitis as independent 
variables. Some specific uveitis entities were not analysed as separate groups (uveitis associated 
with herpes simplex virus (HSV), Sjögren syndrome, HLA B27-associated uveitis and birdshot 
chorioretinopathy), because their numbers were too small. All regression analyses were per-
formed using the natural logarithm of the measured median fluorescent intensities as dependent 
variable. Relative (fold) increases of differences in levels of AOcAs were calculated by exponenti-
ating the estimated regression coefficients. The linear regressions were performed with a robust 
MM-type estimation method, to account for the fact that the model residuals were not normally 
distributed.14 We used the signal intensities as an indication for the levels of intraocular AOcAs. To 
adjust for the multiple comparisons of the different antigens, a Bonferroni correction was applied 
(all p-values were multiplied by 188). P-values of ≤0.05 were considered statistically significant. All 
statistical tests were two-sided. The analyses were performed using SPSS and R (version 3.3.1), 
with the robustbase package for the robust linear regressions.15
RESULTS
The median age of the 76 included uveitis patients was 48 years, and 46% of patients were 
males. Median duration of uveitis was two years (ranging from zero to 36 years), and 51 (67%) 
cases were active during sample collection. Patients’ characteristics are shown in Table 1. The 
most prevalent cause of uveitis in our cohort was sarcoidosis (14/76, 18%). Nine patients with 
sarcoidosis-associated uveitis were biopsy proven and in five patients the diagnosis was based 
on radiologic criteria. Varicella zoster virus (VZV)-induced uveitis included 4 patients with retinitis 
and 3 with anterior uveitis. Cataract patients were older than the uveitis patients (median age of 
69 years, p=0.0001) and 42% were males (p>0.05). 
The levels of 22 different intraocular AOcAs were higher in uveitis than in controls (all p≤0.05 as 
determined by linear regression), but with moderately increased titers (up to 2x compared to 
controls). The most significant results were observed in the AOcA levels specific for RPE-retinal G 
protein-coupled receptor (number 169; p=0.0031) and retinol dehydrogenase 8 (number 160; p= 
0.0042). Levels of intraocular AOcAs varied greatly between different uveitis entities. Intraocular 
AOcAs with at least 5-fold increased titers (compared to cataract controls) were observed in 
three specific entities: VZV-induced uveitis, multiple sclerosis (MS)-associated uveitis and patients 
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with unexplained uveitis but with a positive quantiferon test (all p<0.05; Table 2 and Figure 1). 
Intraocular levels of all AOcAs in FUS (with or without an intraocular rubella virus infection) were 
similar to cataract controls (all p>0.05).  
Table 1. Characteristics of uveitis patients (N=76)
Characteristic Number (%)
Male-to-female ratio 35 - 41 (46% - 54%)
Median age in years (range) 48 (17 - 86)
Median duration uveitis in years (range) 2 (0 – 36)
Location
Anterior
Intermediate
Posterior
Panuveitis
26 (34%)
10 (13%)
23 (30%)
17 (22%)
Specific cause or association
Infectious
Rubella
Toxoplasma gondii
Varicella zoster virus
Cytomegalovirus
Herpes simplex virus
Systemic disease
Sarcoidosis
Multiple sclerosis
Sjögren syndrome
HLA B27 positive
Ocular lymphoma
Clinical entity
Birdshot chorioretinopathy
Fuchs uveitis syndrome
Unknown
Quantiferon positive
36 (47%)
12 (16%)
8 (11%)
7 (9%)
7 (9%)
2 (3%)
24 (32%)
14 (18%)
8 (11%)
1 (1%)
1 (1%)
5 (7%) 
3 (4%)
2 (3%)
1 (1%)
8 (11%)
6 (8%)
Active uveitis 51 (67%)
Presence of cystoid macular edema 19 (25%)
Presence of vasculitis 16 (21%)
Systemic immunosuppressive treatment 16 (21%)
Autoantibody profiling in intraocular fluid of patients with uveitis
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Figure 1. Levels of intraocular tyrosinase (number 149) in different uveitis entities and in 
cataract
* Extreme outliers: <(25th percentile -/- 3x interquartile range) or >(75th percentile +/+ 3x interquartile 
range)
The AOcA levels within the uveitis population and their associations with clinical characteristics are 
shown in Table 3. Significant associations between high levels of specific AOcAs and VZV-induced 
uveitis, MS-associated uveitis or unexplained uveitis with positive quantiferon test were identified. 
Presence of CME was associated with higher titers of tyrosinase (number 79, p=0.0026), although 
with a moderate increased titer compared to uveitis patients without CME (1.4x). Active uveitis 
had lower levels of most AOcAs, but these results did not reach significance after Bonferroni 
correction. No differences in levels of AOcAs were found between all other clinical characteristics 
of uveitis.
Autoantibody profiling in intraocular fluid of patients with uveitis
125
CHAPTER 10
Ta
bl
e 
3.
 P
re
se
nc
e 
of
 a
nt
i-o
cu
la
r 
an
tib
od
ie
s 
co
m
pa
re
d 
w
ith
in
 u
ve
iti
s 
(N
=7
6)
 in
 r
el
at
io
n 
to
 u
ve
iti
s 
ch
ar
ac
te
ris
tic
s*
An
ti
ge
n 
no
.
An
ti
ge
n 
na
m
e
Sh
or
t n
am
e
p-
va
lu
e*
*
Fo
ld
 in
cr
ea
se
Sp
ec
ifi
c 
u
ve
it
is
 e
n
ti
ti
es
Va
ri
ce
lla
 z
os
te
r 
vi
ru
s 
in
du
ce
d 
uv
ei
ti
s
10
4
Re
tin
ol
-b
in
di
ng
 p
ro
te
in
 3
RB
P3
0.
00
80
3.
8
13
4
B
es
tr
op
hi
n-
2
B
ES
T2
0.
00
54
2.
2
M
ul
ti
pl
e 
sc
le
ro
si
s 
as
so
ci
at
ed
 u
ve
it
is
10
7
Re
tin
a 
an
d 
an
te
rio
r 
ne
ur
al
 fo
ld
 h
om
eo
bo
x 
pr
ot
ei
n 
2
RA
X2
0.
00
01
4.
6
86
Ag
e-
re
la
te
d 
m
ac
ul
op
at
hy
 s
us
ce
pt
ib
ili
ty
 p
ro
te
in
 2
AR
M
S2
0.
00
43
2.
9
34
Vi
su
al
 p
ig
m
en
t-
lik
e 
re
ce
pt
or
 p
er
op
si
n
RR
H
0.
03
72
2.
4
18
5
Ro
d 
cG
M
P-
sp
ec
ifi
c 
3’
,5
’-c
yc
lic
 p
ho
sp
ho
di
es
te
ra
se
 s
ub
un
it 
al
ph
a
PD
E6
A
0.
00
06
2.
2
Id
io
pa
th
ic
 u
ve
it
is
 w
it
h 
po
si
ti
ve
 q
ua
nt
ife
ro
n 
te
st
13
9
Cb
p/
p3
00
-in
te
ra
ct
in
g 
tr
an
sa
ct
iv
at
or
 1
CI
TE
D
1
0.
00
08
3.
7
14
3
Cb
p/
p3
00
-in
te
ra
ct
in
g 
tr
an
sa
ct
iv
at
or
 1
CI
TE
D
1
0.
02
20
3.
4
Cl
in
ic
al
 c
ha
ra
ct
er
is
ti
cs
Pr
es
en
ce
 o
f c
ys
to
id
 m
ac
ul
ar
 e
de
m
a
79
Ty
ro
si
na
se
TY
R
0.
00
26
1.
4
* 
P-
va
lu
es
 fo
r 
co
m
pa
ris
on
 o
f i
nt
ra
oc
ul
ar
 A
O
cA
 le
ve
ls
 w
ith
in
 t
he
 u
ve
iti
s 
co
ho
rt
 w
er
e 
de
te
rm
in
ed
 b
y 
ro
bu
st
 li
ne
ar
 r
eg
re
ss
io
n.
 S
pe
ci
fic
 u
ve
iti
s 
en
tit
ie
s 
w
er
e 
co
m
pa
re
d 
w
ith
 
sa
rc
oi
do
si
s 
as
so
ci
at
ed
 u
ve
iti
s 
as
 r
ef
er
en
ce
 c
at
eg
or
y.
 O
nl
y 
si
gn
ifi
ca
nt
 p
-v
al
ue
s 
w
ith
 th
e 
hi
gh
es
t f
ol
d 
in
cr
ea
se
s 
ar
e 
sh
ow
n 
in
 th
is
 ta
bl
e.
 
**
 a
ft
er
 B
on
fe
rr
on
i c
or
re
ct
io
n 
fo
r 
m
ul
tip
le
 te
st
in
g
126
CHAPTER 10
DISCUSSION
Our study documents the presence of a broad spectrum of ocular autoantibodies in intraocular 
fluids of patients with uveitis patients. Significant differences between the levels of intraocular 
AOcAs in uveitis and cataract were identified. However, levels of intraocular AOcAs in uveitis were 
only moderately increased (up to 2x compared to cataract), which may have been caused by the 
merger of heterogeneous autoantibody profiles of different uveitis entities. Comparison of spe-
cific uveitis entities with cataract showed various high intraocular AOcA levels (>5x) in VZV-induced 
uveitis, MS-associated uveitis and idiopathic uveitis with positive quantiferon test. Patients with 
CME exhibited moderately increased titers of anti-tyrosinase.
VZV-induced uveitis was one the entities which was associated with high levels of AOcAs. Spe-
cifically, antibodies directed against retinol-binding protein 3 (RBP-3) were present in high levels 
(compared to cataract, and other uveitis entities). RBP-3, also known as interphotoreceptor ret-
inoid-binding protein (IRBP) is found primarily in the interphotoreceptor matrix of the retina 
and it is thought to transport retinoids between the retinal pigment epithelium (RPE) and the 
photoreceptors. RBP-3 antibodies have been previously observed in some ocular diseases, 
including autoimmune retinopathy, macular telangiectasia type 2 and age related macular 
degeneration.16-18 The RBP-3 antigen has been found to be highly uveitogenic in multiple animal 
models.19,20 RBP-3 might represent a non-specific target involved in the pathogenesis different 
ocular diseases. Another highly prevalent antibody in VZV-induced uveitis was directed against 
bestrophin-2 (Best-2). Within the bestrophin family, bestrophin-1 (Best-1) is the most investigated 
and described ocular antigen. Mutations in the BEST gene may cause bestrophinopathies (such 
as Best’s disease), and antibodies directed against the Best-1 protein are involved in vitelliform 
paraneoplastic retinopathy.21,22 The Best-2 antigen is, in contrast to Best-1, not found in the RPE, 
but in the ciliary body.23  The Best-2 antigen is involved in regulation of intra-ocular pressure by 
antagonizing the formation of aqueous humour.24,25 The relationship between Best-2 antigen 
and uveitis has not yet been reported. Interestingly, all four patients with retinitis as well as one 
patient with VZV-induced anterior uveitis exhibited high titres of Best-2. These patients had no 
eye pressure associated problems. 
In patients with MS (with and without uveitis), the presence of AOcAs in serum and cerebrospinal 
fluid has been repeatedly noted.26-29 In our series, we identified several specific AOcAs in high 
titres in intraocular fluids in MS-associated uveitis, namely recoverin and fructose-bisphosphate 
aldolase C. These two AOcAs were previously related to cancer associated retinopathy, and aldo-
lase C was also observed in patients with diabetic retinopathy.30,31 Another target found in high 
titres in MS-associated uveitis was surprisingly age-related maculopathy susceptibility protein 2 
(ARMS2). ARMS2 is involved in complement activation and its gene was repeatedly reported in 
AMD.32,33 An over-activated complement system has also been noted in MS lesions by immuno-
Autoantibody profiling in intraocular fluid of patients with uveitis
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histochemistry.34-36 It has been suggested that the complement may play a secondary role in the 
pathogenesis of MS by aggravating the course of disease. 
Multiple reports propose the involvement of the immune system in uveitis associated with latent 
tuberculosis infection (LTBI).37 The current hypotheses include a low-grade infection, an immu-
nological reaction induced by the tuberculosis bacilli, or a combination of both. High levels of 
intraocular AOcAs in uveitis with LTBI favour the involvement of immune reactions in the patho-
genesis of LTBI associated uveitis. 
Interestingly, CME was associated with antibodies directed against tyrosinase. Tyrosinase is a 
peptide of the melanocytes, a protein that within the eye is mainly located in the RPE and was 
previously described in serum of patients with Vogt-Koyanagi-Harada (VKH) disease.38 It is thought 
that the pathogenesis of VKH disease involves autoreactive T-cells directed against tyrosinase, 
possibly triggered by molecular mimicry.39,40 Tyrosinase involvement in CME might be in part due 
to damage of RPE, which plays a crucial role in the pathogenesis of CME. Previously, it has been 
noted that use of eye drops toxic for melanocytes also causes increased activity of tyrosinase.41 
It might be that an immune response directed against tyrosinase is indicative for ocular diseases 
that affect the pigmented layers within the eye. 
The spectrum of multiple AOcAs found in different uveitis entities suggest a secondary production 
of AOcAs in uveitis rather than its inciting role. The presence of AOcAs in these patients might 
be explained by a secondary formation induced by ocular tissue damage. Ocular antigen release 
by leakage through the blood-retina-barrier might cause exposure to the immune system and 
activate the production of systemic AOcAs, which then diffuse back into the eye. Intraocular 
AOcAs may contribute to the aggravation of uveitis and have a modulating role in the course of 
the disease. In contrast, an inciting role of intraocular AOcAs has been proposed in the patho-
genesis of autoimmune retinopathies (including cancer-associated- and melanoma-associated 
retinopathies), but the possible intraocular production of AOcAs in patients with AIR was not yet 
investigated.42 However, details on the pathogenicity of most AOcAs are lacking and the presence 
of natural intraocular autoantibodies is unknown.43,44 The mere presence of AOcAs does not 
automatically relate to a disease. The absence of a standardized and validated method for AOcA 
testing complicates the determination of the possible role of specific AOcAs.8,45
In the present study, we have chosen for the use of continuous values of the signal intensities 
from the multiplex assay for our statistical analyses, since this approach is more sensitive than 
the use of dichotomous values. One could argue that by using continuous data, outcomes might 
have been influenced by background signals, which cannot be distinguished from signals from 
measured antibodies bound to the beads. However, the use of dichotomous data has similar 
limitations as this approach demands a specific cut-off determination, which similarly is influenced 
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by the background signal and would be in consequence arbitrary.  Despite this drawback of our 
laboratory method, it has given us the opportunity to analyze a great number of antigens in a 
very small amount of material and indicates the potentially relevant ocular targets. Our study 
includes measurements of intraocular fluids without simultaneous analyses of AOcAs in serum. 
Comparison of intraocular AOcAs levels with the levels of AOcAs in serum might indicate which 
AOcAs are indicative of intraocular production and possibly clinically relevant.5 Exploration of 
simultaneously collected serum and intraocular fluid for potential interesting ocular autoanti-
bodies that were observed in this study could provide valuable information. The multiplex assay, 
which we used for the antibody profiling, however does not allow direct comparison of AOcA 
levels between serum and intraocular fluid. 
In conclusion, our results show moderately increased levels of a broad spectrum of AOcAs in 
multiple uveitis entities. High levels of specific AOcAs were observed in intraocular fluid of patients 
with VZV-induced uveitis, MS-associated uveitis and idiopathic uveitis with positive quantiferon 
test. The results of this study may serve as a platform for future exploration in the pathogenesis 
of specific uveitis entities. 
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ABSTRACT
Purpose: To analyze intraocular cytokine levels and prevalence of intraocular antiretinal anti-
bodies (ARAs) in patients with retinitis pigmentosa (RP), age-related macular degeneration (AMD), 
glaucoma and cataract, and correlate the results to clinical manifestations.
Methods: We collected intraocular fluid samples from patients with RP (N=25), AMD (N=12), 
glaucoma (N=28) and cataract (N=22), and serum samples paired with the intraocular fluids from 
patients with RP (N=7) and cataract (N=10). Interleukin(IL)-1β, IL-1ra, IL-2, IL-6, IL-6rα, IL-7, IL-8, 
IL-10, IL-17A, IL-23, thymus- and activation-regulated chemokine (TARC), monocyte chemoattrac-
tant protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-α), placental growth factor (PlGF) and 
vascular endothelial growth factor (VEGF) were measured using a multiplex assay. ARA detection 
was performed by indirect immunofluorescence.
Results:  Increasing age was associated with increasing levels of IL-6, IL-8, TNF-α and VEGF. All 
patient groups exhibited distinct profiles of intraocular cytokines. Intraocular levels of IL-8 were 
highest in patients with AMD and glaucoma. Cataract patients exhibited high intraocular levels of 
IL-23. Intraocular levels of IL-2, IL-6, MCP-1 and PlGF in RP patients exceeded the levels of serum, 
indicating intraocular production. Intraocular ARAs were found in only one patient with AMD.
Conclusions: Increased levels of inflammatory cytokines in intraocular fluid of patients with 
originally non-inflammatory ocular diseases show that intraocular inflammation is involved in 
their pathogenesis of these entities. Moreover, we  show that increasing age is associated with 
increasing levels of intraocular cytokines, and conclude that future studies on intraocular medi-
ators should be corrected for age of patients.
Intraocular cytokines in non-inflammatory ocular diseases
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INTRODUCTION
Retinitis pigmentosa (RP), age related macular degeneration (AMD) and glaucoma are ocular 
diseases that can cause irreversible damage, resulting in reduced visual acuity and blindness. 
Treatment options are often limited; so far, no cure is available for these diseases and only some 
of their complications can be prevented or treated. The pathogenesis of RP, AMD and glaucoma 
is not fully clarified, but a growing body of evidence documents the involvement of the immune 
system. Further insights into the role of immune activation could lead to potential new therapeutic 
modalities for these blinding diseases.
Recent studies identified autoantibodies directed against retinal tissue in serum of patients 
with RP, AMD or glaucoma.1,2 An association between antiretinal antibodies (ARAs) in serum and 
macular edema has been observed in RP.3 Decrease of serum ARA levels were reported after 
intravitreal anti-vascular endothelial growth factor (VEGF) therapy in AMD.4 Also, a variant of the 
complement factor H (CFH) gene, which causes uncontrolled complement activation, has been 
linked to AMD.2 Presence of ARAs in aqueous humor and serum have been observed in patients 
with glaucoma and in neurodegenerative damage of the optic nerve.5 Further, elevated levels of 
different chemokines, including  monocyte chemotactic protein 1 (MCP-1) and interleukin IL-8, 
as well as the pro-inflammatory cytokine IL-6,  have been described  in aqueous humor of RP, 
AMD and glaucoma.6-11
Autoimmune reactions against retina, choroid and/or retinal pigment epithelium (RPE) might 
contribute to continuation and/or aggravation of some of these initially non-inflammatory ocular 
diseases.2,12 However, the role of autoimmune reactions within the eye and comparison of inflam-
matory reactions between different degenerative ocular diseases has been scarcely addressed. 
Herein, we investigate specific cytokine-, chemokine- and growth factor levels, and presence of 
ARAs in intraocular fluid samples in patients with RP, AMD, glaucoma and cataract, and relate the 
laboratory outcomes to clinical manifestations.
METHODS
Sample collection
In this cross-sectional study, we obtained intraocular fluid samples from 87 patients with RP, AMD, 
glaucoma and cataract (controls) from the biobank at the Erasmus University Medical Center and 
the biobank of the Rotterdam Eye Hospital. Ocular fluids within the biobank were collected during 
the beginning of a cataract extraction. The study was approved by the local ethics committee 
from the Erasmus University Medical Center (Medical Ethics Committee Erasmus MC) and the 
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ethics committee from the institutional research board from the Rotterdam Eye Hospital, and 
adhered to the tenets of the Declaration of Helsinki. All intraocular fluid samples were stored at 
-80°C. Serum samples paired with intraocular fluids of 7 patients with RP and 10 patients with 
age related cataract were also obtained from the biobank. 
Patient and data collection
The diagnosis of RP was based on clinical characteristics such as night blindness, visual field 
constriction, retinal abnormalities observed through fundoscopy, and/or electroretinographic 
changes confirming the presence of RP-related photoreceptor damage. The diagnosis of AMD 
was carried out through clinical examination and optical coherence tomography. Diagnosis of 
glaucoma was based on the clinical presentation with high intraocular pressure, optic nerve 
damage and/or on characteristic visual field loss. Participants suffering from ocular comorbidity 
or from a combination of included ocular diseases were excluded.  
Clinical characteristics of all patients were collected. For RP patients, the presence of cystoid mac-
ulopathy (CM) was assessed as: 1). no CM, 2). any prior CM, and/or 3). current CM (<4 weeks prior 
to sample collection). For patients with AMD, differentiation between exudative and dry AMD was 
made and treatment with anti-VEGF was noted: 1). no anti-VEGF medication, 2). any prior use of 
anti-VEGF medication and/or 3). current use of anti-VEGF medication (<4 weeks prior to sample 
collection).  Patients with glaucoma were classified by the type of their glaucoma. Prescription 
of antihypertensive eye drops and filtrating surgery prior to sample collection were registered.  
Cytokine analysis
Measurement of interleukins (IL-1 β, IL-1ra, IL-2, IL-6, IL-6rα, IL-7, IL-8, IL-10, IL-17A, IL-23), thymus- 
and activation-regulated chemokine (TARC), MCP-1, tumor necrosis factor-alpha (TNF-α), placental 
growth factor (PlGF) and VEGF was performed with a Luminex multiplex bead immunoassay 
system (R&D Systems Europe, Ltd; UK). The selection of the cytokine panel was based on potential 
relevance according to previous reports and/or possible targets for treatment options.7,8,11,13,14 
The assays were performed according to the manufacturer’s instructions with exception of one 
additional dilution step within the standards (in total 7 standard dilutions). Fifty µL of undiluted 
intraocular fluid samples were transferred to the plate, with exception of intraocular fluid samples 
with insufficient amount of material (N =16), which were diluted to a total volume of 50 µL. Serum 
samples were diluted two-fold according to the manufacturer’s standard protocol. Measurements 
were performed on a Bio-Plex MAGPIX machine and data was analyzed using Bio-Plex Manager 
MP software.
Antiretinal antibody analysis
Presence of ARAs was assessed by indirect immunofluorescence (IIF) using primate retinal tissue 
(Euroimmun) and evaluated as described before in ten Berge et al.15 IIF was conducted with 
Intraocular cytokines in non-inflammatory ocular diseases
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intraocular fluids samples with sufficient volume available, and on all serum samples. Samples 
that displayed nuclear staining on retinal tissue were also analyzed in a routine IIF antinuclear 
antibody (ANA) screening test using HEp-2 cells (Inova).
Statistical analysis 
Data from the Luminex immunoassay were analyzed both as continuous data as well as categor-
ical data. For the continuous analyses, values below the lower limit of detection were replaced 
by the lowest value of the reference curve. For categorical analyses, we used the lowest value 
of the reference curve as cut-off point. Continuous variables were summarized using medians 
and ranges and categorical variables were summarized using percentages. Logistic regression 
for categorical data and linear regressions for continuous data with age, gender and diagnosis 
in the model were assessed to compare laboratory outcomes between diagnosis groups. Statis-
tical analyses were performed using IBM SPSS Statistics, version 21 and a p-value of <0.05 was 
considered as statistically significant.
RESULTS
Patient characteristics
Aqueous humor samples were obtained from a total of 87 patients: RP (N =25), AMD (N =12), 
glaucoma (N =28) and cataract (N =22).  Serum samples obtained simultaneously with intraocular 
fluids samples were available from 17 patients: RP (N =7) and cataract patients (N =10). Gender 
distribution did not differ between groups, but age differed significantly (p<0.001); specifically 
patients with AMD were older and patients with RP were younger (Table 1). The AMD group con-
sisted of 10 patients with dry and 2 patients with exudative AMD.  The classification of glaucoma 
included primary open angle glaucoma (POAG, N =22), narrow-angle glaucoma (N =4), normal 
tension glaucoma (N =1) and glaucoma secondary to pigment dispersion syndrome (N =1). 
Table 1. Patient characteristics 
Retinitis 
pigmentosa
Age-related 
macular 
degeneration
Glaucoma Cataract p-value 
Total number of patients N=25 N=12 N=28 N=22
Median age in years (range) 51 (25-86) 84 (68-94) 73 (50-88) 66 (17-80) < 0.001
Gender (male) 12/25 (48%) 3/12 (25%) 13/28 (46%) 8/22 (36%) n.s.
Abbreviation: n.s.= not significant (p>0.05)
138
CHAPTER 11
Prevalence of intraocular cytokines
The prevalence of cytokines, chemokines and growth factors in intraocular fluid is summarized in 
the Supplementary Table. Gender did not influence the prevalence of cytokines. The prevalence 
of intraocular IL-6 and TNF-α increased with age (p=0.012 and p=0.002, respectively). IL-2 and 
MCP-1 were present in all intraocular fluid samples, while IL-1 β and IL-17A were undetectable in 
all intraocular fluid samples. TARC was detected in intraocular fluid of patients with RP, AMD and 
glaucoma, but not in cataract patients. Differences in presence of cytokines in intraocular fluids 
between ocular diseases were however not significant. No associations were found between 
clinical characteristics (such as duration of disease or treatment) and the mere presence of 
cytokines, chemokines or growth factors in intraocular fluid.
Prevalence of cytokines in paired intraocular and serum samples
A similar cytokine profile was found in serum and intraocular fluid in RP patients, except for IL-2 
and IL-6, which were more often present in the intraocular fluid samples, and IL-1ra and TARC, 
which were more frequently observed in serum. Presence of serum cytokines was not different 
between RP patients and cataract patients.
Levels of intraocular cytokines
Linear regressions using specific diagnosis, age and gender in the model showed that intraocular 
levels of IL-6, IL-8, TNF-α and VEGF correlated positively with age (p=0.009, p=0.049, p=0.019 
and p<0.001, respectively; Figure 1). Gender showed no association with intraocular cytokine 
levels. Different cytokine profiles were observed for RP, AMD, glaucoma and cataract, specifically 
intraocular levels of IL-6rα (p=0.019), IL-8 (p=0.032), and IL-23 (p<0.004) differed between the 
studied ocular diseases (Figure 2). RP patients were characterized by low levels of intraocular 
IL-8 and IL-23. Intraocular IL-8 levels were highest in patients with AMD and glaucoma. Cataract 
patients had high levels of IL-23. Intraocular levels of IL-6rα were higher in patients with RP or 
glaucoma than in patients with AMD or cataract. VEGF levels were highest in intraocular fluids of 
AMD patients and lowest in RP, though the differences did not reach significance after correction 
for age (Table 2).
RP patients who ever had CM during their disease course, exhibited lower intraocular IL-2 levels 
than RP patients without CM (p=0.042). Glaucoma patients treated with antihypertensive eye 
drops displayed lower intraocular IL-6 levels compared to glaucoma without this treatment 
modality (p<0.001). Intraocular IL-8 levels were higher in glaucoma patients who underwent 
surgical treatment (p=0.035).  
Intraocular cytokines in non-inflammatory ocular diseases
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Figure 1. Levels of intraocular cytokines in relation to age
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Levels of cytokines in paired intraocular and serum samples
IL-2, IL-6, MCP-1 and PlGF levels were higher in intraocular fluid than in serum in both RP (p<0.001, 
p=0.001, p<0.001 and p=0.006) and cataract (p<0.001, p=0.047, p<0.001 and p<0.001). Moreover, 
cataract patients had higher levels of IL-23 in intraocular fluid than serum (p=0.043). In contrast, 
intraocular IL-23 levels in RP were lower than the serum levels (p<0.001). Intraocular levels of all 
other cytokines, chemokines and growth factors in intraocular fluid did not exceed serum levels. 
Levels of serum cytokines were not different between RP patients and cataract patients.
Prevalence of antiretinal antibodies 
ARAs were not detected in intraocular fluid samples from RP (N = 21), glaucoma (N =18), and 
cataract (N =16). In one patient with AMD (1/8, 13%) intraocular ARA were detected. Serum ARAs 
were detected in 5/7 (71%) patients with RP and 6/10 (60%) patients with cataract. All samples 
with nuclear staining on retinal tissue (N =7) were negative for ANA.
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Table 2. Levels of cytokines in different ocular disease
Cytokines 
(median, 
ranges)
Retinitis pigmentosa Age-related 
macular 
degeneration
Glaucoma Cataract p-value 
(comparison 
of IOF)IOF Serum p-value IOF Serum p-value
Cy
to
ki
ne
s
IL-1β 5 
(5-5)
5 
(5-5)
n.s. 5 
(5-5)
5 
(5-5)
5 
(5-5)
5 
(5-5)
n.s. n.s.
IL-1ra 33 
(9-3673)
576 
(426-2436)
n.s. 121 
(9-1169)
65 
(9-876)
124 
(9-2357)
608 
(328-1043)
n.s. n.s.
IL-2 292 
(142-899)
33 
(33-93)
<0.001 282 
(205-1727)
271 
(151-1371)
275 
(212-1101)
136 
(15-262)
<0.001 n.s.
IL-6rα 95 
(33-489)
41505 
(39074-50271)
<0.001 85 
(42-169)
99 
(22-502)
87 
(24-263)
44327 
(34714-58859)
<0.001
0.019
IL-6 4 
(1-140)
1
(1-1)
0.001 14 
(1-104)
5 
(1-192)
2 
(1-151)
1 
(1-3)
0.047 n.s.
IL-7 3 
(1-6)
4 
(1-7)
n.s. 2 
(1-7)
3 
(1-12)
1 
(1-9)
5 
(2-7)
0.004 n.s.
IL-10 3 
(3-5)
3 
(3-3)
n.s. 3 
(3-8)
3 
(3-7)
3 
(3-8)
5 
(3-24)
n.s. n.s.
IL-17A 8 
(8-8)
8 
(8-8)
n.s. 8 
(8-8)
8 
(8-8)
8 
(8-8)
10 
(8-25)
n.s. n.s.
IL-23 176 
(77-3611)
812 
(539-919)
0.001 240 
(77-2844)
315 
(77-2828)
2592 
(144- 3493)
750 
(510-945)
0.043 0.004
TNF-α 2 
(2-5)
2 
(2-3)
n.s. 3 
(2-4)
2 
(2-4)
2 
(2-3)
2 
(2-4)
n.s. n.s.
Ch
em
ok
in
es
IL-8 3 
(1-46)
6 
(2-21)
n.s. 9 
(1-28)
9 
(1-56)
6 
(1-16)
7 
(1-12)
n.s. 0.032
TARC 28 
(28-57)
180 
(101-681)
<0.001 28 
(28-37)
28 
(28-57)
28
(28-28)
262 
(62-470)
<0.001 n.s.
MCP-1 891 
(339-1805)
256 
(201-451)
<0.001 638 
(256-1035)
731 
(264-3495)
618 
(249-1920)
320 
(120-478)
<0.001 n.s.
G
ro
w
th
 
fa
ct
or
s
PlGF 6 
(0-26)
1 
(0-1)
0.006 6 
(0 -13)
5 
(0-13)
5 
(2-12)
1 
(0-2)
<0.001 n.s.
VEGF 18 
(2-108)
52 
(18-107)
0.020 88 
(45-210)
54 
(9-159)
63 
(7-101)
73 
(18-126)
n.s. n.s.
Abbrevations: IOF = intraocular fluid, n.s.= not statistically significant (p>0.05)
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Table 2. Levels of cytokines in different ocular disease
Cytokines 
(median, 
ranges)
Retinitis pigmentosa Age-related 
macular 
degeneration
Glaucoma Cataract p-value 
(comparison 
of IOF)IOF Serum p-value IOF Serum p-value
Cy
to
ki
ne
s
IL-1β 5 
(5-5)
5 
(5-5)
n.s. 5 
(5-5)
5 
(5-5)
5 
(5-5)
5 
(5-5)
n.s. n.s.
IL-1ra 33 
(9-3673)
576 
(426-2436)
n.s. 121 
(9-1169)
65 
(9-876)
124 
(9-2357)
608 
(328-1043)
n.s. n.s.
IL-2 292 
(142-899)
33 
(33-93)
<0.001 282 
(205-1727)
271 
(151-1371)
275 
(212-1101)
136 
(15-262)
<0.001 n.s.
IL-6rα 95 
(33-489)
41505 
(39074-50271)
<0.001 85 
(42-169)
99 
(22-502)
87 
(24-263)
44327 
(34714-58859)
<0.001
0.019
IL-6 4 
(1-140)
1
(1-1)
0.001 14 
(1-104)
5 
(1-192)
2 
(1-151)
1 
(1-3)
0.047 n.s.
IL-7 3 
(1-6)
4 
(1-7)
n.s. 2 
(1-7)
3 
(1-12)
1 
(1-9)
5 
(2-7)
0.004 n.s.
IL-10 3 
(3-5)
3 
(3-3)
n.s. 3 
(3-8)
3 
(3-7)
3 
(3-8)
5 
(3-24)
n.s. n.s.
IL-17A 8 
(8-8)
8 
(8-8)
n.s. 8 
(8-8)
8 
(8-8)
8 
(8-8)
10 
(8-25)
n.s. n.s.
IL-23 176 
(77-3611)
812 
(539-919)
0.001 240 
(77-2844)
315 
(77-2828)
2592 
(144- 3493)
750 
(510-945)
0.043 0.004
TNF-α 2 
(2-5)
2 
(2-3)
n.s. 3 
(2-4)
2 
(2-4)
2 
(2-3)
2 
(2-4)
n.s. n.s.
Ch
em
ok
in
es
IL-8 3 
(1-46)
6 
(2-21)
n.s. 9 
(1-28)
9 
(1-56)
6 
(1-16)
7 
(1-12)
n.s. 0.032
TARC 28 
(28-57)
180 
(101-681)
<0.001 28 
(28-37)
28 
(28-57)
28
(28-28)
262 
(62-470)
<0.001 n.s.
MCP-1 891 
(339-1805)
256 
(201-451)
<0.001 638 
(256-1035)
731 
(264-3495)
618 
(249-1920)
320 
(120-478)
<0.001 n.s.
G
ro
w
th
 
fa
ct
or
s
PlGF 6 
(0-26)
1 
(0-1)
0.006 6 
(0 -13)
5 
(0-13)
5 
(2-12)
1 
(0-2)
<0.001 n.s.
VEGF 18 
(2-108)
52 
(18-107)
0.020 88 
(45-210)
54 
(9-159)
63 
(7-101)
73 
(18-126)
n.s. n.s.
Abbrevations: IOF = intraocular fluid, n.s.= not statistically significant (p>0.05)
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Figure 2. Levels of intraocular cytokines in relation to ocular diagnosis
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DISCUSSION
Our study describes different pro-inflammatory intraocular cytokine profiles in RP, AMD, glaucoma 
and cataract, and reveals a positive correlation between intraocular cytokine levels and increasing 
age. Interestingly, intraocular fluid samples from cataract patients displayed the highest levels of 
IL-23. Though intraocular levels of VEGF were highest in AMD patients, after age correction no 
significant differences were found between the various diagnostic groups. Comparison of paired 
serum and intraocular fluid samples of RP patients showed that intraocular levels of IL-2, IL-6, 
MCP-1 and PlGF exceeded the serum levels, suggesting a local production. Intraocular ARAs were 
absent in nearly all samples.
Although a genetic mutation is the cause of RP, inflammation was suggested to have a (secondary) 
role in the disease pathogenesis.2,16,17 It has been reported that RP patients with CM exhibited 
more often ARAs in their peripheral blood.18 Conform these findings, in our series we observed 
ARAs in all RP patients with CM. However, in contrast to serum, ARAs were not at all detected in 
intraocular fluids of patients with RP. 
Previous reports on intraocular cytokines in RP show higher levels of IL-6, IL-8, MCP-1 and TARC 
in RP compared to cataract.11,19 We observed also intraocular presence of these mediators in 
RP patients, but their levels were not elevated compared to other groups. This discrepancy may 
be explained by the low number of included patients in our study, or possible differences in 
disease stage and/or extent of degeneration. Yet RP patients, like glaucoma patients, had higher 
intraocular levels of soluble IL-6rα (sIL-6rα) compared to cataract. sIL-6Rα interacts with IL-6, 
forming the IL-6/sIL-6Rα complex, which subsequently induces IL-6 trans-signaling by binding 
cell membrane expressed gp130.20 IL-6 trans-signaling is recognized to enhance IL-6 activity 
under inflammatory conditions and moreover to inhibit intra-ocular T-cell apoptosis in uveitis, 
which likely exacerbates or prolongs the disease process.21-23 Further we observed a significant 
association between lower levels of intraocular IL-2 (a growth factor for regulatory T-cells) in RP 
patients who had CM. This may indicate a deregulated immune function, such as loss of tolerance, 
affecting the clinical manifestation of the disease and the formation of serum ARAs as observed 
in this and other studies. Intraocular VEGF levels were lowest in the RP group, which is in line with 
the rare presence of retinal neovascularization in RP.
Inflammation was implicated in the development and progression of AMD.24 So far, most previous 
studies investigated intraocular fluids of exudative AMD, demonstrating high levels of inflamma-
tory mediators, including IL-6, IL-8, MCP-1 and VEGF.6,25 However, it is still unknown whether these 
cytokines play a role in the primary pathogenesis of AMD or represent a secondary result of the 
disease process. We investigated patients with mainly dry AMD and observed higher intraocular 
IL-8 compared to cataract and RP. Previous studies revealed that elevated (intraocular) levels of 
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IL-8 and IL-8 gene polymorphisms were associated with angiogenesis.26,27 IL-6 and VEGF reached 
highest levels in the AMD group, though not significantly different compared to other diagnosis 
groups. According to previous studies, these mediators have been implicated in angiogenesis, 
and decrease during treatment with anti-VEGF agents.8,28 Retinal neuroprotective effects of VEGF 
have also been described,  yet data on this matter are inconclusive and may be dependent on 
the VEGF variant, disease (stage) or experimental model used.29,30
In glaucoma the role of immune reactions is not known and could be either pathogenic or 
neuroprotective. In our study patients with glaucoma, who consisted mainly of POAG, were 
characterized by high intraocular levels of IL-8, consistently with previous findings.31-34 IL-8 is a 
main chemoattractant for neutrophils which have been found to accumulate in the trabecular 
meshwork in POAG.35 The highest levels of IL-8 were found in glaucoma patients who underwent 
surgical treatment prior to the surgical procedure during intraocular sample collection. This 
suggest that higher levels of IL-8 might be explained by immune activation in response to (sur-
gically inflicted) tissue damage. Increased TNF-α levels have been reported in intraocular fluid, 
the trabecular meshwork, optic head and the retina of glaucoma patients, however in our study 
intraocular TNF-α appeared undetectable in most cases.33,35-39 This discrepancy may have resulted 
from differences in laboratory techniques and specific patient groups. So far, to our knowledge, 
only sporadic studies are available on the effect of anti-TNF medication in glaucoma, which show 
an increase of fibrosis after surgical treatment.40
In our study, cataract was generally characterized by lower levels of pro-inflammatory mediators 
compared to other studied diseases, with the exception of IL-23. IL-23, produced by dendritic 
cells/myeloid cells, is well known for its key role in several autoimmune diseases via the IL-23/
IL-17axis and associated pathological Th17 development.41,42 Despite the presence of IL-23 in 
most intraocular fluids analyzed in our study, IL-17A was never detected. Interestingly, some 
studies report immunosuppressive effects of IL-23 within tumor microenvironments by suppress-
ing lymphocyte effector function and enhanced production of immune-regulatory cytokines.43-45 
Also in a model of experimental autoimmune uveitis it was found that IL-23 receptor expressing 
gd T cells can exert immune suppressive effects due to their ability to bind IL-23.46  Although 
the mechanism by which IL-23 can mediate immune suppressive effects clearly requires further 
study, it is tempting to speculate that the low intraocular IL-23 levels observed in patients with 
RP,  AMD and glaucoma may reflect diminished immune protection of the eye. Intraocular IL-23 
levels revealed no association with serum levels nor age of patients.
Aging is associated with development of a chronic state of low-grade tissue inflammation that also 
involves the retina, and is associated with increased susceptibility to multiple diseases, including 
glaucoma and AMD.47-50 In support of this, we observed a gradual increase of the intraocular 
levels of IL-6, IL-8, TNF-α and VEGF with increasing age. A positive correlation between intraocular 
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cytokine levels and age has been reported in two previous studies.31,34 As a consequence of this 
correlation, all of our results are adjusted for the age of patients. However, systematic corrections 
for age have not been performed in previous studies, which may have affected the interpretation 
of these findings. It should thus be kept in mind that studies on intraocular cytokine profiling 
without age adjustment (and without age matched control groups) may show age-related bias 
rather than disease-associated differences. 
Intraocular levels of IL-2, IL-6, MCP-1 and PlGF were higher than serum levels of patients with 
RP and cataract. The higher intraocular levels of inflammatory components may suggest local 
production, possibly by infiltrated immune cells or resident cells, such as retinal pigment epithe-
lial cells.51,52 These findings may contribute to the understanding of the pathogenesis of RP and 
development of new treatment possibilities. In contrast, the low occurrence of intraocular ARAs 
suggests a negligible role of such antibodies in disease pathogenesis of RP. ARAs detected in 
serum from RP and cataract patients may represent a reflection of altered blood retinal barrier 
properties. 
In conclusion, the expression of inflammatory cytokines within the eye was strongly influenced 
by the age of patients, which shows that the correction for age is necessary in future studies 
on intraocular mediators. Differences in intraocular cytokines profiles were observed between 
originally non-inflammatory ocular diseases, suggesting involvement of inflammation, however 
complex pathways with multiple signaling functions make a diagnostic role rather impossible. 
The role of immune reactions in basically non-inflammatory ocular diseases might influence the 
clinical manifestations and severity of ocular changes. 
SUPPLEMENTARY DATA
Supplementary Table. Prevalence of cytokines in different ocular disease 
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SUMMARY
Autoimmune reactions have been implicated in various ocular diseases but their presence and 
pathogenic role have been scarcely proven. Autoimmunity was especially linked to uveitis (a collec-
tive term for any intraocular inflammation) and autoimmune retinopathy (AIR), but also to retinitis 
pigmentosa (RP), age-related macular degeneration (AMD) and glaucoma. Obviously, if autoimmu-
nity plays a principal role in these diseases, the downregulation of autoimmune reactions might 
bring a beneficial effect to affected patients. The work presented in this thesis aims to assess the 
presence of humoral autoimmunity in uveitis and other chorioretinal diseases, including AIR, and to 
clarify its potential role in their pathogenesis. This summary presents the main findings of this thesis.
Chapter 1 provides a general introduction addressing the presence and the role of humoral 
autoimmunity in uveitis and other chorioretinal diseases. Autoimmunity is characterized by activ-
ity of the immune system directed against the body’s own cells and tissues. The immune system 
stops tolerating ‘self’ antigens, and autoreactive antibodies and/or T-cells attack the body’s own 
antigens. Convincing evidence exists that our immune system is able to react against our own 
retina and can produce antiretinal antibodies (ARAs). These ARAs can presumably attack and 
destroy retinal cells, and rapidly leading to visual loss or even blindness. Such reactions of the 
immune system have long been considered to play a major pathogenic role in uveitis. In other 
ocular diseases, such as RP, AMD and glaucoma, the formation of ARAs has also been observed 
and reported. However, the exact pathogenic role of antiretinal humoral autoimmunity in uveitis 
and other ocular diseases is not yet known. One current hypothesis includes the primary role of 
ARAs in the initiation of the chorioretinal diseases; another possibility addresses the secondary 
role of ARAs and proposes that the formation of ARAs in any ocular disease might cause a mild 
inflammation in the retina, that might negatively influence the course of the disease (e.g. by 
development of chronicity or enhancement of progression of retinal damage). 
In Chapter 2 we determine the prevalence of systemic immune-mediated diseases in a large 
cohort of 1327 patients with uveitis and/or scleritis, and put a special emphasis on prevalence of 
autoimmune and auto-inflammatory diseases according to novel findings in immune mediated 
diseases. In contrast to the widespread belief, it appeared that autoimmune uveitis is a rare 
diagnosis, which comprises only 5% (62/1327) of the total uveitis/scleritis population. The most 
common autoimmune diseases observed in patients with uveitis were multiple sclerosis (1.8%, 
24/1327) and Vogt Koyanagi Harada disease (1.1%, 14/1327). Patients with classical autoimmune 
connective tissue disease (N=17) suffered mostly from rheumatoid arthritis and granulomatosis 
with polyangiitis and exhibited predominantly scleritis (53%, 9/17). Optic neuropathy was the most 
frequent complication of autoimmune uveitis (44%, 27/62), and was predominantly observed in 
MS and Vogt Koyanagi Harada disease. Interestingly, the visual acuity in autoimmune diseases 
with uveitis remained stable during 5-year follow-up, possibly as a result of adequate treatment 
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with systemic immunomodulatory medication. None of the patients with autoimmune uveitis/
scleritis developed permanent bilateral visual acuity of less than 0.1. In this study we emphasize 
that the term “autoimmune uveitis” should be reserved exclusively for intraocular inflammations 
of confirmed autoimmune origin and should not be used as a synonym for all non-infectious 
uveitis cases.
In Chapter 3 we prospectively evaluate the presence of antinuclear antibody (ANA) and the 
diagnostic value of ANA profiling in 105 adult patients with uveitis. ANAs are antibodies directed 
against a variety of nuclear antigens, and can be detected in elevated levels in serum of patients 
with genuine autoimmune diseases such as systemic lupus erythematosus, but can also be prev-
alent in other disease types and in the general population, predominantly in women and elderly. 
Our study showed that 28% of patients with uveitis is positive for ANA whilst only 8-17% of the 
healthy population is considered ANA positive. ANA positivity was more prevalent in patients with 
infectious uveitis (31%) than patients with systemic immune mediated diseases (20%). We did not 
observe any relationship between the presence of ANA, ANA titer, or specific ANA patterns and 
specific diagnoses or clinical characteristics of uveitis. The discrimination of autoimmune systemic 
diseases in uveitis by ANA profiling seems not possible, however this cannot be entirely excluded 
since we included a limited number of patients in the specific diagnostic groups. Based on our 
findings, we concluded that ANA profiling in the adult uveitis population has limited diagnostic 
value and that ANAs are probably not involved in the pathogenesis of uveitis.
Chapter 4 describes the prevalence and possible clinical relevance of ARAs in serum in a pro-
spective study of 126 patients with different uveitis entities and compares it with 60 blood bank 
donors. Screening for the presence of ARAs was performed by indirect immunofluorescence 
(IIF) using primate retinal tissue. Although IIF does not allow antigenic specification of ARAs, this 
technique is very sensitive and therefore represents a useful screening assay. In our study, serum 
ARAs were observed in 47% of patients with uveitis and were more frequent in uveitis when com-
pared with healthy controls (17%, p<0.001). Specific associations between the presence of serum 
ARAs or its subtypes (based on typical staining patterns on IIF) and clinical ocular characteristics of 
uveitis were not observed. These results suggest that serum ARAs reflect a secondary response 
of the immune system to damaged ocular tissue, and probably have no inciting role in uveitis. 
In Chapter 5 we attempt to determine the possible diagnostic role of both known and unknown 
ARAs in patients with AIR. AIR encompasses a group of rare diseases most commonly presenting 
as paraneoplastic syndromes in combination with various malignancies. Multiple serum ARAs 
have been reported in AIR, and it was assumed that ARAs are directly involved in retinal destruc-
tion and rapidly progressive loss of vision. So far, however, only few retinal antigens in AIR were 
specified and studied. To investigate this more extensively, we performed a multicenter study 
in cooperation with the SciLifeLab Autoimmunity Profiling Facility in Stockholm (Sweden). Serum 
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samples of 24 patients with presumed AIR were examined for the presence of antibodies against 
multiple retinal antigens by autoantibody profiling and compared to 151 uveitis patients and 21 
cataract controls. Antigens used for the autoantibody profiling consisted of 188 peptide frag-
ments derived from 97 unique ocular proteins produced within the Human Protein Atlas of the 
Swedish laboratory and profiling was performed by a multiplex bead array based immunoassay. 
We found that patients with presumed AIR were characterized by the presence of multiple serum 
ARAs, and that the spectrum of ARAs differed widely among individual patients with AIR. Autoan-
tibodies directed against the retinal antigen recoverin were the most prevalent ARAs in patients 
with presumed AIR (13%). Despite the high levels of multiple ARAs in AIR, our findings clearly 
show that serum ARAs are also present in patients with cataract and uveitis, and consequently 
the specificity of ARAs as markers for AIR was low. We concluded that the diagnosis of AIR cannot 
be based on the mere presence of (multiple) serum ARAs. 
In Chapter 6 we demonstrate the medical history of a patient with paraneoplastic AIR. The patient 
presented with progressive severe visual loss in both eyes. He also suffered from loss of his 
peripheral vision, and in his serum high levels of ARAs directed against recoverin were detected. 
After referral to an internist he was diagnosed with lung carcinoma. The patient was treated with 
chemo-/radiotherapy and high dosage of corticosteroids, unfortunately without any effect on the 
visual performance of the patient. A lung carcinoma is the most commonly associated malignancy 
in paraneoplastic AIR, however any type of malignancy can be involved in this disease. Usually both 
eyes are affected, but unilateral cases also have been described. Visual complaints may precede 
detection of the malignancy, which makes the role of the ophthalmologist vital.  Treatment options 
in cancer-associated AIR are limited and visual prognosis is often very poor. 
In Chapter 7 we investigate the presence and possible role of ARAs directed against retinal tissue 
in central serous chorioretinopathy (CSC). Although little is known about the exact cause of CSC, 
genetic variants in the complement system of patients with CSC indicate a possible role of the 
immune system. We retrospectively analysed serum of 63 patients with CSC for the presence 
of ARAs by IIF and Western blot with retinal protein extract and compared those to 101 uveitis 
patients, and 60 healthy donors. The Western blot allowed us to approximate the antigen size 
of observed ARAs, which  indicates the presence of specific ARAs. We detected ARAs in 54% of 
patients with CSC compared to 46% of patients with uveitis (p>0.05) and 17% of healthy controls 
(p<0.001). Interestingly, the ARAs in CSC were more often directed against the photoreceptors 
(27%) than in uveitis (15%, p=0.039), however staining patterns on retinal tissue were divers, indi-
cating the presence of various ARAs. Western blot analysis showed multiple ARA reactive antigens 
in retinal extract in the majority of patients with CSC. This heterogeneity and variable presence 
of ARAs in CSC make a primary role of ARAs in CSC unlikely. Furthermore, the mere presence of 
serum autoantibodies does not necessarily indicate an autoimmune basis of the disease and 
shows that, similar to uveitis, ARAs might be secondary and induced by the retinal damage. 
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In Chapter 8 we retrospectively explore the prevalence of systemic and retinal autoantibodies 
in patients from Indonesia with uveitis and either active or latent tuberculosis (TB). In Indonesia, 
uveitis associated with active systemic and latent TB is highly prevalent. The pathogenesis of 
uveitis in the setting of latent TB is not clarified. One of the hypotheses presumes the immune 
reaction to mycobacterial antigens and their molecular mimicry with retinal antigens. We inves-
tigated the presence of ARAs and ANAs in 95 Indonesian patients with uveitis classified into 3 
groups: uveitis associated with active TB (N=10),  with latent TB (N=58) and without evidence for 
prior or current TB (N=85). We found that patients with uveitis and either active or latent TB were 
characterized by a low proportion of ocular-specific auto-reactivity (ARAs) and a high prevalence 
of systemic auto-reactivity (ANA), compared to uveitis patients who had no evidence of previous 
contact with M. tuberculosis (p=0.03 and p=0.021). The lower prevalence of ARAs in serum does 
not point toward an autoimmune pathogenesis in uveitis associated with latent or active tuber-
culosis, however assessment of intraocular ARAs might show an entirely different pattern and 
clinical relevance of autoimmune processes in uveitis with active or latent TB.
In Chapter 9, we perform a retrospective study and assess the presence of ARAs in young Mex-
ican patients with severe pars planitis (N=16) and compare the results to Mexican age-matched 
controls (N=19). An exceptionally severe form of pars planitis of unknown origin is observed in 
pediatric Mexican patients. Despite the extensive examinations, the cause of this disorder is not 
clarified. Pars planitis is considered to be of autoimmune origin, but the exact pathogenesis is not 
known. Investigation of serum samples of pars planitis patients for the presence of ARAs showed a 
prevalence of 57%, however a comparable prevalence (40%) was observed in Mexican control chil-
dren with strabismus. This high prevalence of ARAs in young control patients could be the result 
of a higher exposure to exogenous antigens (e.g. infections). Similar to the Netherlands, these 
results suggest that ARAs are not the primary cause of uveitis, but possibly represent a secondary 
phenomenon. Nevertheless, a cellular autoimmune component or investigation of intraocular 
material might still point in the direction of an autoimmune pathogenesis in pars planitis. 
In the last chapters we left the serological analysis and explore the determination of humoral 
autoimmune reactions in intraocular fluid. Chapter 10 is a retrospective study that investigates 
intraocular fluid samples from 76 patients with uveitis and 19 cataract controls for the presence 
of ARAs. In collaboration the SciLifeLab Autoimmunity Profiling Facility in Stockholm (Sweden), we 
performed a multiplex immunoassay using the same 188 specific ocular antigens as in chapter 
5. We found a spectrum of 22 different ARAs in higher levels in patients with uveitis compared 
to cataract controls (p≤0.05), but in moderately elevated titers. High elevations (5-fold increased 
titers compared to cataract controls) of multiple ARAs were observed in three specific uveitis 
entities: varicella zoster virus-induced uveitis, multiple sclerosis-associated uveitis and patients 
with unexplained uveitis but positive quantiferon test (all p<0.05). Presence of macular edema 
was associated with high intraocular levels of tyrosinase antibodies (p=0.0026). The spectrum of 
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multiple ARAs in intraocular fluid of patients with uveitis favors a secondary production rather 
than their inciting role and implicate that uveitis in the setting of latent TB infection might be joint 
with intraocular autoimmune reactions. The results of this study may provide a platform for future 
exploration of specific ocular antigens in the pathogenesis of uveitis.
Inflammatory autoimmune processes were not only assumed to play a role in the pathogenesis 
of uveitis, but also in various originally non-inflammatory ocular diseases such as RP, AMD and 
glaucoma. Therefore, in Chapter 11 we retrospectively determine the levels of 15 intraocular 
cytokines and the prevalence of intraocular ARAs in patients with RP (N=25), AMD (N=12), glau-
coma (N=28) and cataract (N=22), and correlate the laboratory results to clinical manifestations. 
In addition, we studied serum samples paired with the intraocular fluids from patients with RP 
(N=7) and cataract (N=10). We observed that increasing age was associated with increasing levels 
of multiple intraocular cytokines and other mediators, and detected distinct cytokine profiles for 
each group of diagnoses. Specifically, intraocular levels of IL-6rα (p=0.003), IL-8 (p=0.032), and 
IL-23 (p<0.004) differed between the studied ocular diseases. In RP patients, intraocular levels 
of IL-2, IL-6, MCP-1 and PlGF exceeded the serum levels, which indicates an active intraocular 
production and involvement of these mediators in RP. Intraocular ARAs were found in only one 
patient with AMD, in contrast to serum ARAs that were detected in a majority of studied entities. 
The differences in cytokine profiles between ocular diseases, suggest a role of immune activity 
in the pathogenesis of these originally non-inflammatory ocular diseases. The involvement of 
immune reactions might contribute to continuation and/or aggravation of the disease.
CONCLUSIONS
Our results do not show any evidence for a primary role of retina specific autoantibodies in the ini-
tiation of uveitis and other chorioretinal diseases. The presence of serum ARAs in ocular diseases 
might be explained by a secondary formation induced by ocular tissue damage. Though higher 
levels of serum ARAs were found in patients with ocular disorders than in control population, we 
found no associations with specific disorders or clinical manifestations of studied ocular diseases. 
Moreover, our findings indicate that serum ARAs probably do not have an inciting role in AIR, and 
that the diagnosis of AIR cannot be based on the mere presence of serum ARAs.
The spectrum of intraocular ARAs in uveitis indicate some involvement of humoral autoimmu-
nity, predominantly in three specific disorders: varicella zoster virus-induced uveitis, multiple 
sclerosis-associated uveitis and patients with unexplained uveitis but positive quantiferon test. 
In addition, intraocular autoantibodies directed against tyrosinase have been associated with 
the presence of cystoid macular edema. Intraocular ARA production in AIR, especially in cancer 
associated retinopathies, would be an interesting topic for future research and could help clarify 
its pathogenesis and provide novel treatment opportunities.
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Het immuunsysteem lijkt een belangrijke rol te spelen in de pathogenese van verschillende oog-
ziekten. Met name bij uveïtis, een inwendige oogontsteking, lijkt het immuunsysteem betrokken 
te zijn, maar ook bij andere oogaandoeningen zoals retinitis pigmentosa (RP), leeftijdsgebonden 
maculadegeneratie (AMD) en glaucoom wordt een rol van het immuunsysteem verondersteld. 
Verder inzicht in de rol van het immuunsysteem bij netvliesaandoeningen kan in de toekomst als 
mogelijk aangrijpingspunt dienen voor gerichtere behandelingen van diverse oogaandoeningen. 
Het werk dat in dit proefschrift wordt gepresenteerd, heeft als doel de potentiële pathogene rol 
van (humorale) auto-immuun reacties bij uveïtis en enkele andere netvliesaandoeningen verder 
op te helderen. In deze samenvatting worden de belangrijkste bevindingen van dit proefschrift 
beschreven.
In hoofdstuk 1 wordt een algemene introductie gegeven over auto-immuniteit in uveïtis en 
andere oogaandoeningen. Auto-immuniteit wordt gekenmerkt door activiteit van het immuunsy-
steem gericht tegen eigen cellen en weefsels van het lichaam. Het immuunsysteem stopt met het 
tolereren van lichaamseigen antigenen, en auto-antistoffen (humorale immuniteit) en/of auto-re-
actieve T-cellen (cellulaire immuniteit) vallen het eigen lichaam aan. Er zijn aanwijzingen dat het 
immuunsysteem zich onder bepaalde omstandigheden tegen het eigen netvlies kan richten. 
Hierbij worden zogenaamde anti-retinale antistoffen (ARA’s) geproduceerd die mogelijk schade 
aan het netvlies kunnen aanbrengen. Tot op heden zijn de bewijzen voor de aanwezigheid van 
ARA’s bij oogaandoeningen schaars en is de rol van humorale auto-immuun reacties in de patho-
genese van uveïtis en andere oogaandoeningen onbekend. Diverse theorieën over ARA’s en hun 
mogelijke effect bij oogaandoeningen zijn ontwikkeld. Een van de hypotheses veronderstelt dat 
ARA’s specifieke oogaandoeningen initiëren; een andere hypothese suggereert dat ARA’s slechts 
een bijproduct zijn en de reeds bestaande ziekte nadelig kunnen beïnvloeden, bijvoorbeeld door 
het ontwikkelen van een chronisch of progressief beloop van de oogaandoening. 
In hoofdstuk 2 bepalen we de aanwezigheid van systemische immuun-gemedieerde ziektebeel-
den in een cohort van 1327 patiënten met uveïtis en/of scleritis (ontsteking van de harde oogrok). 
We leggen hierbij nadruk op de prevalentie van auto-immuniteit en auto-inflammatie in uveïtis. 
Het bleek dat auto-immuun uveïtis een zeer zeldzame diagnose is, welke slechts bij 5% (62/1327) 
van de totale uveïtis-/scleritis-populatie voorkomt. De meest voorkomende auto-immuunziekten 
bij patiënten met uveïtis waren multiple sclerose (MS; 1,8%, 24/1327) en de ziekte van Vogt-Koya-
nagi-Harada (VKH; 1,1%, 14/1327). Bij patiënten met systemische auto-immuun collageenziekten 
zoals reumatoïde artritis en granulomatose met polyangiitis kwam scleritis relatief veel voor (53%, 
9/17). Optische neuropathie (een beschadiging van de oogzenuw) was de meest voorkomende 
complicatie van auto-immuun uveïtis (44%, 27/62), en werd voornamelijk gezien bij MS en de 
ziekte van VKH. De visus van patiënten met auto-immuun uveïtis bleef gedurende 5 jaar follow-up 
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stabiel en niemand ontwikkelde een permanente bilaterale gezichtscherpte van minder dan 0.1, 
mogelijk door de adequate behandeling met systemische immunomodulerende medicatie. In dit 
onderzoek benadrukken wij dat de term ‘auto-immuun uveïtis’ uitsluitend gebruikt mag worden 
voor inwendige ontstekingen met bewezen karakteristieken van auto-immuun reacties, en het 
geen synoniem is voor een niet-infectieuze uveïtis.
In hoofdstuk 3 evalueren we de aanwezigheid en diagnostische waarde van antinucleair anti-
stoffen (ANA) bij 105 volwassen patiënten met uveïtis. ANA’s zijn antilichamen gericht tegen 
verschillende delen van de eigen celkern (nucleus). Deze kunnen worden gedetecteerd in een 
verhoogde titer in het bloed van patiënten met auto-immuunziekten, zoals systemische lupus 
erythematosus. Daarnaast kunnen ANA’s ook voorkomen bij de algemene bevolking, met name bij 
vrouwen en ouderen. Uit onze studie bleek dat 28% van de patiënten met uveïtis positief is voor 
ANA, wat hoger is dan de in de literatuur beschreven prevalentie van de ANA positieve gezonde 
bevolking (8-17%). Een positieve ANA in het bloed werd vaker geobserveerd bij patiënten met 
een infectieuze uveïtis (31%) dan bij patiënten met systemische immuun-gemedieerde ziekte 
(20%). We hebben geen verband gevonden tussen de aanwezigheid van ANA, de ANA titer of 
een specifiek ANA patroon en specifieke diagnoses of klinische kenmerken van uveïtis. Hierdoor 
lijkt het onderscheiden van de verschillende soorten uveïtis door middel van ANA-analyse niet 
mogelijk, maar dit kan niet volledig worden uitgesloten gezien het beperkt aantal patiënten in de 
subgroepen. Op basis van onze bevindingen concludeerden we dat ANA-analyse in de volwas-
sen uveïtis populatie een beperkte diagnostische waarde heeft en dat ANA’s waarschijnlijk niet 
betrokken zijn bij de pathogenese van uveïtis.
Hoofdstuk 4 is een prospectieve studie waarin de prevalentie en mogelijke rol van ARA’s in bloed 
van 126 patiënten met uveïtis wordt vergeleken met 60 bloedbankdonoren. Middels indirecte 
immunofluorescentie (IIF) met primaat retinaal weefsel werd serum getest op de aanwezigheid 
van ARA’s. Hoewel het met IIF niet mogelijk is om ARA’s te specificeren, is het een zeer gevoelige 
techniek, wat het een bruikbare screeningsassay maakt. In onze studie werden ARA’s aangetoond 
bij 47% van de patiënten met uveïtis, wat significant vaker was dan bij de gezonde controles (17%, 
p <0,001). Specifieke verbanden tussen de aanwezigheid van ARA’s en klinische oculaire kenmer-
ken van uveïtis werden niet waargenomen. Onze resultaten suggereren dat ARA’s in het bloed 
geen primaire rol spelen in het ontstaan van uveïtis, en waarschijnlijk een secundaire reactie zijn 
van het immuunsysteem op het reeds beschadigde oogweefsel. 
In hoofdstuk 5 bepalen we de mogelijke diagnostische rol van verschillende specifieke ARA’s bij 
patiënten met auto-immuun retinopathie (AIR). AIR omvat een zeldzame groep immuun-gemedi-
eerde oogziektes, die meestal als een paraneoplastische aandoening voorkomen in combinatie 
met een maligniteit. AIR is geassocieerd met de aanwezigheid van verschillende ARA’s, waarbij 
wordt verondersteld dat deze antistoffen schade aan het netvlies veroorzaken en tot progressief 
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visusverlies leiden. Tot nu toe zijn slechts enkele ARA’s bij AIR gespecificeerd en is de rol van 
deze ARA’s bij AIR niet volledig opgehelderd. In dit onderzoek hebben wij in samenwerking met 
SciLifeLab Autoimmunity Profiling Facility in Stockholm (Zweden) serum van 24 patiënten met AIR 
onderzocht de op aanwezigheid van 188 verschillende ARA’s. Middels een multiplex immunoassay 
werden bloedmonsters getest en vergeleken met serum van 151 patiënten met uveïtis en 21 
patiënten met cataract. Uit de resultaten bleek dat individuele patiënten met AIR zeer verschil-
lende ARA’s in hun serum hadden. Er werden ARA’s gevonden die reeds vanuit de literatuur 
bekend waren (zoals anti-recoverine), maar er werden ook een aantal nieuwe ARA’s geïdentifi-
ceerd. Tevens bleek uit onze resultaten dat ARA’s ook voorkomen bij patiënten met uveïtis en 
cataract, waardoor de specificiteit van ARA’s voor de diagnose AIR laag was. We concludeerden dat 
de diagnose van AIR niet kan worden gesteld op enkel de aanwezigheid van ARA’s in het serum.
In hoofdstuk 6 tonen we een casus van een patiënt met een paraneoplastische AIR. De patiënt 
presenteerde zich op de polikliniek oogheelkunde met ernstig visusverlies in beide ogen. In 
het serum van de patiënt werden anti-retinale antistoffen tegen recoverine aangetoond.  Na 
doorverwijzing naar een internist werd hij gediagnosticeerd met longcarcinoom, waarmee de 
diagnose carcinoom geassocieerde AIR werd bevestigd. De patiënt werd behandeld met chemo- 
en radiotherapie en een hoge dosis corticosteroïden, helaas zonder enige verbetering van zijn 
visus. Een longcarcinoom is de meest voorkomende maligniteit die is geassocieerd met een 
paraneoplastische AIR, maar elke vorm van een maligniteit kan bij deze ziekte betrokken zijn. 
Vaak zijn bij AIR beide ogen aangedaan, maar in zeldzamere gevallen presenteert de ziekte zich 
asymmetrisch of zelfs unilateraal. Visusklachten kunnen het eerste symptoom zijn van een para-
neoplastische AIR, waardoor de rol van de oogarts van groot belang is bij het diagnosticeren van 
de maligniteit. De behandelingsmogelijkheden bij een paraneoplastische AIR zijn beperkt en de 
visuele prognose is vaak erg slecht. 
In hoofdstuk 7 onderzoeken we de aanwezigheid en mogelijke rol van ARA’s in centrale sereuze 
chorioretinopathie (CSC). Bij CSC is er sprake van vochtlekkage in het netvlies. Hoewel weinig 
bekend is over de exacte oorzaak van CSC, wordt een mogelijke rol van het immuunsysteem 
verondersteld. We hebben retrospectief serum onderzocht van 63 patiënten met CSC op de 
aanwezigheid van ARA’s middels IIF en Western blot, en de resultaten vergeleken met 101 
uveïtis patiënten en 60 bloedbankdonoren. ARA’s werden bij 54% van de patiënten met CSC 
gedetecteerd, in vergelijking met 46% van de uveïtis patiënten (p>0.05) en 17% van de bloed-
bankdonoren (p <0.001). ARA’s in CSC waren vaker gericht tegen de fotoreceptoren dan ARA’s bij 
uveïtis (p=0.039). Zowel de IIF als Western blot analyse toonde multipele ARA’s bij de meerderheid 
van de patiënten met CSC aan, die tussen de patiënten zeer divers waren. De heterogeniteit van 
ARA’s in CSC maakt dat het onwaarschijnlijk is dat ARA’s een primaire rol spelen bij CSC, eveneens 
het geval is met ARA’s in serum bij uveïtis. 
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In hoofdstuk 8 onderzoeken we de prevalentie van systemische en retinale auto-antistoffen (ANA 
en ARA) bij patiënten uit Indonesië met uveïtis en actieve of latente tuberculose (TB). In Indonesië 
is uveïtis geassocieerd met actieve systemische of latente TB een veel voorkomende oogaan-
doening. De pathogenese van uveïtis en een latent TB is nog niet opgehelderd en verondersteld 
wordt dat een auto-immuun reacties geïnitieerd door M. Tuberculosis hierin een belangrijke rol 
spelen. We hebben de prevalentie van ARA’s en ANA’s onderzocht bij 95 Indonesische patiënten 
met 3 verschillende soorten uveïtiden: uveïtis geassocieerd met actieve TB (N = 10), met latente 
TB (N = 58) en zonder (latente) TB (N = 85). Het bleek dat patiënten met uveïtis en een actieve of 
latente TB vaker systemische antistoffen (ANA’s) en minder vaak retinale autoantistoffen (ARA’s) 
hadden, ten opzichte van patiënten met uveïtis zonder (latente) TB (p = 0,03 en p = 0,021). De 
lagere prevalentie van ARA’s in het serum bij patiënten met uveïtis en een (latente) TB wijst niet 
in de richting van een auto-immuun pathogenese van dit ziektebeeld, echter zou onderzoek van 
intra-oculair materiaal een totaal ander inzicht kunnen bieden.
In hoofdstuk 9 voeren we een retrospectieve studie uit naar de prevalentie van ARA’s bij jonge 
Mexicaanse patiënten met ernstige pars planitis (N=16) ten opzichte van Mexicaanse leeftijds-
genoten (N=19). Pars planitis is een idiopathische vorm van uveïtis, die gekarakteriseerd wordt 
door voornamelijk ontsteking van het glasvocht. Een uitzonderlijk ernstige vorm van pars plani-
tis wordt waargenomen bij kinderen in Mexico. Ondanks eerder uitgebreid onderzoek naar de 
pathogenese van pars planitis, waarbij wordt verondersteld dat het ziektebeeld auto-immuun 
zou zijn, is de exacte oorzaak van deze aandoening niet opgehelderd. In ons onderzoek naar de 
prevalentie van auto-immuun reacties vonden we ARA’s bij 57% van de kinderen met pars plani-
tis, maar een vergelijkbare prevalentie (40%) werd waargenomen bij Mexicaanse kinderen met 
strabismus. De hoge prevalentie van ARA’s bij de controle patiënten kan het gevolg zijn van een 
hogere blootstelling aan exogene antigenen (bijvoorbeeld infecties). Deze resultaten suggereren 
dat ARA’s niet de primaire oorzaak zijn van pars planitis, evenals de resultaten in Nederland met 
uveïtis patiënten laten zien. Een rol van auto-immuniteit bij het ontstaan van pars planitis kan 
echter niet worden uitgesloten, aangezien cellulaire auto-immuun reacties en het van intra-oculair 
materiaal niet onderzocht zijn. Deze zouden alsnog op een auto-immuun pathogenese van pars 
planitis kunnen duiden.
In de laatste hoofdstukken van dit proefschrift hebben we ons geconcentreerd op de bepaling van 
humorale auto-immuun reacties in intra-oculair vocht. Hoofdstuk 10 is een retrospectieve studie 
waarin intra-oculair vocht van 76 patiënten met uveïtis en 19 cataractcontroles wordt onderzocht 
op de aanwezigheid van 188 verschillende ARA’s. In samenwerking met de SciLifeLab Autoimmu-
nity Profiling Facility in Stockholm (Zweden), hebben we een multiplex immunoassay uitgevoerd. 
We vonden 22 verschillende ARA’s in hogere titers bij patiënten met uveïtis in vergelijking met 
controles met cataract (p ≤0,05), maar de titers waren zwak verhoogd. Hoge titers van verschil-
lende ARA’s (5-voudige verhoogde titers in uveïtis in vergelijking met cataractcontroles) werden 
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waargenomen bij drie specifieke uveïtis-entiteiten: varicella zoster-virus geïnduceerde uveïtis, 
multiple sclerose geassocieerde uveïtis en patiënten met onverklaarde uveïtis en een positieve 
quantiferon test (alle p <0,05 ). De aanwezigheid van cystoïd macula oedeem was geassocieerd 
met hoge intra-oculaire titers van tyrosinase antistoffen (p = 0,0026). Het brede spectrum van 
verschillende intra-oculaire ARA’s in patiënten met uveïtis suggereert eerder een secundaire 
productie dan een initiërende rol bij uveïtis. De resultaten van deze studie kunnen als platform 
dienen voor toekomstige onderzoek naar specifieke oculaire antigenen in de pathogenese van 
uveïtis.
Inflammatoire auto-immuun processen werden niet alleen verondersteld een rol te spelen bij 
de pathogenese van uveïtis, maar ook bij verschillende oorspronkelijk niet-inflammatoire oog-
ziekten zoals RP, AMD en glaucoom. In hoofdstuk 11 bepalen we de prevalentie en titers van 15 
verschillende intra-oculaire cytokines en de prevalentie van intra-oculaire ARA’s bij patiënten met 
RP (N = 25), AMD (N = 12), glaucoom (N = 28) en cataract (N = 22) en trachten we de laboratori-
umresultaten aan de klinische manifestaties te correleren. Daarnaast wordt er serum onderzocht 
dat gepaard met intra-oculair vocht werd afgenomen van patiënten met RP (N = 7) en cataract (n 
= 10). We hebben geconstateerd dat een toenemende leeftijd geassocieerd was met stijgende 
concentraties van meerdere intra-oculaire cytokines, en we detecteerden dat de concentraties 
van een aantal cytokines tussen de onderzochte groepen verschilden, zijnde: IL-6rα (p = 0,003), 
IL-8 (p = 0,032) en IL-23 (p <0,004). Bij patiënten met RP waren de titers van IL-2, IL-6, MCP-1 en 
PlGF hoger in het oog dan in het bloed, wat een aanwijzing kan zijn voor een actieve intra-oculaire 
productie van deze mediatoren. Intra-oculaire ARA’s werden gevonden bij slechts één patiënt 
met AMD, in tegenstelling tot serum ARA’s, welke werden gedetecteerd in de meerderheid van 
de onderzochte patiënten. De verschillen in cytokine profielen tussen de onderzochte patiënten-
groepen suggereren een rol van het immuunsysteem bij de pathogenese van deze oorspronkelijk 
niet-inflammatoire oogziekten. Mogelijk dragen deze immuunreacties bij aan een verergering van 
een reeds bestaande aandoening.  
Concluderend, onze resultaten geven geen aanwijzingen voor een primaire rol van ARA’s bij het 
initiëren van uveïtis en andere chorioretinale aandoeningen. De aanwezigheid van serum ARA’s 
bij oogaandoeningen kan worden verklaard door een secundaire vorming van antistoffen welke 
wordt geïnduceerd door oogweefselschade. Hoewel bij patiënten met oogaandoeningen hogere 
titers van ARA’s in serum werden gevonden dan bij de gezonde populatie, vonden we geen asso-
ciaties met specifieke oogheelkundige klinische manifestaties. Tevens wijzen onze bevindingen 
erop dat ARA’s in serum bij AIR zeer waarschijnlijk geen initiërende rol hebben, en dat de diagnose 
van AIR niet kan worden gebaseerd op enkel de aanwezigheid van ARA’s in het bloed.
Het spectrum intra-oculaire ARA’s bij uveïtis duidt op een rol van het humorale auto-immuun 
systeem bij de pathogenese bij uveïtis, voornamelijk bij 3 specifieke entiteiten: varicella zoster-vi-
166
APPENDICES
rus geïnduceerde uveïtis, multiple sclerose geassocieerde uveïtis en patiënten met onverklaarde 
uveïtis en een positieve quantiferon test. Daarnaast zijn autoantistoffen gericht tegen tyrosinase 
geassocieerd met de aanwezigheid van cystoïd macula oedeem. Intra-oculaire ARA’s bij AIR, in 
het bijzonder bij paraneoplastische retinopathie, zouden een interessant onderwerp zijn voor 
toekomstig onderzoek en zouden kunnen bijdragen aan het verduidelijken van de pathogenese 
AIR en het ontwikkelen van nieuwe behandelingsmogelijkheden. 
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